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Abstract
Hormone receptor positive (HR+) breast cancer represent 70% of all breast tumours. Its
oncogenesis is multiple step process thought to be driven by the presence of two
transcription factors, the oestrogen receptor (ER) and/or the progesterone receptor (PR).
Therefore, the endocrine-targeted therapeutic approach has been focused on both receptors
as prognostic markers and therapeutic targets, aiming to alter the oestrogen signalling for
patients with ERα-positive disease. The benefits gained from the treatment appear to be 
limited by developing either de novo or acquired resistance following a period of response to
tamoxifen. In the present work, global quantitative proteomics was combined with the
analysis of fractions enriched in target subcellular locations (nuclear and cytoplasmic
fractions), this has allowed measurement of the changes in total abundance and in the
compartmental abundance/distribution between the nucleus and cytoplasm for several
thousand proteins differentially expressed in MCF-7cells in response to oestrogen and
tamoxifen stimulation in MCF-7 cells.
In the first part of the thesis, we have used a proteomics subcellular spatial razor approach to
look at changes in total protein abundance and in protein distribution between the nucleus
and cytoplasm following exposure of MCF7 breast cancer cells to oestradiol. The dominant
response of MCF7 cells to oestrogen stimulation involves dynamic changes in protein
subcellular spatial distribution rather than changes in total protein abundance. Of the 3604
quantitatively monitored proteins, only about 2% show substantial changes in total
abundance (>2-fold), whereas about 20% of the proteins show substantial changes in local
abundance and/or redistribution of their subcellular location, with up to 16-fold changes in
their local concentration in the nucleus or the cytoplasm.
5The second part of the thesis focuses on the spatial distribution of proteins in the three sub-
proteome fractions (total lysate, nuclear and cytoplasmic fractions) in 4-OHT stimulated
MCF-7 cells. Of the 3493 quantitatively monitored proteins, 97 of quantified proteins were
detected as a core data set with differential abundance (DA) that was significantly changed
in total abundance and/or subcellular location (P < 0.05). More than 50% of the proteins
show significant changes in local abundance and/or redistribution of their subcellular
location, only 19 proteins show substantial changes in the total lysate. Following the
rigorous downstream analysis of the pathways significantly overrepresented and GO terms
significantly enriched, this analysis showed that protein changes in abundance with 4-OHT
across multiple sample types (CNT) were involved in pathways related to metabolism, signal
transduction, growth and proliferation, and development. The nuclear response involved
upregulation of the proteins participating in the GPCR downstream signalling pathway
leading to accumulated response in the cancer pathway by moderately modulating the cell
survival (PI3K/AKT) pathway in a circadian rhythm. Furthermore, this was accompanied by
substantial changes in the local abundance and /or the redistribution of the metastasis
mediating proteins and apoptotic cleavages of cell adhesion proteins.
We propose that dynamic redistribution of the subcellular location of multiple proteins in
response to stimuli is a fundamental characteristic of cells and suggest that perturbation of
cellular spatial control may be an important feature of cancer.
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Chapter 1 Introduction
1.1 Hallmarks of cancer: an emerging concept of cellular complexity
The growth and death of normal cells are not random processes, they take place at
systematically controlled intervals within biological systems; a tumour is a type of growth
formed of abnormal cells that are able to commence immortal growth and escape regulatory
limitations imposed upon normal cells. In ancient medicine, 3000BC, some cases were
described as an abnormal growth of tissue, but classified as idiopathic disorders, with a
simple conclusion: “There is no treatment.” (American Cancer Society, 2016). Since the
mid-20th century, more than 100 types of cancer have been identified (Encyclopædia
Britannica Online, 2016). It is now clear that different kinds of tumours have different
progression patterns and responses to therapy due to heterogeneity that is neither uncommon
among different tumours, nor seldom within individual tumours. For example, in breast
cancer, multiple subtypes may exist within the same tissue (intra-tumour heterogeneity) with
different patterns of progression, cellular markers and responses to treatment (Brafford and
Herlyn, 2005).
In the current era, advanced molecular biology techniques are feasible, and on completion of
human genome sequencing and cataloguing cancer mutational genes in the large-scale
cancer genome sequencing atlas (TCGA), heterogeneity gives rise to widely dissimilar
genetic and phenotypic manifestations among tumour patients. Therefore, inconsistent rates
of disease progression and responses to treatment continue to challenge good management in
clinical settings and a thorough understanding in research laboratories owing to the natural
pathological complexity and poor prognosis of cancer (Brafford and Herlyn, 2005, Patel et
al., 2014, Garraway and Lander, 2013).
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However, scientists have listed and described numerous genetic mutations that contribute to
carcinogenesis from initiation to the metastasis phase; the majority of those genes fall into
two categories, oncogenes or tumour suppressor genes (Garraway and Lander, 2013,
Macconaill and Garraway, 2010). A gain of function mutations (oncogenes) and a loss of
function mutations (tumour suppressor genes) are dynamically chaotic (Andrey, 1989, Calin
et al., 2003, Pham and Ichikawa, 2013). Also, abnormal proliferation of tumour cells is
associated with accumulative mutations and genetic instability; cells are continuously
dividing and accumulating these mutations with each round of cell division, producing
proteins to execute numerous functions in a context-dependent manner (Garraway and
Lander, 2013, Andrey, 1989, Calin et al., 2003, Pham and Ichikawa, 2013). The growth of
cancer is a process known as a carcinogenesis that is neither a single step process nor based
on a single cellular event (Foulds, 1958, Vogelstein and Kinzler, 2004). Hence, cancer is a
progressive dynamic disorder that evolves gradually to escape the boundaries of the tissue of
origin, which ultimately reaches an irreversible phase of metastasis; each stage involves
various forms of alterations that result in either a gain of functions (oncogenes) or a loss of
functions (tumour-suppressor genes), enabling the progression of malignancy (Hanahan and
Weinberg, 2011, Vogelstein and Kinzler, 1993). Malignant tumours are distinguished by six
common alterations defined as ‘hallmarks’ (Figure 1-1): 1] auto-stimulation for growth; 2]
immortality and limitless replicative potential; ability to escape growth limitations including
3] growth suppressors or 4] apoptosis; 5] maintained angiogenesis; and 6] the ability to
invade (metastasis) both proximal and distant tissues. In addition to the above features, four
emerging hallmarks have been added to the pathophysiological manifestations of cancer
cells: 1] abnormal metabolism; and, 2] resistance to the immune system; 3] genome
instability; and 4] inflamation (Hanahan and Weinberg, 2000, Hanahan and Weinberg,
2011).
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It has been widely accepted that tumour cells are driven by genetic instability and metabolic
abnormalities; therefore, currently, cancer is known as a genetic and metabolic disorder
(Coller, 2014, Hemminki and Hemminki, 2005). Collectively, these hallmarks suggest that
neoplastic cells have common themes in their operations and are controlled at different
spatial and temporal levels, also, an individual cancer cell is able to manifest self-governing
capabilities.
Having said that, the research direction and methods have evolved tremendously to enable
the researcher to deeply investigate a very complex disorder aiming towards a better
understanding and better overall management, given that the spectra of cancer mutations
evolve in a non-linear way within a given type of tumour or different tumours.
Many scholars hold the view that the process from gene to the development of an organism
is highly complex and interlinked with complex networks linking hierarchical anatomical
system entities and formulating the function or dysfunction of an organism, implying that the
lack of knowledge, in many aspects, is related to a reductionist approach to understanding
the biology (Figure 1-2) (Grizzi and Chiriva-Internati, 2006, Kitano, 2002, Noble, 2002,
Szathmáry et al., 2001).
The rational approach to tackle highly complex biological phenomena, such as cancer, is to
develop methods that provide more quantitative information about the dynamicity and
plasticity of the nonlinear qualitative multistep cancer progression states (Michor et al.,
2004).
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How can we adapt and use the advanced high- throughput omics-technologies including
genomics, transcriptomics, proteomics and metabolomics to reveal a cancer’s enigmatic
secrets? Answers can show bias due to the lack of an integrative approach and leaping
towards interests that can provide part of a multidimensional image. Having said that, the
large scale global research approaches that have been evolving since early genome
sequencing may reveal more about the dynamicity and plasticity of various tumours, once
they complement one another.
Figure 1-1: The six hallmarks of cancer
This figure shows the six common capability hallmarks shared among cancer types. Adapted
from (Hanahan and Weinberg, 2011).
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.
Figure 1-2: Hierarchical illustration of human cancer
This figure exemplifies how cancer is a very complex biological system that involves
numerous processes at different levels ranging from molecular to environmental.
Adapted from (Grizzi and Chiriva-Internati, 2006).
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1.2 Increasing incidence, mortality, morbidity and risk factors associated with
breast cancer (BC)
The common and dreadful thought that comes to mind upon the diagnosis of a tumour is
whether a cure is possible. This fear has its root in the rates of mortality, morbidity and poor
prognoses associated with tumours. In the United States, cancer has been reported as the
second leading cause of death (Centers for Disease Control and Prevention, 2015). On
December 23, 1971 the President Nixon signed the National Cancer Act and declared a ‘war
on cancer’; this act classified cancer as the most feared disease in the United States, and
governmental agencies were then committed to finding a cure within one decade (Hesketh,
2013). Forty years on, although there has been recorded success in distinguishing types and
subtypes of tumours, the statistical figures, pathogenesis and tailored treatment/screening
(personal) remain a global burden in most types of cancer.
Ferlay et al. (2015) analyse the online global cancer database GLOBOCAN 2012, and
estimate the diagnosis of 14.1 million new cancer cases each year and 8.2 million deaths that
are associated with various types of cancer with different global distribution patterns.
Around 40% of cases were reported in Europe and in the United States, while 60% were
diagnosed across developing countries. Among different types of cancer based on an annual
statistics, Ferlay et al. (2015) find that, 55% of the global incidence burden is represented
over six forms: lung cancer is the most common (1.82 million new cases, 1.6 million deaths),
followed by breast and colorectal cancers (1.67 million new cases, 522,000 deaths and 1.36
million, 694,000 deaths respectively), prostate cancer (1.1 million new cases, 307,000
deaths), stomach cancer (951,000 new cases, 723,000 deaths) and lastly, liver cancer
(782,000 new cases, 745,000 deaths).
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The World Health Organisation in 2011 predicted that there would be 2-fold increase in
cancer-associated mortality, from 7.6 million deaths by 2030; however, 70% of the current
death figures mainly occur in nations with lower living standards (Jemal et al., 2011).
Based on GLOBOCAN, from 2008 to 2012, the incidence rate of breast cancer elevated
sharply to 1.7 million new cases and 522,000 breast cancer related deaths. Although the
mortality rate is declining in industrialised countries, the incidence rate is still higher among
women in those countries compared to less developed parts of the world (International
Agency for Research on Cancer, 2016). The wide variation of incidence rate is in part due to
changing lifestyles and accompanying risk factors, as well as reproductive and hormonal
variations, while the declining death rate is due to the availability of more effective
diagnostic tools and improved strategies in adjuvant treatment (Jemal et al., 2010). Incidence
of breast cancer, in light of current statistical information, is not expected to reduce in the
near future; thus, the public health burden remains highly topical (Gannon et al., 2013).
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1.3 Breast cancer (BC)
The aetiology of breast cancer cannot be linked to a single factor, both genetics and
lifestyle/environment are recognised as risk factors that must be considered in terms of
aetiological implications; BC is a multifactorial disorder.
1.3.1 Reproductive risk factors associated with breast cancer
Extensive experimental, clinical and epidemiological studies have identified that exposure to
ovarian oestradiol (E2) and progesterone hormones, notably oestradiol (E2), is the most
significant risk factor in developing breast cancer (Angelopoulos et al., 2004, Bernstein,
2002, Cui et al., 2013, Yue et al., 2010). Epidemiological studies have led to speculation that
age at menarche, childbearing and menopause, provides explanations concerning the impact
of internal hormonal exposure over a lifetime (Bernstein, 2002). Although age is the most
speculated risk factor often used to identify the women at high risk of developing breast
cancer (Nelson et al., 2012), it resides among unconvincing evidence.
Women with late menopause at 55 plus years of age, seem to be at high risk, possibly due to
long term exposure to internal hormones from menstrual cycles (Colditz and Rosner, 2000).
An early onset of the menstrual cycle (early menarche), at 12 years or younger at regular
intervals, increases the chance of developing breast cancer fourfold than women with late
menarche (Bernstein, 2002). In short, we need to emphasise the specific point that chronic
exposure to internal oestrogens may be described as the long term menstrual cycles, i.e. early
onset and late cease.
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Among other speculative proposals, (Bernstein et al., 1986) believe that child bearing age is
considered to be of paramount importance in developing breast cancer whose first pregnancy
was at age 30, than those younger than 20 years. The protective effect of early full term
pregnancy before the age of 20 has been demonstrated in many epidemiological studies
(Albrektsen et al., 2005, MacMahon et al., 1970). A 50% decrease in cancer risk is noted in
comparison to late pregnant and nulliparous women (Meier-Abt and Bentires-Alj, 2013).
Furthermore, women that breastfeed can form protection against developing breast cancer;
35% lower possibility than non-lactating women (Enger et al., 1997, Enger et al., 1998).
Breastfeeding has the greatest effect on the delay and reduction in menstrual cycles; its
protective effect is linked to the low level of hormonal exposure during lactation (Bernstein,
2002).
Body weight, at the age of menopause, is associated with breast cancer incidence, since
adipose tissue is the main endogenous reservoir of androgens (Lamas et al., 2013,
Stephenson and Rose, 2003), and obesity reduces the level of circulating sex hormones
binding globulin (SHBG), and subsequently, the level of free oestradiol increases in blood
circulation (Key et al., 2011, Moore et al., 1987). Furthermore, Lamas et al. (2013) correlate
the enhanced proliferation of oestrogen receptor (ER+) in MCF-7 breast cancer cells to fat
intake. Nevertheless, improving lifestyle by controlled body weight with frequent physical
exercise, and a reduction in fatty diets could have an impact on reducing the risk of breast
cancer (Bernstein, 2002). Oral contraceptives and hormone replacement therapy (HRT) are
both considered exogenous sources for circulating hormones; however, risk of developing
breast cancer does not appear to be similar among women exposed to these agents. New
recommendations for oral contraceptive have helped to reduce the risk (Kumle et al., 2002),
but HRT, notably oestrogen replacement therapy (ERT), is not always safe and an individual
assessment with a tailored and structured plan prior to prescription, aiming to reduce
35
postmenopausal symptoms, would provide a more effective benefit and reduce the risk of
over-exposure to oestrogen (Hou et al., 2013).
1.3.2 Heterogeneity of breast cancer
All enabling characteristics of cancer hallmarks are shared by most types, including breast
cancer. In addition to those hallmarks, breast cancer has inherited enigmatic heterogeneity,
which makes the clinical manifestations of the disease unpredictable, and thus can lead to
ineffective management (Ellsworth et al., 2010). However, finding an indefinite way to
rationally diagnose, treat and provide an accurate prognosis is the ultimate goal of current
research, and the current trend of treatment is amenable to be targeted and individualised, i.e.
a drug working by design, as opposed to chance.
With regard to the diagnosis and prognosis of breast cancer, pathologists have a crucial role
in translating the biological changes associated with breast cancer into useful information
that helps in the neoadjuvant/adjuvant treatment or when estimating the probability of
recurrence and metastasis. They rely on traditional sets of methods/indicators, such as
morphological changes, tumour size and grade, lymph node status, and the
immunohistochemistry determination of diagnostic/prognostic markers, such as ER/PR and
human epidermal growth factor receptor 2 (HER2) (Kittaneh et al., 2013). However,
molecular techniques, in addition to the clinical pathological paradigm, have illustrated the
diversity of breast cancer subtypes and justified the inconsistencies in clinical behaviours of
same-stage cancers, and therefore, highlighted the importance of a personalised
diagnosis/prognosis treatment plan in clinical decision making (Allison, 2012). High
throughput technologies such as gene expression microarray, have revealed a distinct breast
cancer cellular classification with innate biological characteristics for each subtype that may
influence initiation, proliferation, recurrence and thus rationalise personalised treatment
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based on an individual biomarker (Eroles et al., 2012). Immunohistochemical expression of
receptors has joined gene expression profiling to provide a platform for the current most
common subtypes: luminal A, luminal B, HER2, basal and normal forms (Perou et al., 1999,
Perou et al., 2000). Each subtype has specific molecular characteristics as shown in Table
1-1 with examples of cell lines, as a research model, representing each subtype (Holliday and
Speirs, 2011, Neve et al., 2006, Prat et al., 2010).
Table 1-1: Five common subtypes of breast cancer
Classification *Immunoprofile Other characteristics **Example celllines
Luminal A ER+, PR+/–, HER2– Ki67 low, endocrine responsive, oftenchemotherapy responsive
MCF-7, T47D,
SUM185
Luminal B ER+, PR+/–, HER2+
Ki67 high, usually endocrine responsive,
variable to chemotherapy. HER2+ are
Trastusumab responsive
BT474, ZR-75
Basal ER–, PR–, HER2–
EGFR+ and/or cytokeratin 5/6+, Ki67
high, endocrine nonresponsive, often
chemotherapy responsive
MDA-MB-468,
SUM190
Claudin-low ER–, PR–, HER2–
Ki67, E-cadherin, claudin-3, claudinin-4
and claudinin-7 low. Intermediate
response to chemotherapy
BT549, MDA-
MB-231,
Hs578T,
HER2 ER–, PR–, HER2+ Ki67 high, Trastusumab responsive,chemotherapy responsive
SKBR3, MDA-
MB-453
*Immunohistochemical and molecular characteristics of five subtypes of breast cancer
(Holliday and Speirs, 2011).
**Research cell line models for each subtype (Neve et al., 2006, Prat et al., 2010).
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1.3.3 Endocrine therapy
Breast cancer subtypes are not yet universally applied to clinical settings, and required
further standardisation. However, they have contributed to an understanding that the
treatment response is inconsistent and can be linked to an individual molecular marker,
therefore, we know today that ER is a therapeutic target for hormone therapy, and that
human epidermal growth factor receptor 2 (HER2) is potentially a target protein for
Trastuzumab therapy (Bang et al., 2010, Eroles et al., 2012, Lynch et al., 2004, Marty et al.,
2005, Pao et al., 2004, Piccart-Gebhart et al., 2005, Van Cutsem et al., 2011). The triple
negative forms of breast cancer (TNBC) with no expression of any of these receptors. TNBC
still represent the most aggressive subtypes, hence no historical therapeutic targets have been
established and adjuvant treatment is restricted to chemotherapy (Perou et al., 2000).
In adjuvant hormonal treatment, women with ER and/or PR positive tumours, irrespective of
the stage, show better survival rates in a typical response to the targeted approaches that
include ER modulator tamoxifen (Block ER), E2 synthesis inhibition by aromatase inhibitors
(AIs), and ER-degrading agent Fulvestrant (Figure 1-3) (Gradishar, 2010). However, a
disease free interval would develop a resistant relapsed form (acquired resistance), hence
limiting the long term efficacy of endocrine treatment (Ring and Dowsett, 2004). A better
understanding of the mechanism of action of both nuclear and cytoplasmic ER would clarify
the mechanism underlying this resistance.
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There is a significant difference between hormonal replacement therapy (HRT) and
endocrine targeted therapy (ETT); the former is prescribed to alleviate postmenopausal
symptoms, particularly osteoporosis, and has since been proved to be unsafe for breast
cancer patients, while the latter is an antioestrogen approach of treatment targeting the
oestrogenic signalling pathways.
In 1896, a link was found between breast cancer and hormones, given that the tumour
regression was associated with the deprivation of hormones following oophorectomy
(Dixon, 2014). The first synthetic non-steroidal oestrogen that has been shown to have
natural anti-tumour characteristics was Diethylstilbestrol (DES), but severe side effects were
encountered along with the administration, therefore the Food and Drug Administration
(FDA) soon banned its use (Haddow et al., 1944).
In the early 1960s, researchers developed the contraceptive tamoxifen, but this drug has
shown that it deprives oestrogen signals that favour cancer development rather than
preventing pregnancy (Jordan, 2003); therefore, the FDA licensed tamoxifen in 1973 as an
essential antioestrogen treatment (Jordan, 2003), which has been extensively used to date.
The endocrine treatment approach can be administered alone in ER-positive patients, or
along with other chemotherapeutic agents (Colleoni et al., 2001). Figure 1-3 shows that the
main theme of endocrine targeted therapies is to reduce the growth of oestrogen-dependent
tumours by inhibiting oestrogen synthesis (aromatase inhibitors, Letrozole) (Buzdar, 2005),
antagonising oestrogen binding with ERs by selective modulators (SERMs, tamoxifen)
(Shiau et al., 1998), and selective down-regulators (SERDs, Fulvestrant) (Long and Nephew,
2006), which are frequently prescribed to premenopausal and postmenopausal women with
breast cancer characterised as ER positive.
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It has been found that 5-year adjuvant treatment of tamoxifen reduces the relapse rate in a
period extended up to a decade from the day the treatment commences, and enhances the rate
of survival to a one third reduction of breast cancer associated mortality (Davies et al.,
2011). Moreover, further reduction in both mortality associated breast cancer and recurrence,
has been reported with continuing treatment for up to 10 years, rather than a 5-year treatment
cycle (Davies et al., 2013).
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Figure 1-3: Endocrine targeted therapy in ER positive breast cancer
Diagram showing that through the action of the peripheral aromatase, androgens are
converted into oestrogen (E), oestrogens are diffused into the intracellular space, bind ER,
and activates the ER signalling cascades. For the three groups of the endocrine treatments,
three targets are shown in the pathway: aromatase inhibitors targeting oestrogen synthesis,
tamoxifen (SERM) modulating ER, and fulvestrant (SERD) downregulating ER. Adapted
from (Dixon, 2014).
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1.3.4 Mechanisms of endocrine resistance
The complete mechanism underlying the acquired resistance to the endocrine targeted
therapeutic approach, remains to be elucidated. It is important to note that we gained
incomplete knowledge regarding how signalling transduction pathways and their
components affect the rate of cellular survival, proliferation or death; we are still far from
determining the exact mechanism by which oestrogen mediated processes in breast cancer
are interconnected with such a complex system (Chang, 2012). Therefore, antioestrogen
resistance is unlikely to arise due to a single cellular event/mechanism that is not linked to
various cellular events that are enigmatic and heterogenic in different breast tumours (Clarke
et al., 1990). However, in relation to tamoxifen resistance, there are several mechanisms
attributable to developing resistance, some are discussed below. Several molecular
characteristics seem to be involved in the balance between agonistic and antagonistic
activities that include, but are not limited to: modulation of coregulatory proteins, the
crosstalk with growth-factor transduction pathways (Ali and Coombes, 2002, Girault et al.,
2003, McDonnell et al., 2002), dysregulation of ER expression, redox regulation, cellular
origin and stem cells, and autophagy regulation (Chang, 2012, Seo et al., 2012). These
mechanisms reflect the complexity of tumours and impose the need for further studies to
uncover the pathological manifestations of breast cancer.
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1.3.4.1 Loss of ER expression and function
The main aim of tamoxifen treatment is to deprive tumour cells from oestrogenic mediated
signalling via its ability to inhibit E2 binding to ER, then resistance is eventually developed
due to a loss of expression of the molecular target ER, in particular de novo resistance
(Jaiyesimi et al., 1995). Complete loss of ER at progression of the tamoxifen resistance
tumours was ruled out in ER positive tumours patients by showing responses to other
antioestrogens such as aromatase inhibitors (letrozol) after 5-years of tamoxifen treatment
(Goss et al., 2005).
In a study using two heterogeneous ER-positive cell line models (T47D and ZR-75-1), it has
been suggested that a switch from ER-positive to ER-negative can result from a repression of
the ER transcription gene and lead to an overpopulation of ER negative cells (Fuqua, 1994,
Jiang et al., 1992). Epigenetic modifications reportedly play a role in the diminished ER-
positive phenotype, inactivation of ER-expression via hypermethylation of CpG islands or
histone deacetylation inhibition, subsequently, this can reactivate ERα expression in ER-
negative breast cancer cells using inhibitors of histone deacetylases (HDAC) and DNA
methyltransferases (DNMT). This model of study assumes that epigenetic modulations may
improve the response to antioestrogens by desensitising ER-negative cells (Sharma et al.,
2005, Zhou et al., 2007).
Although, antioestrogen resistance can promote relapse or cancer recurrence in the absence
of any mutations (Brunner et al., 1997), the loss of ER function can be linked to ER gene
mutations, which is a negative feedback loop controlling the level of ER translated proteins,
and abnormal splice variants (Fuqua, 1994, Jiang et al., 1992). Since tamoxifen has a partial
43
agonistic activity, the naturally mutated ERs as seen in patients, have also been shown to
influence the agonistic actions of tamoxifen in culture cells (Chang, 2012).
1.3.4.2 Modulation of agonistic and antagonistic activities via coregulatory
proteins
Coregulatory proteins are categorised according to the roles they play in modulating the
ligand-bound ER transcription into either activators (coactivators) or inhibitors
(corepressors). They are involved in the transcription complex at the promotor region of ER
target genes (Girault et al., 2006). Level of expression and type of these coregulatory
proteins are essential determents of downstream ER transcriptions; agonist or antagonist
ligand-bound ER induces the conformation changes of the receptors associated with changes
in the recruitment patterns to the coregulatory proteins by ERs (Zajchowski et al., 2000).
Tamoxifen has been found to exert agonistic activity via recruiting coactivator SRC-1 with
the ER AF-1 domain, demonstrating the balance between agonistic and antagonistic
activities of the SERMs that are promotor context-dependent (Webb et al., 1998). Such a
demonstration of the partial agonistic activity of tamoxifen implies that the contribution of
the coregulatory proteins to induce resistance may take two forms: high expression level of
coactivators may terminate the antagonistic activity of tamoxifen, while low levels of
regulation may favour the switch to agonistic action of tamoxifen. Eventually this could
enhance the commencement of the growth of tumour cells and resistance to treatment
(Chang, 2012).
Amplified in breast cancer 1 (AIB1), a synonym to steroid receptor coactivator 3 (SRC-1)
and thyroid hormone receptor activator molecule 1 (TRAM-1), has been studied extensively
in many breast tumours and cell lines, particularly MCF-7 - the higher level of the
expression of this protein that is essential for cellular proliferation (List et al., 2001).
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Comparing two groups of patients, tamoxifen treated and those not treated with tamoxifen, it
has been reported that in the tamoxifen group, patients demonstrated a high level of
expression (AIB1) associated with poor prognosis in terms of survival (Osborne et al., 2003).
This led to a conclusion that upregulated AIB1 is associated with tamoxifen agonistic
activity, and a possible interaction between upregulated AIB1 with HER2 would develop
tamoxifen resistance through enhancing the expression of cyclin D1 and interfering with the
subsequent signalling pathways and cell cycle (Chang, 2012). Hence the coregulatory
proteins are not limited to interact with ERs and may interact with other types of nuclear
receptors (Klinge, 2000, Myers et al., 2005). The exact role and extent of the altered
expression of these proteins remains unclear and may play a role in developing resistance for
tamoxifen treatment (Chang, 2012).
1.3.4.3 Resistance to endocrine therapy due to regulation of redox status
In the reduction/oxidation cycling process, the resulting reactive oxygen species (ROS),
particularly hydroxyl radicals, from the metabolism of tamoxifen by the molecular oxygen
CYP450 system leading to aggressive breast cancer progression in response to DNA damage
and adduct formation, in particular 8-hydroxydeoxyguanosine (8-OHdG) (Fan and Bolton,
2001, Kryston et al., 2011). Furthermore, hydroxytamoxifen (4-OHT) undergoes further
activation by peroxidases that result in a formation of DNA adducts (Pathak et al., 1996),
and tamoxifen genotoxic effects are linked to the formation of a metabolite known as E
(cis/trans-1,2-diphenyl-1-(4-hydroxyphenyl)-but-1-ene) that shares a similar structure with
4-OHT, but undergoes further metabolism to produce a highly reactive, quinone methide,
that can alkylate the DNA (Fan and Bolton, 2001). In general, the cells are undergoing
various forms of metabolic reaction associated with ROS produced from mitochondria
(Murphy, 2009); to survive the oxidative stress, cells adapt diverse mechanisms against
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ROS. Hence, cancer cells are exposed to long term production of ROS during antioestrogen
treatment; the cells may adapt protective mechanisms via modulating ROS-mediated
dysregulation of a-dependent redox-sensitive signalling pathways (Penney and Roy, 2013),
notably, peroxiredoxin proteins. For example, it has been found that Prox5 is highly
expressed in breast cancers (Karihtala et al., 2003), and the level of expression involves the
modulation of the GATA1 (transcription suppressor) via agonist–bound ER. Therefore, one
of the proposed activities is tamoxifen-bound ER, that can prevent the repression of Prox5,
and therefore enhance cell survival (Chang, 2012, Seo et al., 2012).
1.3.5 Oestrogen receptor and signalling
In the late 1950s the first isoform of oestrogen biding proteins, ERα, was discovered and 
characterised by Elwood Jensen (Heldring et al., 2007). The ERα knockout mouse survived 
and changed a three-decade overview of oestradiol-mediated genomic signalling pathways
via ERα, as a sole mediator (Lubahn et al., 1993). The discovery of ERβ several years later 
(Kuiper et al., 1996), led to more questions, because the survival of the ERα knockout mouse 
was due to the role of ERβ to sustain the functions missed by the knocked out ERα. With 
double ERαβ knockouts, mice models were able to survive, but with impaired reproductive 
systems (Krege et al., 1998). These two forms of ER are neither coded by the same gene nor
have the same amino acid sequence. ERα gene is located in chromosome 6 while a gene in 
chromosome 14 follows the encoding of ERβ. The number of amino acids in each protein 
subset is inconsistent: 595 and 530 amino acids, respectively. Alternative splicing may
produce several isoforms of each subtype with different functions, such as ERα46 (Heldring 
et al., 2007). Based on current available data, ER effects can be divided into two major
categories: nuclear (direct transcription) and extra-nuclear effects (Figure 1-3) (Kampa et al.,
2013).
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Oestrogens are not only vitally essential to maintain and develop a normal reproductive
system, but are involved in a wide range of physiological processes (Harvey, 2009). Among
oestrogen metabolites that are produced in the body, 17β-oestradiol (E2), the most potent 
oestrogen metabolite, has the strongest agonistic effect on ERs (Harvey, 2009). ERs form,
with other androgen receptors, a large superfamily of nuclear receptors that can act as DNA
binding proteins of transcriptional activities when their matched hormones are diffused into
the cytoplasmic matrix (Ruff et al., 2000). Both types of ERs are distributed in different
tissues with different ratios including the gastrointestinal tract (ERα/β), lung (ERβ), liver 
(ERα), breast (ERα/β), urogenital tract (ERα/β) and bone (ERα/β) (Della Torre et al., 2016, 
Kuiper et al., 1997, Teng et al., 2008). Interestingly, the role of these receptors in
carcinogenesis is paradoxical and always thought to be in opposition whereby ERα is a 
carcinogenic mediator, and ERβ has an anti-proliferative effect (Thomas and Gustafsson, 
2011). In the classical role of ERs, 17β-oestradiol (E2) is diffused to the cytoplasm and 
bound to the cytoplasmic ERs, each ligand-bound receptor undergoes conformational
changes and dimerization with other receptors. This is followed by the translocation to
complex, with a specific sequence on the promotor region of the target DNA, called ERE
(Oestrogen Response Element) (Figure 1-3) (Dixon, 2014, Thomas and Gustafsson, 2011).
Actually, the transcription of the target gene is mediated via two transactivation domains of
ER, named AF-1 (ligand independent N-termini domain) and AF-2 (ligand binding carboxy
termini domain) (Dixon, 2014, Nilsson et al., 2001), full agonistic activities of E2 require
both domains to be active in addition to the recruitment of several coactivator/repressor
proteins that are localised on the target gene (Dixon, 2014). Of the coactivators that are
specific to ER/PR receptors, are P160 SRC-1 (NCOA-1), SRC-2 (GRIP1/TIF2/NCOA2),
and SRC-3 (AIB1) (Tien and Xu, 2012). However, this complex can act directly on the
target genes or tethering via other transcriptional factors, which eventually leads to produce
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the protein executors of specific functions related to proliferative growth. Nevertheless,
unbound ERs remain inactive and anchored in the cytoplasm by the associated heat shock
protein (HSP-90), which readily dissociates upon ligand binding. Additionally, growth
factors may replace the ligand activation and initiate the downstream phosphorylation and
receptor activation (Dixon, 2014).
Indeed, the rhythm of the classical (genomic) pathway is very slow and may last days, in
comparison with the non-genomic pathway, which is faster, reversible and initiates a growth
cascade via the steroid receptors localised in the plasma membrane of the cytoplasm. In this
pathway, the activated enzymatic cascades lead to the activation of the proliferative
signalling pathways that ultimately turn on the mitogen activated protein kinase (MAPK)
and subsequent cell growth (Silva et al., 2010).
Furthermore, compartmental oestrogen biosynthesis has been reported to take place in
mitochondria, in the presence of 3β-hydroxysteroid dehydrogenase and aromatase, 
moreover, the lipophilic property of exogenous oestrogen enhances its transportation into
this organelle (Felty and Roy, 2005). Therefore, analysis of interactions between
mitochondria and oestrogen is of no less importance and may play an important role in
revealing a new target for treatment and prognosis. An enlargement of the mitochondrial
morphology in response to a physiologically significant concentration of E2 (10nM), a dose
of choice in our project, has been visualised by electron microscopy in MCF-7 cell line (Vic
et al., 1982).
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1.4 Mass Spectrometry based proteomics
Finding the links between the proteins and their coding genes is a ‘landmark’ that should
change the direction of life sciences (Domon and Aebersold, 2006). Hence, protein identities
and their structures can be used to provide researchers with high resolution images that
reflect the real complexity governing living systems; the trend was geared towards
developing high throughput platforms to enable researchers to make use of the available
resources provided by high throughput genomics and genomic projects.
Advances in genomics and high throughput technologies in the last few years, have provided
the basis for developing very rich datasets that are accessible to the scientific communities
and have paved the way in gaining a better understanding of the underlying mechanisms of
cancer developmental steps. Here, and owing to the maturity in gene sequencing
technologies, we can have access to several informative platform datasets, such as: The
Cancer Genome Atlas (TCGA), the International Cancer Genome Consortium (ICGC) and
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) (Kazma
et al., 2012, Nik-Zainal et al., 2012, Pugh et al., 2013, The Cancer Genome Atlas Research,
2008, The Cancer Genome Atlas Research, 2011, Verhaak et al., 2010). It is becoming
clearer, that relying on functional genomics (transcriptome level) alone, is not sufficient for
the generation of information on the overall signalling pathways governing the biological
properties of cancer (Boyd et al., 2008). This is for several reasons: first, gene transcriptions
may be up-regulated/downregulated in response to a specific signalling cascade; therefore,
when signal transduction pathways are activated at a specific time, it is not easy to predict
the real time (temporal change) of activation (Shaulian and Karin, 2002). Second, several
studies have proven that the level of protein expressed in cells is not directly proportional to
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the gene expression level (Anderson and Seilhamer, 1997, Celis et al., 2000, Gygi et al.,
1999, Nishizuka et al., 2003). Thirdly, post-translational modification is a natural process
that plays a complex role in protein activation, deactivation or degradation (Boyd et al.,
2008). Furthermore, a vast amount of powerful proteomic generated data show considerable
instability inside living systems and the spatiotemporal dynamicity appears to be a way of
assuring bodily function, organ, cells and organelles relationships (Eckersall and Whitfield,
2011, Kholodenko, 2006, Scott and Pawson, 2009).
In light of these observations and complementary to the genomic approach, proteomics is a
reliable branch of research that can provide information about rapid dynamic changes
(spatial) in real time (temporal) in cell signalling pathways. It can help in refining cancer
subtype classification and in tackling cellular processes involved in tumour malignancy,
developing new tumour biomarkers and therapeutic targets (Boyd et al., 2008, Lam et al.,
2014).
The proteome encoded by the human genome is much more complex, and this is illustrated
by the number of protein coding genes (20-25,000 genes), where each gene can give rise to
more than one protein at a time, and each protein is eventually subjected to modifications by
different mechanisms and plays out its functions in different spaces at different times, with
significant differences in order of magnitude (Anderson and Anderson, 2002, Domon and
Aebersold, 2006).
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In 1995, a proteomics term was coined to describe a new field of research as a large-scale
functional proteome (phenotype) encoded by genome (genotype) in a particular cell line,
tissue or organism (Anderson and Seilhamer, 1997, Wasinger et al., 1995, Wilkins et al.,
1996). In respect to the complexity of biological systems, mass spectrometry (MS) based
proteomics has been widely recognised as an essential method with high sensitivity for
functional analysis at the protein level (Aebersold and Mann, 2003). There is a general
consensus that the developments in this field are closely tied to the completion of the
genome sequencing database and the advances of particular techniques and concepts, most
notably, the enhanced separation of peptides by coupling online liquid chromatographic (LC-
MS) and the introduction of soft protein/peptide ionisation ESI and MALDI. The latter is
recognised by the Nobel Prize of 2002 to Fenn and Tanaka (Fenn et al., 1989, Tanaka,
2003).
Every MS system has the following components (Figure 1-5): the Inlet system, ion source,
mass analyser and mass spectrum detector. Based on these components, MS can accomplish
several tasks including: ionising the neutral molecules contained in the introduced analytes,
providing indirect measurement of the mass by separating ions based on mass to charge
(m/z), detecting ions and plotting their m/z verses abundances, and in the tandem MS
(MS/MS), the ions of interest are fragmented to provide structural information and peptide
sequencing by means of low-energy collision-induced dissociation (CID), high energy
collision-induced dissociation, and electron transfer dissociation (ETD).
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For secure identification of very small amounts in complex mixtures, resolving power and
mass accuracy are two most important parameters used to evaluate the performance of MS to
separate and distinguish various constituents of the mixture with accurate mass detection.
These two parameters determine the selectivity (resolution) and sensitivity (accuracy) of
mass analysers.
It is fundamental to the researcher, when selecting a method of choice, to link the selected
approach to the research objectives; therefore, a priori knowledge originates from addressing
many topical questions. For example, why do we use MS in molecular sciences? Or, how
many MS analysers are available and why should we carefully select between them?
The heart of a mass spectrometer is a mass analyser. To understand the importance of this
part of a whole MS, the emphasis should lay on two important parameters: high resolution
and accuracy of mass spectrometry (Koulman et al., 2009). Hence mass is a fundamentally
important piece of information, and to obtain highly accurate mass measurements, the MS
analysers have evolved tremendously during recent decades. As of late developed MS
analysers is the Orbitrap mass analyser (Eliuk and Makarov, 2015). In the standard MS
analysis, ions are generated and their mass to charge ratios is measured (m/z), but not the
structure or abundance of ions. Tandem mass spectrometry (MS/MS) led to the identification
of structures more feasible by adding further fragmentation step in the analysis. There are
two classes of tandem MS experiments: First, tandem in space: making ions, mass selecting
ions, fragmentation (dissociation), and measuring products all the time, so that everything is
conducted in parallel, but at different physical locations, i.e. all processes are occurring all
the time, but separated in space, and ions are transmitted from one place to another, which
comprises, for example, triple/tandem quadrupole (QqQ) and Orbitrap hybrid instruments.
Secondly, tandem in time: it is in situ ionisation which is truly a tandem in time experiment,
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where ions generation, mass selection, ions fragmentation, and measure the products all in
the same physical space, but the processes are separated in time. Examples of this type of
tandem mass spectrometry include, but are not limited to, linear ion traps (LIT) and Fourier
transform ion cyclotron resonance (FT-ICR) instruments (Hird et al., 2014).
To meet the growing demands of high performance MS analysers that combine both high
mass resolution and accurate mass detection (HR/AM), the Orbitrap was coupled with linear
trap mass analysis (Eliuk and Makarov, 2015). This hybridisation in technology has helped
to develop hybrid instruments, where they combine transmission and trapping events. Linear
ion trapping leads to an enhancement of speed and sensitivity for both LC-MS and tandem
LC-MS/MS detection, providing multiple measurements for the parental ions (MSn)
followed by fragmentations of the precursors and the production of spectra for those
fragmented ions at high rates suiting the needs of large scale proteomics (Glish and
Burinsky, 2008).
Back to 2005, the first commercial release of this hybrid instrument (LTQ-Orbitrap mass
spectrometer) was introduced by Thermo Fisher Scientific (former Thermo Electron)
(Makarov et al., 2006). Figure 1-4 shows the design of the LTQ-Orbitrap mass analyser.
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Figure 1-4: Schematic of the LTQ-Orbitrap mass spectrometer.
Hybridisation of the traditional linear ion trap with Orbitrap mass analysers. Adapted from
(Eliuk and Makarov, 2015).
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The most common types of discovery proteomics fall into three main categories: (1) global
proteomics aimed to identify proteins in the sample and the changes in abundance associated
with biological perturbations, (2) studying the global post-translational modifications (PTM),
and, (3) affinity proteomics to identify proteins that interact with other proteins, nucleic
acids or small molecules.
It is now known, as demonstrated by large group proteomics projects such as PROSPECTS
(Proteomics Specification in Space and Time), that there are a number of important
differences between proteomics and transcriptomics (Lamond et al., 2012). First, proteomics
technology is a reliable and truly quantitative branch of research that can provide
information about the actual changes in the protein level, considering the life cycle of protein
from synthesis through ultimate degradation (post-translational modifications) and relating
that to the rapid dynamic changes (spatial) in real time (temporal) in the cell signalling
pathways, while transcriptomics is less likely to provide that information. Secondly, the
localisation of subcellular proteins, both on a large scale and under endogenous conditions,
can be elucidated on large scale proteomics workflows. In sum, proteomics is not a replicate
of transcriptomic data, though it can add more unique and accurately obtained information to
existing knowledge gained from transcriptomics (Lamond et al., 2012).
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Figure 1-5: MS based proteomics pipeline
Complex sample mixtures of proteins are obtained from cell lysate, tissue or subcellular
fractionation. The solubilised proteins in the sample mixture can be subjected to further
fractionation using gel electrophoresis before the tryptic digestion of the peptides (1).
Molecular species generated from Electrospray liquid eluted techniques (LC-ESI) Liquid is
introduced to MS analyser (2,3). The selected parent peptides are fragmented (4) and
generated MS/MS spectra are analysed followed by selecting an appropriate downstream
bioinformatics application (5). Adapted from (Walther and Mann, 2010).
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1.4.1 Quantitative Stable Isotope Labelling by Amino Acids in Cell Culture
(SILAC)
Currently, MS provides a powerful analytical technique for the study, characterisation and
quantitation of proteins. The high complexity of a proteomics sample poses a significant
analytical challenge and places demands on LC-MS workflows. LC-MS experiments can be
designed to generate quantitative data by following one of two approaches, either label or
label-free. Hence, MS is not a quantitative method per se, and protein ID is sufficient for
locating the key players in biological pathways; achieving a deeper understanding requires
an investigation into the differential regulation of proteins between two cellular states
(treated vs. control) (Walther and Mann, 2010).
This has resulted in a growing emphasis on quantitative workflows; alternative methods have
been developed to gain accurate absolute or relative quantitation of proteomes on a large
scale, such as chemical isobaric (iTRAQ) (Ross et al., 2004) and metabolic labelling
(SILAC) of digested peptides (Ong et al., 2002). Although thousands of peptides can be
generated from a single run of LC-MS on a complex mixture, biased data can be expected
with different runs (replicates) and subsequent protein quantification and identification
would be meaningless (Michalski et al., 2011). Therefore, selecting the most suitable and
relevant labelling strategy is a current trend in achieving accuracy in abundant measurements
(quantity) of identified proteins, allowing an in-depth analysis of the systems biology with a
better resolution (Cox and Mann, 2011). SILAC labelling is a method of choice for
metabolic labelling of entire proteomes in cell culture, and full incorporation can be achieved
with several cell culture doublings in the media containing natural amino acids enriched with
stable isotopes, such as 13C and 15N. A shift in mass can be determined by LC-MS/MS
(tandem mass spectrometer) in the parent ions (precursors) and the fragmented ions of light
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and heavy peptide pairs (light and heavy SILAC) (Ong, 2012). The downstream analysis of
the generated LC-MS/MS data can acquire better identification and quantification by
integrating bioinformatics software, notably MaxQuant and a peptide search engine
(Andromeda) integrated into MaxQuant (Michalski et al., 2011).
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1.4.2 Quantitative subcellular proteomics
Protein is not a static component of the cell, and it is a continual challenge facing the
biologist to address the impact of a specific treatment on protein localisation and how to
measure those changes. Several proteomics approaches have been used to quantitatively to
measure the protein abundance/flux in response to biological perturbations. For example,
Andersen et al. (2005) used the SILAC labelling to assess the abundance/redistribution
between the nucleolus and nucleus of 489 endogenous nucleolar proteins in response to three
metabolic inhibitors.
Spatial-based proteomics evolved because the metabolic labelling (SILAC) allowed the
comparison of two SILAC ratios between two experiments, i.e., under different stimuli the
changes in location from one compartment to another can be quantified; therefore, allowing
for the characterisation of dynamic changes in protein subcellular localisation as a result of
induced DNA damage of HCT116 cells treated with etoposide (Boisvert et al., 2010).
Many proteomics methods have allowed researchers to study the localisation of proteins into
specific organelle and subcellular structural compartments following various sets of
enrichment protocols (Andersen et al., 2002, Andersen and Mann, 2006, Dunkley et al.,
2004, Sadowski et al., 2006). Collectively, these methods are known as organellar
proteomics or subcellular proteomics; hence, these methods are quantitative approaches and
differ from the high-throughput proteomics such as protein correlation profiling (Wiese et
al., 2007) or the localisation of organelle proteins by isotope tagging (LOPIT) (Dunkley et
al., 2004), in two senses. First, they can provide insight into the protein localisation
considering the nature of the protein and its redistribution dynamicity to different locations,
under biological perturbations, and not exclusively expressed and/or localised to a specific
subcellular structure (Gauthier and Lazure, 2008, Hall et al., 2009, Qattan et al., 2010,
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Qattan et al., 2012). Second, they can provide the relative and/or absolute measures of the
protein abundance at different cellular subsets and physiological states (Baqader et al., 2014,
Mulvey et al., 2013, Pinto et al., 2014). It is necessary here to differentiate between the
single organelle proteomics and the systematic approach of subcellular proteomics. Although
both methods are based a combination of biochemical enrichment protocols and MS-based
proteomics, they differ in that the former provides a list of the identified proteins in a
specific and isolated organelle, while the latter can provide a quantitative overview of
protein distribution/change over multiple compartments in broad biological systems (Drissi
et al., 2013, Gauthier and Lazure, 2008).
In general, methods of subcellular fractionation aim to reduce the complexity of the cellular
system prior to the proteomics workflow, and enrich the proteome samples with the isolated
target organelle(s)/subcellular structures from the rest of cellular compartments. Figure 1-6
shows that the eukaryotic cells are multi-compartmental, and that the purification of specific
set(s) of the subcellular structures requires either classical approaches, such as deferential
centrifugation (Lee et al., 2010), density gradient centrifugation (de Araujo et al., 2008,
Qattan et al., 2010) and differential detergent fractionation (Abdolzade-Bavil et al., 2004,
Ramsby et al., 1994), or emerging methods of fractionation, such as free-flow
electrophoresis (Zischka et al., 2006), immunoaffinity purification (Ackermann and Berna,
2007) and fluorescent-assisted organelle sorting (FAOS) (Bock et al., 1997, Gauthier and
Lazure, 2008). Protein content in the original cell line/tissues are vulnerable to variation
during multistep enrichment and fractionation phases; therefore, variability induced by pre-
MS steps and the development of a reliable method for quantitative analysis is still
considered a challenge (Wasinger et al., 2013). Several methods can be used to roughly
characterise the purity of the generated fraction using known localised protein markers, and
such markers are less sensitive in detecting contamination than MS/MS (Drissi et al., 2013).
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These methods include: enzymatic activity of a particular organelle (Takatalo et al., 2006),
immunofluorescence microscopy (Takatalo et al., 2006) and immunoblotting for the
presence or absence of a specific known protein (Qattan et al., 2010, Qattan et al., 2012). No
one can guarantee quantitative precision based on quantitative mass spectrometry alone;
protein concentration in the original sample is vulnerable to variation during multistep
enrichment and fractionation phase (Cox and Mann, 2011, Wasinger et al., 2013).
Considering the variability induced by pre-MS steps, the development of a reliable method
for quantitative analysis remains a challenge (Wasinger et al., 2013). However, continued
assessment of the variability introducing methods has led some researchers to produce data
with a high degree of accuracy and reproducibility (Mulvey et al., 2013, Pinto et al., 2014,
Qattan et al., 2010, Qattan et al., 2012). The dynamics of the subcellular distribution of
thousands of proteins in MCF-7, under two different biological perturbations, were
investigated in the current project using a high-throughput large scale proteomic quantitative
approach (SILAC labelling) taking advantage of the developed subcellular spatial razor
model for interpretation (Baqader et al., 2014, Mulvey et al., 2013, Pinto et al., 2014). Figure
1-7 shows the MS-based quantitative proteomics workflow used in this project combining
the subcellular proteomics and differential isotope labelling by metabolic incorporation.
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The subcellular spatial razor formulation can distinguish between changes in total protein
abundance (St) and redistribution (Sn/Sc) (Figure 1-8) to/from a target organelle (e.g. the
nucleus). For all three of systems analysed with this framework, correlation between changes
in total abundance and in subcellular nuclear/cytoplasmic redistribution has been found to be
low, i.e., changes in compartmental abundance do not simply mirror changes in total protein
abundance (Baqader et al., 2014, Pinto et al., 2014). The orthogonal basis set {St, Sc/St, Sn/St}
for the three measured SILAC ratios separates changes in total protein abundance (St) from a
distribution plane (Sc/St, Sn/St) that reflects the redistribution of a protein. Conservation of
mass (highly reproducible subcellular fractionation and no differential protein losses
between stimulated/unstimulated samples during MS sample preparation) requires that the
data points lie in 2 quadrants corresponding to N → C or C → N redistribution of the 
protein. The subcellular spatial razor model assumes that a given protein can be in the
nucleus (n) and in the cytoplasm (c) for both unstimulated (u) cells and stimulated (s) cells.
The corresponding abundances (Figure 1-8) are . There are three
SILAC ratios given by:
, [1]
,
.
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The values for the fractions of the protein in the nucleus in unstimulated and stimulated cells,
, are closely related to the SILAC ratios:
, [2]
. Furthermore, the fractions
are closely related to the parameters used in a three-dimensional orthogonal basis set for the
experimental results (see below).
, [3]
Experimental application of the spatial razor requires fractionating the total cellular proteins
(total fraction) into two subcellular fractions such that: nucleus-enriched fraction + nucleus-
depleted fraction (cytoplasm) = total fraction and measuring the set of SILAC ratios {Sn, Sc,
St}. Although formulated here for the nucleus, a spatial razor could also be applied to other
subcellular locations through the use of sample triplets such as {mitochondria-enriched,
mitochondria-depleted, total-fraction}.
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Figure 1-6: Sub-compartmental composition of eukaryotic cell.
Adapted from (Lee et al., 2010).
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Figure 1-7: Workflow for subcellular analysis with quantitative shotgun proteomics
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Figure 1-8: Subcellular spatial razor model.
A protein (A) has different abundances in unstimulated (u) or stimulated (s) cells and in the
nucleus (n) or in the cytoplasm (c). The ratio of the abundance of the protein between
unstimulated/stimulated cells is measured by SILAC isotope ratios for the nucleus (Sn), the
cytoplasm (Sc) and for a total cell lysate (St).
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1.5 Objectives of this project
The nuclear genome is dramatically altered (unstable) in cancer cells, to escape the apoptotic
growth restrictions imposed on normal cells while mitochondrion associated metabolism
abnormality is considered to be an essential supplier of the new cellular components during
cancer proliferation (Hanahan and Weinberg, 2011). Indeed, multiple lines of evidence
primarily view cancer as a metabolic disease and more dependent on aerobic glycolysis
and/or glutaminolysis to provide new cellular components for the new proliferated
populations of cancer cells (Vander Heiden et al., 2009). Further findings suggest that
growth response in cancer cells can be mediated by ER in one of two ways: classical
genomic pathways that have a very slow onset of action, several hours or days, and
cytoplasmic signalling pathways that can occur in seconds. In this manner, oestrogen could
rapidly act on mitochondria, consequently, the cross talk between subcellular organelles,
nucleus and mitochondria, seem to be channelled through oestrogen-mediated signalling
pathways involved in the proliferation (Chen et al., 2009). For these reasons, the overall goal
of this project is to use the high throughput proteomics technology combined with the
enrichment of subcellular target proteins after SILAC labelling to elucidate the possible
relationship between major changes in the compartmental proteins and the cellular response
to biological perturbations of oestrogen (E2) and tamoxifen (4-OHT) in the MCF-7 breast
cancer cell line.
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To that end, the following aims are specifically addressed:
1. To quantify the spatial dynamics of subcellular large scale proteomics of MCF-7
cells under oestrogenic and anti- oestrogenic stimulation.
2. To apply quantitative shotgun SILAC-based global proteomics to reveal changes in
protein expression and redistribution between subcellular compartments in response
to the biological perturbations E2 and 4-OHT.
3. To validate the spatial razor formulation in estimating whether the changes in
protein quantitation are due to changes in the total abundance or re-localisation of
proteins between subcellular compartments.
4. To identify major pathways and groups of proteins related to oestrogen-dependent
breast cancer and/or drug resistance.
Such quantifications of the dynamical response under biological perturbations will help to
gain a better insight into spatial control of breast cancer and elucidate the possible
mechanisms underlying the proliferative action of oestrogen and/or the partial proliferative
action of tamoxifen that may lead to the acquisition of resistance over time.
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Chapter 2 Materials and methods:
2.1 Starting cell culture from frozen cells
The SILAC protein quantisation kit with DMEM was ordered from the Thermo Scientific
(Rockford, USA, 89983) and contained all reagents for isotopic labelling including the
following: SILAC Dulbecco’s Modified Eagle’s Medium, 2 × 500mL; 13C6 L-Lysine-2HCl
(heavy Lysine), 50mg; L-Lysine-2HCl (light Lysine), 50mg; L-Arginine-HCl (light
Arginine), 2 × 50mg; and Dialyzed Foetal Bovine Serum (DFBS), 2 × 50mL (separate
dispatching at -20°C). For double labelling, 13C6 15N4 L-Arginine-HCl (heavy Arginine)
was ordered separately (89990). Storage, preparation, and SILAC procedure were carried out
as per the manufacturer's instructions.
2.1.1 Cell counting
Following the trypsinization of cells, uniform suspension of containing a single cell was
obtained by diluting the cells in a suitable volume of medium to ensure that the cells are
neither too diluted nor too concentrated. A 1:1 dilution of the cell suspension was prepared
in trypan blue solution, 0.4% (Thermo Fisher Scientific, UK) and pipetted up and down
several times to ensure a uniform cell suspension, and 10 µl out of the trypan blue-cell
suspension was used to charge one chamber of a hemocytometer (Hausser Scientific,
Horsham, PA, USA). A trypan blue-cell suspension was transferred to one of the chambers
of the hemocytometer and placed carefully on the edge of the cover slip to fill the chamber
by capillary action. The phase contrast microscopy visualized the live cells (unstained) and
dead cells (blue stained) at 40x magnification. The cells in four corner squares plus the
middle square were counted, the total number of cells average overlying 1 mm2 was doubled,
for the dilution with trypan blue, to obtain the number of cells per ml suspension.
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2.2 Metabolic labelling (SILAC)
The SILAC protein quantisation kit with DMEM was ordered from the Thermo Scientific,
Rockford, USA (89983) and contained all reagents for isotopic labelling including the
following: SILAC Dulbecco’s Modified Eagle’s Medium, 2 × 500mL; 13C6 L-Lysine-2HCl
(heavy Lysine), 50mg; L-Lysine-2HCl (light Lysine), 50mg; L-Arginine-HCl (light
Arginine), 2 × 50mg; and Dialyzed Foetal Bovine Serum (DFBS), 2 × 50mL (separate
dispatching at -20°C). For double labelling, 13C6 15N4 L-Arginine-HCl (heavy Arginine)
was ordered separately (89990). Storage, preparation, and SILAC procedure were carried out
as per the manufacturer's instructions.
2.2.1 SILAC media preparation
Each SILAC Dulbecco’s Modified Eagle’s Medium ( 2 × 500mL) was supplemented with
10% of thawed dialyzed FBS and 1% antibiotic antimycotic (10,000 units penicillin, 10 mg
streptomycin, and 25μg Amphotericin B per ml). Heavy amino acids, 13C6 L-Lysine-2HCl, 
and 13C6 15N4 L-Arginine-HCl were dissolved in one of the DMEM and used later for
“heavy” isotope metabolic labelling, while the light amino acids, L-Lysine-2HCl, and L-
Arginine-HCl, were dissolved in a medium and used later to adapt cells in the natural amino
acids that referred to as “light”. Media containing dissolved amino acids were sterile-filtered
using a 0.22 µm filter (TPP, Switzerland) and stored at 4 °C.
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2.2.2 Adaptation phase
MCF-7 cells were adapted to grow in a DMEM: F12 medium; the cells were then divided
into two different populations and seeded into two culture flasks with one containing non-
radioactive isotopic labelled heavy amino acids (13C6 L-Lysine-2HCl and 13C6 15N4 L-
Arginine-HCl) and the other containing normal essential amino acids (L-Lysine-2HCl and L-
Arginine-HCl) in SILAC media. Both cell populations were grown at 37°C in a humidified
incubator of 5% CO2 and were passaged for at least five cell doublings by splitting cells at
70-80% confluence. After passage five, incorporation efficiency of heavy amino acids,
(13C6 L-Lysine-2HCl and 13C6 15N4 L-Arginine-HCl) was verified by comparing MS
analysis of peptides that were heavy- and light-labelled in gel tryptic digested proteins. After
full isotopic incorporation was verified to be fully incorporated (>95%), both cells
populations (light and heavy) were expanded to the desired number required for treatment
and subsequent fractionation.
2.2.3 Treatment phase
2.2.3.1 E2
After six passages, cells were allowed to reach 70% confluency in both heavy and light
SILAC media. To eliminate the hormonal effect of phenol red SILAC growth medium that
contained phenol red were aspirated off, flasks were washed with PBS, and media changed
into the phenol red free MEM for SILAC (Thermo Scientific, Rockford, USA, 88214) with
the same “Heavy” and “Light” amino acids labelling. After 24 h, oestrogen (17 beta-
oestradiol, E2, Sigma) was added into the cells grown in a heavy SILAC medium to a final
concentration of 10 nM, and the control cells (light SILAC medium) were treated with the
0.1% of vehicle ethanol. Finally, both cell pools (E2 stimulated and control) were re-
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incubated at 37°C with 5% CO2 for 48 h further with one more new media replacement at an
interval of 24 h calculated from the time of stimulation.
2.2.3.2 4-OHT
In order to deliver the treatment of 1 µM 4-OHT (Sigma-Aldrich, H7904) into the desired
number of cells for the subsequent fractionation, the SILAC media were changed into the
phenol red free MEM for SILAC supplemented with 10% dialyzed FBS and 1% of antibiotic
antimycotic solution and incubated for 24 hours at 37°C in a humidified incubator of 5%
CO2. Both cells populations were subjected to further 24 h (total of 48 h) incubation in a
fresh phenol red free MEM for SILAC before delivering the dose of treatment into the heavy
labelled cells population. After 48 h, the protein abundance in a heavy cell population was
altered by applying a dose of 1 µM 4-OHT for further 24 hours incubation while the media
were changed into a fresh phenol red free MEM for SILAC (without treatment) in the light
labelled cell population.
2.2.4 Cytotoxicity/proliferation assay
The concentration of 1 μM (10-6M) of 4-OHT was previously used in different laboratories,
to name a few. It was selected for complete inhibition of oestrogen-dependent ZR-75-1 cells
without influencing the growth of tamoxifen-resistant derivatives (Meijer et al., 2006). This
dose has been routinely used because of the absence of toxicity and to effectively counter
variations in oestrogen content of different batches of bovine serum (Lykkesfeldt et al.,
1984, van Agthoven et al., 2012) and an IC50 concentration of a drug that is required for
50% inhibition of in vitro tamoxifen is 1000 nM (Kijima et al., 2005). Therefore, in this
project, the dose of 4-OHT was selected to have a non-cytotoxic (non-lethal dose) effect, but
a cytostatic (growth inhibition) effect on MCF-7 cells. Cell survival/cytotoxicity assay was
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assessed using cell counting kit-8 reagent (CCK-8) (Dojindo Laboratories, Kumamoto,
Japan) with various doses of 4-OHT including choosing a dose of 1 μM (10-6M).
2.2.4.1 Cell preparation and standard curve
To determine the cell number to be used in the viability assay and the cck-8 incubation time
specific for the MCF-7 cell line, the number of cells was plotted against the absorbance in
order to establish the standard curve. The cells were recovered from the culture flasks and
the cell number in the suspension was adjusted to 5x105 cells/ml. The wells of 96-well
microplate were prepared with 100 µl of media. Then, 100 µl of 5x104 cells suspended to the
first well was added and made triplicate serial dilutions of 2.5x104, 1.25x104 and 6.25x103 in
a 96-well plate. However, the last well was reserved for the negative control (blank). This
well contained only media (no cells) for measurement of background.
For the first time, the 96-well microplate was incubated for 24-48 h in the CO2 incubator to
determine the optimal growth time for the standard curve. 10 µl of cell counting kit-8
reagent (one tenth of the media containing cells) was added to each well on the 96-well
microplate. The plate was placed in a CO2 incubator to react for 1-4 h, and the colorimetric
readings used a microplate reader using a filter for 450 nm at different time point intervals,
from 1 to 4 h, to plot the number of cells versus the absorbance and establish the standard
curve. The upper portion (80%) of the linear range of the standard curve was used to adjust
the number of the cells to be used with the test substance (4-OHT) to assess the cell
proliferation and cell toxicity.
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2.2.4.2 Cell survival/cytotoxicity assay
A 200 µM stock solution of 4-OHT was prepared in absolute ethanol and stored at -20°C.
Cells were plated at density of 12.5  103 cells by adding 100 µl in a 96-well plate and
incubated for 24 h at 37°C in a humidified incubator of 5% CO2. Upon confluence, media
were changed into DMEM-F12 phenol red-free medium supplemented with 10% charcoal
treated FBS and medium was changed every 24 h before 4-OHT stimulation. At 48 h, cells
were treated with various concentrations of 4-OHT (0.5, 0.1, 1.5, 2.0 μM) in three replicates 
for each dose. With each dose, a negative control was plated with the same cell number and
treated with an equivalent volume of 0.1% ethanol (maximum 0.1%). After 24 hr from the
stimulation time point, 10 µl of cell counting kit-8 (one tenth of the cells plus media) was
added to each well including the negative control and blank wells. The plate was placed back
in a CO2 incubator for 3:30 hr. The colorimetric readings were taken on a microplate reader
using a filter for 450 nm. To calculate the survival rate (%) was obtained for the samples and
the negative control using the following equation:
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2.3 Sample preparation
Differential centrifugation was used to obtain the nuclear, cytoplasmic, and total lysate
fractions according to the protocol previously described (Pinto et al., 2014, Qattan et al.,
2012). All the subsequent steps were performed at 4°C with all buffers containing protease
and phosphatase inhibitors cocktail tablets (Roch,UK). Light- and heavy-labelled cells
populations grown as monolayers in T75 flasks were washed in ice-cold phosphate buffer
saline (PBS) pH 7.4, for three times, cells were scraped from culture flasks on ice using a
plastic cell scraper and collected in 15mL conical centrifuge tubes.
2.3.1 Total lysate
12 x106 cells were scraped, from heavy and light cells populations in ice cold PBS, and the
pellets were collected by cold centrifugation at 300 x g for 5 min. Two pellets were collected
and each pellet was dissolved and re-suspended in a cold RIPA lysis buffer (50 mM Tris-
HCL at pH 7.5, 300 mM NaCl, 1 % NP40, 0.5 % Sodium deoxycholate, 0.1 % SDS, 1 mM
EDTA) and transferred to a pre-chilled 1.5 ml microcentrifuge tube, the mixture was agitated
on ice for 15-30 min (vortexed every 5 min) and centrifuged at 300 x g for 5 min (Heraeus
Biofuge Pico, Thermo Fisher Scientific, U.K.). The cell debris was pelleted by cold
centrifugation at 300 x g for 5 min (Heraeus Biofuge Pico, Thermo Fisher Scientific, U.K.),
and the supernatant was collected as total lysate (T).
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2.3.2 Nuclear and cytoplasmic fraction
The cells were counted and 12x106 cells from light and heavy cell populations were
recovered from the culture flasks in a cold PBS using a manual rubber policeman scraper.
The pellets were obtained by cold centrifugation at 300 x g for 10 min (Mistral 3000i
Refrigerated Centrifuge, 4312-708 BS 4402 rotor). Each pellet was allowed to stand on ice
for 10 min ,in a hypotonic osmotic buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl
at pH 7.4) which was used to swell the cell membrane of the cells; the supernatant was
removed by a subsequent step centrifugation at 300 x g for 10 min (Mistral 3000i
Refrigerated Centrifuge, 4312-708 BS 4402 rotor). Each pellet was suspended in ice cold
isotonic sucrose (breaking) buffer containing (300 mM sucrose, 1 mM EDTA, Heparin 5
U/mL, 10 mM HEPES, 5 mM MgCl2 at pH 7.4), and the cells were homogenized by 10–25
strokes of the pestle of a tight-fitting Dounce homogenizer (0.05-0.08 clearance). Under
phase contract microscope, the suspension was inspected after every 10 strokes and
homogenization was continued until about 90% of cells were broken. The obtained lysate
that contained the subcellular homogony was subjected to a cold centrifugation at 800 x g for
10 min to separate the crude nuclear pellet (N) from the crude post nuclear cytoplasmic
supernatant (C).
To release the nuclear proteins, the nuclear pellet was suspended in a high salt breaking
buffer containing (20 mM HEPES at pH 7.9, 700 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA,
10 % glycerol), for 2 h at 4°C on an end-over-end rotator. The supernatant was collected and
labelled as nuclear fraction (N).
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Both nuclear fraction (N) and post nuclear supernatant (C) were subjected to acetone
precipitation by adding four volumes of 80% acetone at -20 °C for 1 hr, and the pellets were
precipitated by a further cold centrifugation step at 16000 x g (Heraeus Biofuge Pico,
Thermo Fisher Scientific, U.K.) and left to dry. The dried pellets were solubilised in a 1x
protein solubilisation buffer (20 mM PIPES at pH 7.3, 300 mM NaCl, 2 % Triton X-100, 0.2
% SDS, 2 % sodium deoxycholate). The protein concentration, in each fraction, was
quantified using the BCA protein assay kit (Thermo Scientific Pierce, Rockford, USA) by
measuring the absorbance of protein samples at 562nm, see below.
2.3.3 Microplate (BCA) protein assay
Bicinchoninic acid (BCA) protein assay kit (Pierce Biotechnology, US) was used for the
colorimetric detection and quantification of total protein. In this method, bicinchoninic acid
containing reagent is used to enhance the sensitivity and selectivity of the colorimetric
detection of the reduced cuprous cation (Cu+1) by protein in an alkaline medium (the biuret
reaction) (Smith et al., 1985). The purple-coloured reaction product of this assay is
proportional to the protein concentration in the sample and the absorbance of Albumin
Standard (BSA) was diluted over broad working range concentrations (20-2000µg/mL) to
obtain a nearly linear curve. In the microplate, BCA working reagent (WR) was added to the
standards and unknown samples, mixed, and incubated at 37°C for 30 minutes. The plate
was allowed to cool down at RT before the absorbance was measured at λ=562nm. 
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2.3.4 Assessment of subcellular fractionation by western blotting
Fractionation was evaluated by western blot using protein markers for nuclear and
mitochondrial subcellular compartments to assess the protocol’s enrichment capacity.
Therefore, two constitutively protein markers were selected, VDAC, for mitochondrial
localization on the total lysate and cytoplasmic fractions, and Histone H3, for total lysate and
nuclear fractions.
Twenty micrograms of each sample (total lysate, cytoplasm, and nuclear fractions) were
electrophoretically resolved by 12% SDS-PAGE. The resulting gels were transferred to a
PVDF membrane using a Mini trans-blot cell and Powerpac basic power supply (BioRad,
Herts, U.K.) at a constant 100 V/350 mA. After 1 h, the blots were blocked with 5% milk-
TBS-Tween saline buffer (TBST: 20 mM Tris buffer, 150 mM NaCl, 0.1% Tween-20,
pH=7.5) for 2 h at 4°C under slow agitation, followed by a rinse for 5 s in TBST. The
membranes were incubated overnight at 4°C with two different primary antibodies: anti-
VDAC (ab34726, Abcam, Cambridge, U.K.) and anti-Histone H3 (ab1791, Abcam), at
1:1000 and 1:2500 dilutions, respectively. After washing the membranes with TBST three
times (10 min for each washing) under agitation, the membranes were incubated for 1 h with
a secondary antibody conjugated to horseradish peroxidase (#7074, Cell Signalling
Technology, New England BioLabs, Hitchin, U.K.) at a dilution of 1:1000 for VDAC and
1:5000 for H3. The membranes were washed three times with TBST (10 min for each wash)
and with TBS for 5 min, under agitation. Finally, proteins were visualised using
chemiluminescence reagents ECL Plus and Hyper Film (GE Healthcare, Bucks, U.K.) and a
Xograph imaging system Compact x4 (Xograph Healthcare, Stonehouse, U.K.).
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2.4 Sample preparation for mass spectrometry and the “Bottom-up” MS
approach
In-gel digestion protocol was introduced in the proteomics investigations to increase the
protein coverage and the number of identified proteins, however, it has been used for many
years and can be optimized with accumulative experience to the particular objectives of the
experiment (Shevchenko et al., 2006).
2.4.1 SDS-PAGE and in-gel digestion
The solubilised protein concentration was measured in the cytoplasmic, nuclear, and total
lysate sample types (CNT) obtained from the SILAC labelled (heavy) and unlabelled (light)
cell populations. Both labelled and un-labelled protein extracts were mixed in 1:1 ratio for
each sample type and the proteins in the complex samples were separated based on their
molecular sizes using 4–15% SDS-PAGE (BIO-RAD, UK). The separated protein bands
were visualized by silver staining (ProteoSilver Plus, Sigma Aldrich, Poole, U.K.) and the
bands were excised (27-30 horizontal slices/lane) from the gel lane starting from the higher
molecular weight-separated band (top) to the lower molecular weight separated band
(bottom). Each band was cut into 1mm cubs, placed in 96-well plate, and incubated at RT for
10 min in 100 µl ddH2O.
Silver stain was removed by immersion the bands in 100 µl of a distaining solution (100 mM
sodium thiosulfate and 30 mM potassium ferricyanide solutions mixed in a 1:1 (v:v) ratio) at
RT for 10 min. After several washes with ddH2O to pull off the rest of destining solution,
cycles of dehydration (100% acetonitrile), rehydration (25 mM Ammonium bicarbonate),
reduction (10 mM DTT, and alkylation (100 mM Iodoacetamide) for 5 h in the ProGest
Investigator Instrument (DigiLab, Genomics Solutions, Cambs, UK). Upon completion of
these cycles, Trypsin Gold, Mass Spectrometry Grade (Promega, Madison, USA) in 50 mM
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ammonium bicarbonate was added in each well containing dried gel piece and incubated for
overnight at 37°C. Next day, 0.1 formic acid was added to stop the trypsinolysis and the
elute containing the tryptic digested peptides was collected in MS glass vials, vacuum dried
and dissolved in 0.1% formic acid for LC-MS/MS.
2.4.2 Mass spectrometry
LC–MS/MS analysis was performed with an LTQ-Velos mass spectrometer (Thermo Fisher
Scientific). Peptide samples were loaded using a nanoACQUITY UPLC (Waters, U.K.) with
Symmetry C18 180μm × 20 mm (Waters part number 186006527) trapping column for 
desalting and then introduced into the mass spectrometer via a Stonearch fused silica
capillary column 100μm i.d.; 360μm o.d.; 15 cm length; 5μm C18 particles (Nikkyo Technos 
CO, Tokyo, Japan part number NTCC 360/100-5-153) and a nanoelectrospray ion source at
a flow rate at 0.42μL/min. The mobile phase comprised H2O with 0.1% formic acid (buffer
A) and 100% acetonitrile with 0.1% formic acid (buffer B). The gradient ranged from 5% to
30% buffer B in 95 min followed by 30% to 60% B in 15 min and a step gradient to 85% B
for 5 min with a flow of 0.42μL/min, finally a return to the initial conditions of 5%B. The 
full scan precursor MS spectra (400–1600 m/z) were acquired in full profile with the Velos-
Orbitrap analyzer with a resolution of r = 60,000. This was followed by data dependent
MS/MS fragmentation in centroid mode of the most intense ion from the survey scan using
collision induced dissociation (CID) in the linear ion trap: normalized collision energy 35%;
activation Q 0.25; electrospray voltage 1.5kV; capillary temperature 200°C; and isolation
width 2.00. This MS/MS scan event was repeated for the top 20 peaks in the MS survey
scan, the targeted ions were then dynamically excluded for 30s. Singly charged ions were
excluded from the MS/MS analysis and Xcalibur software version 2.1.0 SP1 build 1160
(Thermo Fisher Scientific, U.K.) was used for data acquisition.
80
2.5 Protein identification and quantification
For the samples prepared under the biological perturbation of E2, raw MS files from the
three technical replicates for SILAC total, nucleus, and cytoplasm experiments were
automatically assembled by MaxQuant (version 1.3.0.5) and visualized by Perseus (version
1.3.0.4) software platforms. A matrix of SILAC ratios with rows corresponding to proteins
and columns to different ‘samples’ or ‘conditions’ was automatically assembled by
MaxQuant software and cross-experiment protein ratios were successfully compared for the
quantification of SILAC pairs, identification of individual peptides, and assembly into
protein groups (Cox and Mann, 2008, Cox et al., 2009). The derived peak list generated by
Quant.exe (the first part of MaxQuant) was searched using the Andromeda search engine
against human FASTA files (HUMAN.fasta.gz) obtained from the UNIPROT website:
(ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/proteomes, last
modified 5/10/2012.
For the samples prepared under the biological perturbation of 4-OHT, peptides and proteins
were identified and quantified using the MaxQuant software package (version 1.5.2.8) with
the integrated Andromeda search engine against human FASTA files obtained from the
UNIPROT website:
(ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/proteomes, last
modified 04-12-2014) and the Perseus (version 1.5.1.6) to statistically visualize the obtained
data. The following section describes the settings that were selected, for old version and new
version software, for SILAC identification and quantifications.
The processed raw files from the three technical replicates of each SILAC labelled protein
fractions (total, nuclear, and cytoplasmic) generated tables containing the MaxQuant
parameters, information of the raw file contents, and statistics on the peak detection. The
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protein and peptides tables contained the information on the reconstructed proteins from the
identified peptides in the processed raw files.
MaxQuant parameters for two-state SILAC included multiplicity of 2 for the labelling with
lys0/arg0 as light and lys6/arg10 as heavy proteins. The maximum number of labelled amino
acids that a peptide can have is 3, and 2 maximally tolerated missed cleavages, uploaded
protein sequences that are digested in silico (human FASTA files) was used in the
Andromeda search, carbamidomethyl Cys as a fixed modification, revert decoy mode.
Identification parameters included a value of 0.01 as the desired false discovery rate (1%
FDR) at the peptide and protein match level, which the minimum peptide length is 6 amino
acids. In addition to imposing the desired FDR to consider the protein group identification in
the final table, a value of 1 was selected as the minimum required of total peptides, including
razor and unique peptides, and a minimal Andromeda score of 0 and 40 for accepting
unmodified and modified peptides, respectively. The set of protein quantification parameters
were selected at a minimal ratio count of 2, using unique and razor peptides to calculate the
protein ratios, and only peptides contained specific modifications (Acetyl protein (N-term)
and Oxidation (M)) that were used in addition to unmodified peptides.
82
2.5.1 Correlation and quantisation of proteins across samples.
2.5.1.1 E2
The MaxQuant software package was used to identify and quantify proteins for 16 analysis
sets: (a) each nucleus (N) sample replicate and the union of the three N samples, (b) each
cytoplasm (C) sample replicate and the union of the three C samples, (c) each total (T)
sample and the union of the three T samples, and, (d) each C&N replicate and the union of
the three C&N samples. C&N denotes that for each individual replicate, the MS data for the
C and N samples were jointly processed with MaxQuant to estimate changes in total protein
abundance. For this data, a correction for enrichment of nuclear proteins in the MS data
collection was applied during estimation of total protein abundance. Across all samples, a
total of 4386 different proteins were identified by sequenced peptides. Of these, 110
corresponded to 55 proteins with multiple isoforms from the same gene that could not be
unambiguously resolved across all replicates of the three sample types and were not further
analysed for present purposes.
2.5.1.2 4-OHT
A schematic diagram (Figure 3-13) is showing the number of output datasets that are used in
this study and summarized the data sets that were generated by MaxQuant with the identified
and quantified proteins from the peptide sequencing MS raw files. Three individual
replicates for each sample type cytoplasm (C1, C2, C3), Nucleus (N1, N2, N3), and total
lysate (T1, T2, T3) were processed before merging the replicates in the denoted UNION
dataset. The three replicates of each fraction were merged and processed in MaxQuant to
correlate the distinct protein sequence groups and identify the total number for the union of
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consensus protein groups across the union data set for the three replicates of each fraction
(C-UNION, N-UNION, T-UNION).
2.5.2 Selection of the most significantly changed proteins and bioinformatics:
Two data sets were obtained as the most significant changes proteins obtained from the
merged final dataset of the three sample types (CNT) of the 3493 proteins quantified under
4-OHT stimulation, as follows:
2.5.2.1 The extended significance set (overall response) (Tam-270):
For which proteins were selected as differentially expressed proteins (DE) out of a
total of proteins with measured expression in the merged union of each sample type
(CNT) (Supplementary Table 7). These were obtained using a threshold of 0.05 for
statistical significance adjusted p-value (Sig. B) and ±1 for absolute log2 fold
expression change. To reduce the impact of the relaxed selection criteria, applied to
obtain the Tam-270 significant set, on the downstream bioinformatics, two stringent
criteria were applied using Advaita Bio’s iPathwayGuide
(http://www.advaitabio.com/ipathwayguide): (1) Scoring the pathways based on the
impact analysis as described in (Draghici et al., 2007, Tarca et al., 2009). Two types
of evidence (p-value) were combined in a unique global p-value in this type of
analysis: i) the over-representation analysis (pOVR) verses ii) the perturbation across
the pathway topology that propagated by DE genes/proteins upstream or downstream
a given pathway. This p-value is then corrected for multiple comparisons using
FDR to ensure that the overall percentage of false positives is below the chosen
threshold (<0.05) (Benjamini and Hochberg, 1995). These data were analyzed in the
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context of pathways obtained from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database (Release 73.0+/03-16, Mar 15) (Kanehisa and Goto, 2000,
Kanehisa et al., 2002). The pathway topologies, comprised of genes and their
interactions, are obtained from the KEGG database (Kanehisa and Goto, 2000,
Kanehisa et al., 2010, Kanehisa et al., 2012, Kanehisa et al., 2014).
(2) For Gene (GO) annotation enrichment analysis (Ashburner et al., 2002; Gene
Ontology Consortium, 2004), iPathwayGuide uses the classical over-representation
approach to compute the statistical significance followed by corrected p-value using
the elim method proposed by Alexa et al. (Alexa et al., 2006) to remove the genes
mapped to a significant GO term from more general (higher level) GO terms. These
data were analyzed in the context of gene ontology obtained from the Gene Ontology
Consortium database (2014-Sep19) (Ashburner et al., 2000, Gene Ontology
Consortium, 2001).
2.5.2.2 Core significance set (reliable/specific response) (Tam-97):
All proteins in the CNT dataset were considered as low confidence proteins if they were
identified by only one peptide; therefore, the dataset was filtered by “sort” function to
remove the entries for proteins lacking more than one peptide. Overall, only proteins
identified by at least two peptides (one unique) were considered in the next step of selection.
Hence, some of the remaining proteins were quantified with at least two SILAC ratio counts,
and the list of proteins was further reduced by imposing another filtration criterion of a
minimum three SILAC ratio counts for the reliable quantification of the identified protein.
Based on adjusted P-value below 0.05 (Sig B) and log2 fold changes above 1 or below -1,
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both up-regulated and down-regulated proteins were obtained and used for the downstream
bioinformatics/validation. Of the 916 proteins selected from the correlation data set (CNT)
according to the above mentioned criteria, a set of 97 proteins are showing the most
significant changes, the distribution scores of significance over the CNT are shown in figure
(Figure 3-16) and summarized in Table (Table 3-4). In this data set, 51 proteins were
selected as DE expressed out of a total of 97 proteins with measured expression in the
cytoplasmic fraction (Sc), 51 proteins out of 97 in the nuclear fraction (Sn), and 29 proteins
out of 97 in the total lysate (St). Using InnateDB database (Breuer et al., 2013, Lynn et
al., 2008), these data were analysed in the context of pathways incorporated in InnateDB
database from major public databases including KEGG, Reactome, NetPath, INOH,
BioCarta, and PID and these data were not restricted to immune relevant databases. Hence,
we applied a stringent selection criteria to obtain this list of DE proteins, and we conducted
the downstream analysis to obtain the pathways significantly overrepresented and GO terms
significantly enriched based on uncorrected p-values.
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2.6 Confocal microscopy
2.6.1 Effect of E2 using fluorescence imaging of live cells
MCF-7 cells were grown in DMEM-F12 medium on a 35 mm imaging dish with a glass
bottom (WillCo-dish® "Series GWSt-3512", WillCo Wells, Amsterdam, Netherlands). Upon
reaching 60% confluence, the cells were washed with PBS and incubated for 48 h with
DMEM-F12 phenol red-free medium supplemented with 10% charcoal treated FBS and
medium was changed every 24 h before E2 stimulation. At 48 h, cells were divided into two
parts, non-stimulated (control) and stimulated with 10 nM E2 for further 24 h. After 24 h
post-oestrogen stimulation, cells were washed twice in 1x PBS+ (137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4 x 2H2O, 1.8 mM KH2PO4, 1mM CaCl2, 0.5mM MgCl2 x 6H2O at
pH 7.4). For mitochondrial labelling, each dish of treated and untreated cells was incubated
for 30 min with 20 nM, 100 nM, and 200 nM of MitoTracker Green (M7514 from Life
Technology) in PBS+ buffer at 37°C, 5% CO2. Before respective nuclear labelling, cells
were washed twice with PBS+ buffer and then incubated with 1 µg/ml Hoechst 33342
nuclear probe (R37605 from Life Technology), in dark at room temperature, for 30 further
min. Prior to imaging, each dish was washed three times with PBS+ buffer, each wash
followed by incubation for five minutes at 37°C in 5% CO2. After the final wash, HEPES
containing phenol red and serum free medium was added to each dish to maintain cells alive
during confocal imaging. Mitochondria and nucleus were visualized by Perkin Elmer
Ultraview Vox spinning disc confocal microscope equipped with ×63 Plan Apo (NA 1.4) oil
immersion objective using fluorescence excitation (Ex) and emission (Em) of (490/516nm)
and (353/483nm), respectively.
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2.6.2 Effects of 4-OHT using fixed cell fluorescence staining
To observe the changes in the cellular morphology in the treated and non-treated cells, the
cellular (nuclear membrane(s), mitochondria, fibres, and nucleoli) and nuclear staining was
combined using the Chromeo Red Fluorescent Fixed Cell Staining Kit (Active Motif
Europe). Cells were grown to the desired confluence in DMEM-F12 medium on coverslips
(#1.5 thickness, 13 mm diameter) inside a 24-well plate. The phenol red containing medium
was aspirated off and replaced with a fresh phenol free DMEM/F12 supplemented with 10%
charcoal treated FBS for 48 h at 37°C in a humidified incubator of 5% CO2, with the culture
medium replaced every 24 h. The control cells were treated with ethanol (vehicle) and the
treated cells with 1 µM 4-OHT and incubated further for 24 h at 10 min at 37°/5% CO2.
Both control and treated cells were washed with cold PBS and fixed by adding 100% ethanol
and the 24-well plate was placed at -20°C for 20 min (manufacturer’s instructions). The
fixed cells were washed twice with PBS and incubated with 1 µM of diluted cell stain
solution in PBS at room temperature (protected from light) for 30 min. The stained cells on
the coverslips were mounted on glass slides using MAXflour DAPI Mounting Medium and
the coverslips were sealed with nail polish prior to imaging. The images were obtained using
Confocal Laser Scanning Module LSM 510 with ×63 oil immersion objective and the DAPI
stained nuclei was detected using a standard DAPI filter set (370-410 nm/435-485 nm). To
detect the cellular stain in combination with stained nuclei, the fluorescent spectra were
separated using a filter set (550-580 nm/590-650 nm).
88
2.6.3 Immunofluorescence validation
2.6.3.1 Subcellular localization of proteins under E2 stimulation
Cells were grown in DMEM-F12 medium on glass cover slips (#1.5 thickness, 13 mm
diameter) and treated as described in the live cell fluorescence microscopy section. Control
(no E2 starvation/stimulation), unstimulated, and stimulated cells were then fixed in 4%
paraformaldehyde for 10 minutes and permeabilized with a fresh 0.3 % Triton X-100
solution in PBS for 5 min. After blocking with 5% BSA in PBS for 1 hour at room
temperature, the stimulated and unstimulated cells were both incubated overnight at 4 °`C
with primary Anti-Rabbit antibodies to NQO1 (ab34173, Abcam) and PARK7/DJ1
(ab76008, Abcam) diluted in 1% BSA in PBS according to the manufacturer's specifications.
Secondary antibody (green) incubation was performed for 2 h at room temperature in the
dark using goat Anti-Rabbit IgG H&L (DyLight 488) antibody (ab96899, abcam) diluted
1/250 in 1% BSA/PBS. Control coverslips were divided into two parts: a control-A labelled
coverslip was incubated only with secondary antibody, while the control-B coverslip with
both anti-PARK7/DJ1 and secondary antibodies. All coverslips were then stained with 1.43
µM of DAPI (D3571, Invitrogen) and incubated for 5 min at room temperature in the dark.
In all procedures, every step was followed by washing with PBS for three times. Finally,
cover slips were mounted with the Dako Fluorescent Mounting Medium. The
immunofluorescence images were obtained with a Perkin Elmer Ultraview Vox spinning
disc confocal microscope equipped with ×63 Plan Apo (NA 1.4) oil immersion objective and
nuclei were visualised using Ex of 358 nm and Em of 461 nm.
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2.6.3.2 Subcellular localization of proteins under 4-OHT stimulation
MCF-7 cells were seeded on coverslips (#1.5 thickness, 13 mm diameter) inside 24-well
plate grown under the same growth condition described in the florescence staining section.
The cells were exposed to a dose of 1 µM 4-OHT (stimulated cells) and were vehicle treated
(non-stimulated control) for 24 hr prior to fixation and immunolabelling. At room
temperature, the cells were fixed on coverslips in 4% (w/v) paraformaldehyde for 10 min,
permeabilized with 0.3 % Triton X-100 detergent for 5 min at room temperature, and
blocked with 5% BSA in PBS for 1 hour. The stimulated and non-stimulated cells were
incubated with with primary Anti-Rabbit antibodies to MTCO2 antibody (ab79393, 5µg/ml)
and CASPASE-14 (ab174847, 1/250) overnight at 4°C. Next day, a further 1 h incubation at
room temperature was conducted with goat polyclonal secondary antibody to rabbit IgG -
H&L (Green DyLight® 488), pre-adsorbed (ab96899) at 1/1000 dilution for primary anti-
MTCO2 antibody and 1/250 for primary anti-CASPASE antibody. The unspecific binding
was assessed by incubating the cells with only secondary antibody at 1/1000 and 1/250
dilutions for 1 h at room temperature. DAPI (D3571, Invitrogen) (Excitation/Emission (nm)
358/461) was used at 1.43 µM concentration to stain the nuclei of fixed cells for 5 min in
dark at room temperature. Prior to imaging with Confocal Laser Scanning Module LSM 510
(×63 oil immersion objective), coverslips were mounted on glass slides using Vectashield
antifade mounting medium (Vector Labs, H-1000) and sealed with nail polish.
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Chapter 3 Results
3.1 Part-I: Systematic Nucleo-Cytoplasmic Trafficking of Proteins Following
Exposure of MCF-7 Breast Cancer Cells to Oestradiol
Despite scientific progress in diagnosis and treatment, breast cancer continues to be one of
the main causes of death in women. Excluding hereditary predispositions to the onset of this
disease, reproductive aspects, such as early menarche and late menopause or an advanced
age at the first pregnancy, or behavioral aspects, such as the increased use of hormone
replacement therapy, are factors positively correlated to a higher risk of breast cancer
occurrence, and all of these factors involve a more prolonged exposure to sex hormones,
primarily estrogens (Colditz, 1998, Henderson and Bernstein, 1991). Extended exposure to
exogenous or endogenous damaging agents causes an accumulation of irreversible
abnormalities in the genome and epigenome that reprogram the cell to accelerate growth and
to inhibit its death. Many investigations at the cellular level have been based on measuring
gene expression of breast cancer cells using transcriptomic and molecular biology
techniques. There are imperative reasons (Chen and Yates, 2007, Laronga and Drake, 2007)
to supplement this research with high quality as well as quantity output proteomics
strategies (high throughput) to leverage automation to acquire inside and out comprehension
of the miniscule premise of malignancy. These incorporate that protein abundance might be
not quite the same as transcript plenitude and that for genetic variation, translation and
protein stability might be more determinants for protein abundance than transcript levels
(Foss et al., 2011). Additionally, as an extremely complex disease, tumour cells incorporate a
very complex protein networks to induce the capacity of tumour progress and that requires
continuous fine-tuning to this networks through post-translational alterations, for example,
phosphorylation (Shaw and Cantley, 2012) and methylation/acetylation.(Dumitrescu, 2012,
Liu et al., 2012). A rising theme is that the proteins are not anchored to one single cellular
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location, and therfore, subcellular dispersion of proteins (Henke et al., 2011, Mulvey et al.,
2013) and other molecules such as tRNA(Chu and Hopper, 2013) is dynamic and context-
dependent and that proteins may have different functional roles at different subcellular
locations (He et al., 2012, Sirover, 2012, Tristan et al., 2011). For MCF-7 (Michigan Cancer
Foundation–7) cells, no less than 50% and possibly as much as 75 % of proteins have been
exhibited to have numerous subcellular locations (Qattan et al., 2010). About 1000 proteins
have been appeared to be available in both the nucleus and mitochondria of MCF-7 cells and
a large number of these proteins are known to have distinctive functions in the two
subcellular locations (Qattan et al., 2012). Massive spatio-temporal distribution of proteins is
a process by which cells response to an assortment of factors including environmental stress,
cell-cycle signals, development components, and hormone exposure (Sorokin et al., 2007).
The importance of nucleo-cytoplasmic trafficking of BRCA1 in hereditary forms of breast
cancer (Thompson, 2010) is well-known. Given these emerging themes, the present work
presents a high throughput proteomics study of the redistribution of proteins between the
nuclear and cytoplasmic compartments of MCF-7 breast cancer cells when exposed to
estradiol.
Effects of treatment of estradiol stimulated breast cancer cell line, particularly its active
metabolite E2 (17β-estradiol), are extensively researched in order to elucidate the underlying 
mechanisms of carcinogenesis. The solitary stimulation of E2 persuaded propagation of
serum-starved MCF-7 cells, E2 induced mitogenic response which contributed to the MCF-7
straining (Hamelers et al., 2003). ). In addition, the stimulation of cells with E2 is evident to
induce propagation of MCF-7 cells, as well as to initiate apoptosis in MCF-7:5C cells (Hu et
al., 2011). The role of oestrogen as the potent at proliferation stimulation of the receptive
cells; it is also openly proliferate the consumption of glucose and indirectly stimulate the
rate of glycolysis by direct upregulation of regulating glucose transporter 1 expression
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(GLUT1) (Rivenzon-Segal et al., 2003) or of the catalytic activity of glyceraldehyde-3-
phosphatedehydrogenase(GAPDH) (Joe and Ramirez, 2001). However, the proteomics
technologies have been used to detect the over-expression of fructose-1,6-bisphosphatases
FBP2 and FBP1, glycolytic enzymes, and oestrogen-regulated proteins, for example TFRC,
TPD52L1, GREB1, TFF1, and PGR in MCF-7 cells stimulated with10 nM E2 (Drabovich et
al., 2012).
The intracellular biological influences of E2 are mediated via interaction with ER,
particularly, the classical ERαβ receptors (ERs) (Nilsson et al., 2001, Parl, 2000). Upon 
activation via E2 binding to the ERs, the E2 bound ERs undergo conformational changes
leading to the development of the stable receptor dimers and detachment of heat-shock
chaperone proteins (Kumar and Chambon, 1988). The ligand-bound ERs modulating the
transcriptional activities by recognizing and binding to a specific response sequence (ERE)
located at the promotor region of the target genes (Brown and Sharp, 1990). In this manner,
activation or suppression of the cellular gene expression regulates wide range of mechanisms
through the transcriptional initiation/inhibition of the target genes in the cell-specific and
promotional manner (Tora et al., 1989), as well as directly introduce certain cell cycle
regulatory genes expression (Cicatiello et al., 1993, Hyder et al., 1995). Moreover, in
addition to the transcription influences on the genes, the bound E2 controls ER profusion by
significantly reducing the half-life up to three to five hours (Nirmala and Thampan, 1995).
Indeed, ER is preferentially ubiquitinated in the presence of E2 and the ER-hormone
complex is degraded by a cytoplasmic fraction of the proteasome system (Lonard et al.,
2000, Wijayaratne and McDonnell, 2001). Apart from transcriptional activities, ER receptors
have other activities in the cytoplasm, mitochondria, and at the plasma membrane suggesting
that dynamic subcellular trafficking of ER receptors and other proteins might be essential to
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the properties of ER-related functional networks (Echeverria and Picard, 2010, Mavinakere
et al., 2012, Renoir, 2012).
Our group has focused on the molecular mechanisms related to the dynamic aspects of
protein subcellular dispersion in response to the biological perturbations, therefore, global
quantitative proteomics high-throughput technology was consolidated with a model enabling
the enrichment of subcellular compartments and estimation of the subcellular proteome
changes against total changes (Mulvey et al., 2013). Such methodology has permitted
estimation of the changes in total abundance and in the compartmental
plenitude/dissemination between the nucleus and cytoplasm for a few thousand proteins DE
in E2-stimulated MCF-7 cells. A Corollary improvement of a “subcellular spatial razor”
model of the dynamic redistribution of proteins has significantly helped to overcome the
difficulties of interpretation of big datasets generated by the combined metabolic labelling of
stable isotope amino acids in cell culture (SILAC) and high resolving power of mass
spectrometry.
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The present results demonstrate that as an outcome of estradiol incitement of MCF-7 cells,
massive numbers of proteins redistributed between the nucleus and cytoplasm and that many
of those proteins show apparent changes in compartmental abundance than in absolute
protein abundance, suggesting that dynamic changes in the subcellular distribution of
proteins after E2 stimulation is the fundamental response of MCF-7. Furthermore, spatial
and temporal changes in localizations of the compartmental proteins may be regulated
predominantly by the ER and other nuclear receptors that are driving the response and
responding to the spatially distributed functional networks of proteins. Additionally, the
strong perturbation of subcellular spatial regulation may be a crucial feature of breast cancer.
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3.1.1 Results
The proteomics subcellular spatial razor experiments described in the following are based on
a model which envisages that in response to a cellular perturbation, proteins may show both
changes in total cellular abundance and in their subcellular spatial distribution between the
nucleus and cytoplasm (Figure 1-8). Experimental measurements of protein abundance ratios
(SILAC ratios) between stimulated/unstimulated cells are made on three samples: (1) an
unfractionated, total cell lysate (T), (2) a nucleus-enriched sample obtained by subcellular
fractionation (N), and (3) the corresponding nucleus-depleted sample (C), which we refer to
as the “cytoplasm” in the following. The corresponding SILAC ratios provide measures for
each protein of the overall change in total cellular abundance (St), or of the localized change
in abundance in the nuclear (Sn) or cytoplasmic (Sc) subcellular compartments. A
mathematical formulation of the model is given in the introduction (see sction 1.4.2).
Stringent purification of organelles (e.g., nucleus) was not attempted in this study as we
believe it is not feasible to purify to homogeneity organelles that are subject to dynamic
changes in their protein content and that unnecessary protein loss is incurred during such
organelle isolation methods. We preferred to use highly enriched fractions rather than highly
purified organelles. This is a strategy that has previously been shown to successfully detect
nucleo-cytoplasmic trafficking and characterized in detail samples obtained with the present
subcellular fractionation protocols (Qattan et al., 2012), including extensive evidence that the
nuclear-enriched fraction contains very little if any contamination with other cytoplasmic
components such as mitochondria, endoplasmic reticulum, Golgi apparatus, etc. As routine
controls for the present preparations, we checked the morphology of stimulated/unstimulated
cells using fluorescence imaging to verify the morphological changes associted with
stimulation in live cells and checked the purity of the nuclear/cytoplasmic fractions using
Western blotting (see below). For each sample type, we measured three replicates. Across all
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samples, a total of 4386 different proteins were identified by sequenced peptides. Of these,
110 corresponded to 55 proteins with multiple isoforms from the same gene that could not be
unambiguously resolved across all replicates of the three sample types and were not further
analysed for present purposes. Supplementary Table 1 contains the full experimental data for
the remaining 4276 proteins. For quantitative analysis of the distribution of the subcellular
abundance of these proteins, we imposed the conservative limits that at least two different
sequenced peptides (1 unique) and at least 3 SILAC ratio counts in a single sample replicate
were required. This gave 3604 quantified, reliably identified proteins, with the subcellular
distribution shown in Figure 3-3, that were used in the analyses described below.
3.1.1.1 Reproducibility of the sample preparation procedures
As shown in Figure 3-1, the proteins chosen as potential organelle markers (mitochondria:
VDAC and nucleus: Histone H3) confirm the enrichment capacity of the preparation
procedures. They were observed in the expected subcellular locations: VDAC was detected
in the total lysate and cytoplasmic fraction while Histone H3 was observed in both the total
lysate and nucleus fractions, respectively, but not in the cytoplasmic (nuclear depleted)
fraction. Overall, results of the WB experiment are consistent with highly enriched
fractionation rather than highly purified, and that is what we aimed to achieve, in the current
stage, to avoid loss of protein during purifications, this is a strategy that has previously been
shown to successfully detect nucleo-cytoplasmic trafficking (Mulvey et al., 2013).
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Figure 3-1: Characterization of total lysate (T), cytoplasmic (C), and nuclear (N)
fractions of MCF-7 cells.
Immunoblot analysis of the reproducibility of the fractionation procedure using known
subcellular markers in the three sample types (TCN). (A) The mitochondrial marker VDAC
was found in fractions C and T while the nuclear marker H3 (B) was detected in fractions N
and T.
98
3.1.1.2 Effect of oestradiol on the subcellular morphology
Live cells deprived from E2 (control) had apoptotic activity as visualized by confocal
microscope (Figure 3-2.A).Their mitochondria were small and started to disconnect
themselves from the perinuclear zone (Figure 3-2.C). After E2 treatment, the majority of
nuclei showed absence of apoptotic activity and contained completely dispersed chromatin
(Figure 3-2.B), moreover, mitochondrial clustering in a high number around nuclei was
observed (Figure 3-2.D). These morphological changes were observed by electron
microscope at the physiological relevant concentration of E2 (10 nM) in MCF-7 cells (Vic et
al., 1982).
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Figure 3-2: Morphological changes in E2-stimulated MCF-7 cells.
Effect of oestradiol (10 nM) on the subcellular morphological changes in live MCF-7 cells
stained with 200 nM of MitoTracker Green (mitochondrial fluorophore) and 1 µg/ml
Hoechst 33342 (blue nuclear fluorophore) and visualized by fluorescent microscope. (A)
Control cells (deprived from E2 for 72 h) with condensed chromatin and fragmented nuclei
brighter blue-whitish (red arrows), were reported as apoptotic cells. E2-treated cells (B)
uniformly stained blue with evenly distributed chromatin (white arrows), with normal and
round nucleus, and were scored as non-apoptotic cells. (C) Control cells (starved from E2 for
72 h) show small size and small number of mitochondria in the perinuclear area compared
with E2 treated cells (D) where high number of large and clear mitochondria are clustered in
the perinuclear space.
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Figure 3-3: Venn diagram of the distribution over sample types for proteins
quantified with ≥3 SILAC ratio counts in each sample. 
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3.1.1.3 Changes in abundance in the nuclear and cytoplasmic compartments
The overall changes in abundance for the proteins are shown in Fig. 3.4. For 2809 total
lysate (T) proteins with ≥ 5 SILAC ratio counts across the three replicates (median of 39 
counts per protein), only 7 T proteins (0.2%) showed greater than 4-fold increase/decrease in
abundance and only 64 T proteins (2.3%) showed greater than 2-fold increase/decrease in
abundance in response to estradiol exposure (Figure 3-4A). To check for possible distortion
of the distribution profile by lower abundance proteins and/or by variation between
replicates, these results were compared with a smaller set of 2197 more abundant proteins
for which the lower limit was set to ≥ 3 SILAC ratio counts in all three T replicates (median 
of 62 counts per protein, (Figure 3-4B). The profile for the distribution of the SILAC ratio St
for total cellular proteins was hardly changed, which indicates that it is a reliable indicator of
total cellular abundance changes.
In the nuclear compartment, very different behaviour was observed (Figure 3-4A). For 1791
nuclear proteins with ≥ 5 SILAC ratio counts across the three replicates (median of 22 
counts per protein), only 2 proteins (0.2%) showed greater than 2-fold increase in nuclear
abundance. However, 109 proteins (6.1%) showed greater than 4-fold decrease and 560
proteins (31.3%) showed greater than 2-fold decrease in nuclear abundance. For 1064 more
abundant nuclear proteins with ≥ 3 SILAC ratio counts in all three N replicates (median of 
49 counts per protein), a similar distribution profile for the SILAC ratio Sn for nuclear
proteins indicated that lower abundance proteins and/or variation between replicates had
little effect on the observed distribution (Figure 3-4B).
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For cytoplasmic proteins, largely inverse changes were observed. For 1758 cytoplasmic
proteins with ≥ 5 SILAC ratio counts across the three replicates (median of 39 counts per 
protein), 21 (1.2%)/130 (7.4%) of proteins showed greater than 4-fold/2-fold decreases in
cytoplasmic abundance, but 65 (3.7%)/407 (23.2%) of the proteins showed greater than 4-
fold/2-fold increases in cytoplasmic abundance. Exclusion of lower abundance proteins by
requiring ≥ 3 SILAC ratio counts in all C replicates (median of 54 counts per protein) caused 
only very modest change in the distribution profile for the SILAC ratio Sc for cytoplasmic
protein abundance (Figure 3-4B).
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Figure 3-4: Distribution of SILAC ratios for proteins from the total lysate (St), nuclear
(Sn) and cytoplasmic (Sc) samples.
(A) All proteins with ≥ 5 ratio counts for the union of the three replicates for each sample type. (B) 
All proteins with ≥ 3 ratio counts for all replicates of each sample type.  The inset tables show the 
number and percentage of proteins that show >4-fold or >2-fold changes in total abundance (St),
nuclear compartment abundance (Sn) and cytoplasmic compartment abundance (Sc). The tables also
show for each distribution the total number of proteins included, the median number of SILAC ratio
counts and the number of proteins with smaller numbers of SILAC ratio counts. Figure was designed
by JGZ and published in (Pinto et al., 2014).
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3.1.1.4 Coupling between total and compartmental changes in abundance
Because the abundance of a protein in the nucleus/cytoplasm can be altered by changes both
in total cellular protein abundance and in distribution between the two compartments, the
SILAC ratios Sn and Sc do not directly measure redistribution of a protein between the two
compartments. If fs and fu denote the fraction of a protein in the nucleus in
stimulated/unstimulated cells respectively, then Sn/Sc = fs(1-fu)/fu(1-fs) provides a direct
measure for redistribution to/from the nucleus (see section 1.4.2). We directly tested for
correlation between total and compartmental changes in abundance by plotting Sn/Sc vs St for
724 abundant proteins that had ≥ 3 SILAC ratio counts for all three C, N and T replicates 
(median of 307 counts per protein, (Figure 3-5A). 424 proteins showed |log2(Sn/Sc)| > 1
and/or |log2(St)| > 1. However, there was no apparent correlation between overall changes in
abundance (St) and changes in subcellular distribution (Sn/Sc), that is, the abundance changes
in the nuclear and cytoplasmic compartments do not simply mirror changes in total
abundance. It should be noted that the distribution profiles for St and Sn/Sc show good
reproducibility over the three biological replicates (Figure 3-5, B&C), although there is some
scatter for major changes in distribution, i.e. log2(Sn/Sc) -2 (see below).
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The strong skewing of log2(Sn/Sc) to negative values (Figure 3-5C) reflects predominant N
 C subcellular redistribution. To further characterize the nature of the redistribution for
individual proteins, we used the full 3D model of the subcellular spatial razor. For the 3D
space of measured parameters {Sn, Sc, St}, the orthogonal basis set {Sc/St, Sn/St, St} separates
an axis with changes in total protein abundance (St) from a plane (Sc/St, Sn/St) that depends
only on the redistribution of a protein between the nucleus and cytoplasm. Figure 3-6B,
shows that in the distribution plane, the data points are constrained by conservation of mass
(no differential protein losses between stimulated/unstimulated samples during subcellular
fractionation or MS sample preparation) to lie in 2 quadrants that correspond to N C or N
 C redistribution of the protein respectively. Figure 3-6A,C shows typical behaviour for 6
proteins from Figure 3-5A. In the 3D space (Figure 3-6C), the changes in total abundance,
perpendicular to the distribution plane, have been color-coded for the average over the 3
replicates. The locations of the data points in the distribution plane (Figure 3-6C) are
sensitive to the basal nucleus/cytoplasm distribution of the protein in unstimulated cells. For
example, NHP2L1 corresponds to a protein with an abundance distribution strongly skewed
to the nucleus. Upon stimulation the nuclear/total abundance is hardly changed (log2(Sn) ~
log2(St) ~ 0.03), but the small fraction of the protein in the cytoplasm is increased 6-fold.
This might be the behaviour of a protein involved in transmission from the nucleus to the
cytoplasm of information about cellular state. Conversely, upon exposure to estradiol the
abundance of CASP14 decreased 3-fold, with little or no change in subcellular distribution.
ERP29, AGR3 and EZR represent proteins with strong basal distribution to the cytoplasm.
ERP29 and AGR3 both show 2-fold increases in total abundance, accompanied by enhanced
depletion of the protein in the nucleus. These might be proteins that transmit information
about cellular state from the cytoplasm to the nucleus, or this might even reflect negative
regulation of their own abundance. EZR shows a moderate decrease in abundance (St =
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0.71), but this is preferentially in the cytoplasm and leads to a 2-fold increase in the fraction
of the protein in the nucleus. Finally, SUB1 (PC4) represents a protein with very little
change in total abundance (St=1.02), but substantial, coupled changes in abundance in the
two compartments (Sn = 1.56, Sc= 0.48). Note that in the 3D space the distribution plane is
sensitive to changes in the fractional abundance in both subcellular locations; even where
this might, for example, represent an increase/decrease in the nucleus for a trace fraction of
the total protein if the protein has a basal abundance strongly skewed to the cytoplasm (see
Discussion). There is some scatter between the replicates (Figure 3-6). This together with the
inherent precision of the SILAC measurements, especially of the ratios Sn/St or Sc/St for
proteins with basal abundances strongly skewed to one location, can lead to minor apparent
violations of conservation of mass and contributes to the scatter in (Figure 3-5C) for
log2(Sn/Sc) ≲ -2. However, in most cases the overall behaviour of the proteins could be
clearly ascertained.
There were appreciable numbers of proteins for which no substantial change in either
abundance or subcellular location was detected (bounding box in Figure 3-6A), i.e. the
effects of estradiol exposure seem to be selective. Only a handful of proteins showed
appreciable changes in total abundance without changes in subcellular distribution (Figure 3-
5A). Overall there was very little correlation between changes in total protein abundance and
changes in protein abundance in the two subcellular compartments. For some individual
proteins, initially counterintuitive results were detectable, e.g. AGR3 increases in total
abundance but decreases in abundance in the nucleus (Figure 3-6C).
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Figure 3-5: Evaluation of the correlation between changes in total abundance and
redistribution of abundance between the nucleus and cytoplasm.
(A) Plot of the redistribution parameter (Sn/Sc) vs the changes in total abundance (St) for the
union over the replicates. The red, dashed bounding box corresponds to 2-fold changes. (B)
Distribution of St for the three replicates. (C) Distribution of (Sn/Sc) for the three replicates.
Figure was designed by JGZ and published in (Pinto et al., 2014).
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Figure 3-6: Two- and three-dimensional data representations for the subcellular spatial
razor.
(A) 2D plot of changes in redistribution between the nucleus and cytoplasm (Sn/Sc) versus total
abundance (St) for six proteins from Figure 4 showing the experimental scatter. The union is the
average over the replicates weighted by the MS intensity recorded for the protein in each replicate.
The orange bounding box shows 2-fold changes. (B) For the orthogonal 3D space {Sn/St, Sc/St, St}, the
theoretical distribution plane {Sn/St, Sc/St} for different values of fu (the fraction of protein in the
nucleus in the unstimulated cells) as the fraction of the protein in the nucleus in the stimulated cells
(fs) varies over 0 <fs< 1. Conservation of mass restricts the cellular response to two quadrants
corresponding to N C or C N redistribution of the protein upon stimulation. (C) The six proteins
of (A) plotted in the 3D space {Sn/St, Sc/St, St}. The axis perpendicular to the page is colour coded for
changes in total abundance (St). The orange bounding lines show 2-fold changes in (Sn/Sc). Figure was
designed by JGZ and published in (Pinto et al., 2014).
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3.1.1.5 Redistribution of proteins between the nucleus and cytoplasm
We expanded the analysis to proteins that were detected in only one compartment and
screened for inadequate MS sampling and/or fractionation artefacts by using the fact that the
spatial razor model explicitly includes conservation of mass. This provides a strong
framework for screening experimental results for artefacts and obtaining a set of proteins
with high confidence changes in compartmental abundance. For example, for proteins
present in a single subcellular compartment, changes in abundance in that compartment are
necessarily coupled by conservation of mass to changes in total abundance, i.e. Sn/St = 1
(nucleus) or Sc/St = 1 (cytoplasm). A similar principle applies to proteins present in both
compartments: for ideal sampling and fractionation, joint co-processing of the C and N MS
data sets (a C&N data set) should give an apparent change in abundance St* such that St*/St =
1. For the proteins which had at least 3 ratio counts in the appropriate samples and for which
the ratio S/St could be calculated, all of these ratios showed a Gaussian distribution. Outliers
represent proteins for which strict conservation of mass is less reliable due to reduced MS
sampling and/or fractionation/extraction artefacts. Of the 3604 proteins in our quantified set,
a substantial majority (2597) were detected in more than one sample. However, most such
proteins were detected in the CNT subset (1683): only 217/598 proteins were included in the
CT/NT subsets and only 160/374 were quantified in both samples. For those single-
compartment proteins with good consistency with conservation of mass, the table in Figure
3-7 shows that there were very few proteins with >2-fold changes in abundance. Although
the total number of quantified single-compartment proteins is small, the results are consistent
with the observation that of 3057 quantified T proteins, only 71 (2.3%) showed >2-fold
changes in total abundance.
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For the 1363 proteins quantified in all three samples of the CNT data subset, the table in
Figure 3-7 shows how the proportion of proteins with appreciable changes in total
abundance (St), compartmental abundance (Sc, Sn) or redistribution (Sn/Sc) varies with the
range of inclusion relative to the center of the Gaussian distribution for St*/St. There were no
proteins for which the nuclear abundance doubled, only 8 proteins (~1.3%) for which
cytoplasmic abundance was halved and only 5 proteins (~1%) for which there was a 2-fold
change in total abundance. In contrast, ~14% of cytoplasmic proteins showed doubled
abundance and ~30% of nuclear proteins showed halved abundance. About 50% of the
proteins showed |log2(Sn/Sc)| > 1. These percentages were largely independent of the total
number of proteins included in the conservation of mass selection range around St*/St = 1
(Figure 3-7). The behaviour of the individual proteins is shown in Figure 3-7A. Overall, with
|log2(St*/St)| < 0.5 the CNT data set included 331 proteins that showed >2-fold change in at
least one of the SILAC ratios Sn, Sc, St or Sn/Sc. Only 5 proteins showed >2-fold change in St
and only for CASP14 did the >2-fold decrease in total abundance result in corresponding >2-
fold decreases in both the nuclear and cytoplasmic compartments. For the other proteins that
showed >2-fold increase/decrease in total abundance (TUFM, AGR3 / BASP1, ACBD3),
redistribution resulted in a >2-fold change in only one of the nuclear/cytoplasmic
compartments. For 326 proteins there were >2-fold changes in Sn, Sc or Sn/Sc without a >2-
fold change in St. There were 166 proteins that showed a >2-fold decrease in abundance only
in the nucleus, but none that showed a >2-fold increase only in nuclear abundance. There
were 83 proteins that showed >2-fold changes in abundance only in the cytoplasm, 77 of
which were increased abundance. A >2-fold decrease in abundance in the nucleus coupled
with a >2-fold increase in the cytoplasm was detected for 10 proteins. Finally, there were 67
proteins that showed substantial redistribution between the N and C compartments without a
2-fold change in either compartment, e.g. for PSME3, Sc = 1.83; Sn = 0.64; Sn/Sc = 0.35.
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To test the robustness of the distribution over the five classes of proteins shown in Figure 3-
7A, we extracted a set of 134 proteins for which a 2-fold variation in one or more of Sn, Sc, St
or Sn/Sc was obtained for at least 2 replicates, with at least 10 SILAC ratio counts in each
replicate (Figure 3-7B, median of 549 ratio counts per protein). A summary of the data for
these proteins is given in Supplementary Table 2. The distribution over the five classes
showed at most modest changes (Figure 3-7A,B) and we therefore take this distribution as
characteristic of the response of MCF-7 cells to estradiol. Quantitative data (Supplementary
Table 2) show that after E2 stimulation, a marked decrease of compartmental abundance
were detected for Protein DJ-1 (PARK7) with a more than 4-fold decrease in the nuclear
compartments (Sn= -2.0) and a minor decrease in the cytoplasmic one (Sc= -0.355). In
response to E2, PARK7 was significantly redistributed in cytoplasm (N → C). Same 
reduction in the nuclear level of NQO1 was observed after E2 stimulation (Sn= -2.0) while
the cytoplasmic abundance was increased (Sc= 0.89) pointed out the same redistribution (N
→ C). These relevant proteins, PARK7 and NQO1, were also chosen for MS validation by 
confocal microscopic analysis. Using immunofluorescence imaging (Figure 3-8), PARK7
was massively reduced in the nucleus in response to E2 while NQO1 was increased in the
nucleus of the dividing cells, suggesting a protective role for NQO1 (see discussion).
Notable was that in all of the above data subsets, there were very much larger numbers of
proteins that showed >2-fold changes in compartmental abundance compared to those with
>2-fold changes in total abundance. The functional significance of this data is considered
further below and in the discussion. From the proteins in the CT, NT and CNT data sets that
showed good consistency with conservation of mass, the 134-set of abundant proteins was
used to investigate possible correlations with database/literature information on subcellular
location, functional processes, involvement of nuclear import/export proteins, and
partitioning of proteins between the nucleus and mitochondria.
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Figure 3-7: Redistribution of proteins.
Table inset. Top: number of proteins detected in a single subcellular compartment with >2-
fold changes in abundance. Bottom: number of proteins detected in both compartments with
>2-fold changes in abundance (Sn, Sc or St) or in Sn/Sc. The number of proteins included
varies with the selection range around Sn/St, Sc/St or St*/St = 1 (see text). (A) 3D plot for 331
proteins with |log2(S/St)| < 0.5. (B) 3D plot for 134 proteins with |log2(S/St)| ≤ 0.5 that were 
quantified with ≥ 10 SILAC ratio counts in at least two replicates. The legend (lower left) 
shows the symbol coding for >2-fold changes only in Sn, only in Sc, in both Sn and Sc, for
Sn/Sc only and for St. Increases/decreases are color coded (upper right legend). Figure was
designed by JGZ and published in (Pinto et al., 2014).
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Figure 3-8: Immunofluorescence (IF) of the sub-cellular redistribution of PARK7 and
NQO1 proteins in MCF-7 cells.
(A) Goat polyclonal secondary antibody to rabbit IgG - H&L (Green DyLight 488) used as
negative control. Oestrogen untreated (B) and treated (C) MCF-7 cells were incubated with
primary Anti-Rabbit antibody to PARK7 and goat Anti-Rabbit IgG H&L secondary
antibody. Also, untreated (D) and E2-treated (E) MCF-7 cells were incubated with Anti-
Rabbit antibody to NQO1 and goat Anti-Rabbit IgG H&L as secondary antibody. DAPI was
used to stain the cell nuclei (blue) at a concentration of 1.43µM. Merged images are
presented.
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3.1.1.6 Subcellular Location Annotation for Proteins with Compartmentalized
Abundance Changes
For the 134-set of proteins, we analyzed their current GO CC (cell component) annotation
terms. The complete set of 733 annotations to 152 GO CC terms is given in Supplementary
Table 2. Table 3-1 shows the distribution of the current annotations over four main top-level
cellular locations (nucleus, cytoplasm, plasma membrane, extracellular region), with a
further breakdown of cytoplasmic locations. There was no subcellular location annotation for
5 of the 134 proteins. With the vocabulary of Table 3-1, the remaining 129 proteins had an
average of 2.7 locations per protein, and a maximum of 6 locations, i.e. many of these
proteins are known to have multiple subcellular locations. For example, of the 66 proteins
currently annotated to the nucleus, 58 are also annotated to the cytoplasm (Table 3-1). Of the
120 proteins currently annotated to the cytoplasm, 58 are also annotated to the nucleus and
25 to the plasma membrane. This is consistent with the concepts that protein spatial location
and organelle composition are dynamic properties that depend on context and that protein
function is intimately coupled to subcellular spatial distribution.
On the other hand, we detected 76 proteins in both the cytoplasm and nucleus that have not
previously been annotated to nucleus and 14 proteins in both the cytoplasm and nucleus that
have not previously been annotated to cytoplasm. These results are consistent with previous
studies indicating that current subcellular annotations in the GO CC database underestimate
the dispersion of proteins over multiple locations in MCF-7 cells (Qattan et al., 2010, Qattan
et al., 2012) and suggest that coupling of cellular function to protein spatial distribution is
even more prevalent than is implicit in current subcellular location annotations (see
Discussion).
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In this context, we recently identified 985 proteins that are present in both the nucleus and
mitochondria of MCF-7 cells (Qattan et al., 2012). With the greater number of MS replicates
used in the present study, 1069 proteins that were previously detected in mitochondria
(Qattan et al., 2012) were detected in the nucleus in the present samples. This included
confirmation of the unexpected presence in the nucleus of mitochondrial respiratory chain
proteins and of many other metabolically interesting proteins such as pyruvate decarboxylase
(PC) and mitochondrial phosphoenolpyruvate carboxykinase (PCK2) (Qattan et al., 2012).
At the level of at least 2 peptides and 3 SILAC ratio counts, 829 of these proteins were
quantified in both the nucleus and cytoplasm in the present experiments. Following estradiol
exposure, N  C redistribution involving >2-fold reduction in nuclear abundance was
detected for 249 of these proteins. The 134-set of proteins showing the most reliable changes
contained 87 of these proteins, which are included in the functional analysis below. While
possible redistribution of these proteins to/from mitochondria will have to be confirmed by
additional experiments, this suggests that dynamic subcellular protein distribution may have
a major role in communication/coordination between the nucleus and mitochondria.
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Table 3-1: Distribution of GO CC annotation for the 134 protein Set
Table 1. Distribution of GO CC Annotations for the 134 Protein Set
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extracellular region 14 12 7 2 6 1 3 0 0 1
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3.1.1.7 Functional processes associated with proteins showing
compartmentalized abundance changes
For the 134-set of proteins, we used the Reactome software programs (Croft et al., 2011,
Milacic et al., 2012) to search for associated functional processes (Table 3-2). Our goal was
to test whether the sets of redistributed proteins are likely to have important functional
consequences and to obtain a qualitative appraisal of what kinds of processes might be
involved rather than to specify exact functions. For example, all 5 proteins involved in
glycolysis (a cytoplasmic process), show N C redistribution involving >2-fold reductions
in their nuclear abundance with no appreciable change in their cytoplasmic abundance
(Table 3-2). This should not be interpreted as evidence for glycolysis in the nucleus, but
rather as an indication for cross-talk between glycolysis and unknown nuclear process(es)
that are influenced by estradiol exposure. Similarly, the Reactome p-value can only be
moderately indicative since it is normalized to the proportion of all glycolytic proteins and
does not assess the significance of redistribution of multiple glycolytic proteins to a “wrong”
location differing from the cytoplasm.
With these kinds of caveats in mind, Table 3-2 nonetheless suggests that exposure to
estradiol leads to changes in protein distribution that reflect processes over a wide spectrum
of functions/subcellular locations. Because of substantial, different skewing in the basal,
non-stimulated distribution of the various proteins between the nucleus and the cytoplasm,
only some of the redistribution patterns shown for the functions in Table 3-2 are easily
interpreted. For example, all 7 subunits of the CCT complex involved in chaperone-assisted
protein folding show >2-fold reductions in nuclear abundance, suggesting that this complex
might be involvedin protein import/export/folding in the nucleus (see Discussion).
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Similarly, all 5 proteins involved in nucleosome assembly show >2-fold increases in
cytoplasmic abundance, with very minor changes in their nuclear and total abundance,
suggesting this group might reflect signalling to the cytoplasm about a nuclear process.
Seven proteasome subunits (see protein degradation in the cytoplasm section of Table 3-2)
figure prominently in the functional groups in Table 3-2. Proteasomes occur in both the
nucleus and cytoplasm and the distribution pattern includes 4 proteins that show substantial
redistribution without 2-fold changes in abundance in either compartment. We suggest that
this type of redistribution pattern may reflect balancing of multiple functions between the
nucleus and cytoplasm (see Discussion). Other functional groups show more complex
redistribution patterns that may reflect wide functional cross-talk that is coupled to basal
skewing of abundance over cellular location. This was the case for the plasma membrane
functional groups, where it was intriguing to see indications for functions associated with
actin-related processes in phagosome formation and for neuronal migration (L1CAM
interactions). As with glycolysis, such groupings might reflect cross-talk with nuclear
processes. For example, nuclear actin imported via importin-9 supports transcription (Dopie
et al., 2012) and myosin isoforms show directed, Ca2+-dependent nuclear import (Dzijak et
al., 2012).
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Table 3-2: Analysis of Functional Groups with Reactome
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3.1.1.8 Proteins involved in nuclear import/export
With at least 5 ratio counts in the C, N and T samples, there were 13 quantified proteins
(median of 185 ratio counts per protein) in the full data set that have GO annotation
corresponding to nuclear import/export/localization/maintenance (Figure 3-9). These
proteins showed at most modest changes in total abundance (St = 1.19 CALR; 0.65 KPNA2)
and essentially no change for RAN or KPNB1. In general, this subgroup of proteins showed
a similar pattern to the overall set of quantified proteins, i.e. a trend of N  C redistribution
following oestrogen stimulation, with RAN as the only exception. There is little indication
for general impairment of nuclear import/export. Indeed, the asymmetric distribution of
RAN and karyopherins required for nuclear import is if anything enhanced.
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Figure 3-9: Three-dimensional spatial razor plot for proteins with GO annotations
corresponding to nuclear import/export/localization/maintenance.
This figure was designed by JGZ and published in (Pinto et al., 2014)
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3.2 Part-II: Quantitative Global Proteomics Reveals Nucleo-Cytoplasmic
Trafficking of Proteins Following Exposure of MCF-7 breast cancer cell to
Tamoxifen
Hormone receptor positive (HR+) breast cancers represent 70% of all breast tumours. Their
oncogenesis is a multiple step process thought to be driven by two transcription factors, the
ER and/or the progesterone receptor (PR) (Valentina Contrò, 2015). Consequently, the
endocrine-targeted therapeutic approach has focused on both receptors as prognostic markers
and therapeutic targets (Davies et al., 2011), aiming to alter the oestrogen signalling for
patients with ERα-positive disease (Dixon, 2014). The benefits gained from the treatment are 
limited by development of either de novo or acquired resistance following a period of
response to tamoxifen. For both types of resistance, the lack of pathological response to
tamoxifen is manifested when the tumour cells commence proliferation, challenging the
clinical management (Larionov and Miller, 2009) of patients (Larionov and Miller, 2009).
Over the past four decades tamoxifen has been extensively used in neoadjuvant and adjuvant
settings for the treatment of hormonal dependent breast cancers by acting as a competitive
inhibitor of ER (Dixon, 2014, Shiau et al., 1998, Wakeling, 2000). The ER mediated
signalling pathways involve genomic, non-genomic, or mitochondrial pathways that
contribute to amplification of the multistep process of tumour development (Bjornstrom and
Sjoberg, 2005). It is well established that binding of oestrogen (E2) to ERs leads to
subsequent receptor dimerization and recruitment of other coactivators such as SRC-3 and
(tethering) transcription factors such as AP-1. This complex acts directly as transcriptional
factor by binding to oestrogen responsive elements (EREs) that are located on the promotor
regions of the target genes. This initiates transcription of the target genes leading to
proliferation, apoptotic inhibition, and uncontrolled growth (Schiff et al., 2005). Full
agonistic activity of E2 is achieved via the activation of two transactivation domains known
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as activation function 1 (AF-1), regulated by growth factors, and activation function 2 (AF-
2), regulated by E2 binding (Wakeling, 2000). Tamoxifen acts as a selective modulator with
partial agonistic activity in which the active metabolite of tamoxifen, 4-OHT binds to a
ligand binding domain (LDB) of ER. This promotes conformational changes of the ER
dimers, leading to recruitment of transcriptional repressors that relocate helix 12 and prevent
the coactivator binding and activation of AF-2. Subsequently, the transcriptions of AF-2
dependent genes are downregulated, but partial agonistic activities can be initiated for the
AF-1 dependent genes (Schiff et al., 2005). Consequently tamoxifen can inhibit the
transcriptional activities of ER in some tissues such as the breast tissue but activate
transcriptional cascades in other tissues such as uterus. Therefore, tamoxifen and related
compounds show mixed agonist/antagonist properties and are classified as oestrogen
selective modulators (ERSM).
In breast tissue tamoxifen acts predominantly as antagonist but there is some evidence that
tamoxifen agonistic activities can enhance breast tissue proliferation, thereby leading to
limited efficacy and resistance (Gottardis and Jordan, 1988, O'Regan et al., 2006).
Furthermore, at the molecular level the active metabolite of tamoxifen, 4-hydroxytamoxifen
(OHT), can cause the induction of gene expression related to the the cell cycle, particularly
for those genes induced by E2 (Hodges et al., 2003).
Numerous studies have tackled antioestrogen resistance therapy using different approaches.
These include various cell line models in culture and/or as xenografts as well as in studies in
the clinical adjuvant and/or neoadjuvant settings (Larionov and Miller, 2009). Owing to the
complexity and heterogeneity of breast cancer, understanding of the exact mechanisms
underlying resistance to tamoxifen remains far from being completely elucidated.
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The proposed mechanisms are diverse and consistently indicate that complex cellular
mechanisms are involved in the developing resistance. Studies related to the differential
metabolism of tamoxifen, mutated/downregulated ER, cross-talk between ER and growth
factor transduction pathways, dynamic changes in cell signalling, and cellular responses to
oxidative stress have all been carried out with limited success (Chang, 2012, Dixon, 2014).
These studies suggest that numerous pathways are intertwined and that more integrative
approaches using high-throughput technologies are required to elucidate tamoxifen function,
to predict and overcome resistance, and to ultimately lead to better therapeutic interventions.
We have recently developed high-throughput proteomics methods suitable for investigating
dynamic aspects of protein subcellular distribution in the response of cells to stimulations
(Baqader et al., 2014, Mulvey et al., 2013, Pinto et al., 2014, Pinto et al., 2015, Pinto et al.,
2016, Radulovic et al., 2016). This approach, which combines global quantitative proteomics
with the analysis of fractions enriched in target subcellular locations, has allowed
measurement of the changes in total abundance and in the compartmental
abundance/distribution between the nucleus and cytoplasm for several thousand proteins DE
in MCF-7 cells in response to oestrogen stimulation. Using stable isotope labelling in cell
culture (SILAC) and quantitative high-resolution mass spectrometry analysis demonstrated
that oestradiol stimulation of MCF-7 cells results in strong redistribution of massive numbers
of proteins between the nucleus and cytoplasm. Many more proteins showed appreciable
spatial changes in compartmental abundance than in total protein abundance (Pinto et al.,
2014).
We suggested (Pinto et al., 2014, Pinto et al., 2015) that major alterations in the spatio-
temporal subcellular distribution of proteins are the dominant response of MCF-7 cells to
oestradiol exposure and that a major role of the ER and possibly other nuclear hormone
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receptors may be the “polling” of and response to spatially distributed functional networks
and that strong perturbation of subcellular spatial regulation may be a crucial feature of
breast cancer.
In the present work we apply global, quantitative proteomics analysis of changes in nucleo-
cytoplasmic distribution of proteins and of total protein abundance for MCF-7 cells exposed
to tamoxifen. Extensive bioinformatics analysis suggests that cellular spatial reorganization
is a major component of the molecular basis of tamoxifen function and its use in breast
cancer therapy.
126
3.2.1 Results
We prepared MCF-7 cells according to previously published procedures (Pinto et al., 2014,
Qattan et al., 2010, Qattan et al., 2012). Their response to tamoxifen was measured for total
change in protein abundance and for compartmental changes in protein abundance in the
nuclear and “cytoplasmic” (nucleus-depleted) compartments (Baqader et al., 2014, Jung et
al., 2013, Mulvey et al., 2013). Stringent purification of organelles (e.g. nucleus) was not
attempted since such organelle isolation procedures can lead to loss of ability to monitor
important characteristics of dynamic cellular function (Radulovic et al., 2016, Pinto et al.,
2016). We have previously characterized in detail the purity of samples obtained with the
present subcellular fractionation protocols (Pinto et al., 2014, Qattan et al., 2010, Qattan et
al., 2012, Mulvey et al., 2013, Radulovic et al., 2016). The purity of the nuclear/cytoplasmic
fractions used for MS analysis were routinely tested using western blotting as decribed in
(section 2.3.4) and shown in (Figure 3-1).
A concentration of  4-OHT (1 μM) was previously characterized as a cytostatic dose for 
various cell lines and used in different laboratories. It was originally selected for complete
inhibition of oestrogen-dependent ZR-75-1 cells without influencing the growth of
tamoxifen-resistant derivatives (Meijer et al., 2006). This dose has been routinely used
because of the absence of complete toxicity, to effectively counter variations in oestrogen
content of different batches of bovine serum (Lykkesfeldt et al., 1984, van Agthoven et al.,
2012), and because an IC50 concentration of a drug that is required for 50% inhibition of in
vitro tamoxifen is 1 μM (Kijima et al., 2005).  
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Exposure of cells to 1µM 4-OHT for 24 h was used in the present experiments. The dose
dependent (0.0-2.0µM) impact of 4-OHT treatment on the survival rate of MCF-7 cells
showed that the chosen dose (1µM) was of a cytostatic effect (non-lethal) to MCF-7 cells,
whereas a survival rate of less than 50% of the seeded cells was associated with higher doses
of 1.5 and 2.0 µM 4-OHT (Figure 3-10A). As a routine control for the present preparations,
we checked the morphology of stimulated/unstimulated cells using fluorescence staining
with a proprietary dye that can label the nuclear membrane(s), mitochondria, fibers, and
nuceleoli in fixed cells. Confocal imaging revealed no remarkable changes in overall cell
morphology or in peripheral membranes in the 4-OHT treated MCF-7 cells compared to
untreated cells (Figure 3-10B). To further validate the proteomics results and confirm the
redistribution of the selected protein(s), immunfluorescence was performed with specific
antibodies angainst protein of interest in unstimulated and 4-OHT-stimulated MCF-7 (Figure
3-11Figure 3-12).
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Figure 3-10: Toxicity assay and assessment of morphological changes.
A. Survival rate (%) of MCF-7 cells following stimulation with increasing concentrations of
4-OHT. B. Morphology of MCF-7 cells with/without tamoxifen treatment. The fixed cells
were stained DAPI (for nuclei) and counterstained with Chromo Red Fluorescent dye (a
proprietary dye) that can label the nuclear membrane(s), mitochondria, fibers, and nucleoli in
fixed cells. Merged and DIC (Differential interference contrast) images are presented.
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Figure 3-11: Immunofluorescence (IF) of the sub-cellular redistribution of CASPASE-
14 protein in MCF-7 cells.
(A) Goat polyclonal secondary antibody to rabbit IgG - H&L (Green DyLight 488) used as
negative control. 4-Hydroxytamoxifen untreated (B) and treated (C) MCF-7 cells were
incubated with CASPASE-14 primary Anti-Rabbit antibody and goat Anti-Rabbit IgG H&L
secondary antibody. DAPI was used to stain the cell nuclei (blue) at a concentration of
1.43µM. Merged and DIC (Differential interference contrast) images are presented.
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Figure 3-12: Immunofluorescence (IF) of the sub-cellular redistribution of MT-CO2
protein in MCF-7 cells.
(A) Goat polyclonal secondary antibody to rabbit IgG - H&L (Green DyLight 488) used as
negative control. 4-Hydroxytamoxifen untreated (B) and treated (C) MCF-7 cells were
incubated with MT-CO2 primary Anti-Rabbit antibody and goat Anti-Rabbit IgG H&L
secondary antibody. DAPI was used to stain the cell nuclei (blue) at a concentration of
1.43µM. Merged and DIC (Differential interference contrast) images are presented.
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A schematic summary of the experimental workflow, including SILAC labeling, stimulation,
and MS quantification, is shown in Figure 3-13. Experimental measurements of protein
abundance ratios (SILAC ratios) between stimulated/unstimulated cells were obtained for
three samples: (1) an unfractionated, total cell lysate (T), (2) a nucleus-enriched sample
obtained by subcellular fractionation (N), and (3) the corresponding nucleus-depleted sample
(C), which we refer to as the cytoplasm in the following text. The corresponding SILAC
ratios provide measures for each protein of the overall change in total cellular abundance
(St), or of the localized change in abundance in the nuclear (Sn) or cytoplasmic (Sc)
subcellular compartments. Across the three data sets, 2125, 1979, and 3358 proteins were
observed in the C, N and T samples respectively (Figure 3-14, Supplementary Table 3-6).
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Figure 3-13: Schematic summary of the experimental workflow.
Figure 3-14: Venn diagram showing the number of output data sets and identified
proteins in the three sample types (CNT).
The merged final dataset of the three sample types (CNT) of the 3493 proteins quantified
with ≥ 1 peptide count and quantified with ≥2 SILAC counts.  
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3.2.1.1 Changes in abundance for the nuclear and cytoplasmic fraction
For each sample type, we measured three technical replicates (Figure 3-13). The three data
sets representing each fraction showed high correlation between the three replicates
(0.85<R2<0.88, 0.90<R2<0.91, 0.64<R2<0.85 for the total lysate, cytoplasmic, fractions, and
nuclear fraction, respectively: Figure 3-15).
The overall changes in abundance for the proteins are shown in Table 3-3. The inset tables
show the number and percentage of proteins with >4-fold or >2-fold changes in total
abundance (St), nuclear compartment abundance (Sn), and cytoplasmic compartment
abundance (Sc). The table also shows for each distribution the total number of proteins
included, the median number of SILAC ratio counts, and the number of proteins with smaller
numbers of SILAC ratio counts.
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Figure 3-15: Correlation of SILAC ratio between three replicate for the total,
cytoplasmic and nucleus.
All the proteins with ≥ 3 ratio counts were included in the calculation of correlation. Outliers 
mostly correspond to proteins with low numbers of ratio counts. Outliers mostly correspond
to proteins with low numbers of ratio counts.
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Table 3-3: Distribution of SILAC ratios (5 versus 3) for proteins from the total lysate
(St), nuclear (Sn), and cytoplasmic (Sc) samples.
(Upper)_All proteins with ≥5 ratio counts for the union of the three replicates for each 
sample type; (Bottom)_All proteins with ≥3 ratio counts for all replicates of each sample 
type.
T union ≥ 5 counts C union ≥ 5 counts N union ≥ 5 counts 
Log 2 (St) Proteins %Proteins Log 2 (Sc) Proteins
%
Proteins Log 2 (Sn) Proteins
%
Proteins
>2 146 7.2 >2 13 1.1 >2 25 2.7
>1 367 18.2 >1 116 9.8 >1 176 19.1
-1<and<1 878 43.4 -1<and<1 989 83.7 -1<and<1 667 72.2
<-1 776 38.4 <-1 81 6.8 <-1 79 8.6
<-2 200 9.9 <-2 33 2.9 <-2 43 4.7
Number of proteins Number of proteins Number of proteins
Counts=5 5≤ and <8
Average
SILAC
counts=32
Counts=5 5≤ and <8
Average
SILAC
counts=24
Counts=5 5≤ and <8
Average
SILAC
counts=17
188 516 2021 95 237 1181 95 224 922
T replicate ≥ 3 counts C replicate ≥ 3 counts N replicate ≥ 3 counts 
Log 2 (St) Proteins %Proteins Log 2 (St) Proteins
%
Proteins Log 2 (Sn) Proteins
%
Proteins
>2 144 9.1 >2 11 0.8 >2 34 3.0
>1 303 19.3 >1 151 11.6 >1 224 19.9
-1<and<1 697 44.4 -1<and<1 1049 80.6 -1<and<1 803 71.5
<-1 571 36.3 <-1 102 7.8 <-1 96 8.5
<-2 150 9.5 <-2 33 2.5 <-2 45 4.0
Number of proteins Number of proteins Number of proteins
Counts=9 9≤ and <12
Average
SILAC
counts=6
Counts=9 9≤ and <12
Average
SILAC
counts=13
Counts=9 9≤ and <12
Average
SILAC
counts=17
46 164 1571 41 121 1302 40 105 1123
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For 2021 total lysate (T) proteins with ≥ 5 SILAC ratio counts across the three replicates 
(average SILAC counts of 32 counts per protein), 513 proteins (roughly 25%) were
upregulated with 146 (7.2 %) and 367 (18.2%) proteins showing greater than 4-fold and 2-
fold increase in abundance, respectively (Table 3-3, upper). Differently, a double number of
proteins (976 proteins, almost 50%) were downregulated with 150 (9.5 %) and 571 (36.3 %)
proteins greater than 4-fold and 2-fold decrease in abundance, respectively. This massive
downregulation of total proteins was even supported by a greater number of the
downregulated metabolic pathways versus upregulated ones in the total lysate as reported
below.
To check for possible distortion of the distribution profile by lower abundance proteins
and/or by variation between replicates, these results were compared with a smaller set of
1571 more abundant proteins for which the lower limit was set to ≥ 3 SILAC ratio counts in 
all three T replicates (average of 6 SILAC counts per protein, Table 3-3, bottom).
A lower number of the nuclear proteins with ≥ 5 SILAC ratio counts across the three 
replicates (average of 17 SILAC counts per protein) predicted a very different behaviour in
nuclear compartment (Table 3-3, upper). For 922 nuclear proteins with ≥ 5 SILAC ratio 
counts across the three replicates (average of 17 SILAC counts per protein), 176 proteins
(19.1%) showed greater than 2-fold increase in nuclear abundance. However, 43 proteins
(4.7%) showed greater than 4-fold decrease and 79 proteins (8.6%) showed greater than 2-
fold decrease in nuclear abundance. For 1123 more abundant nuclear proteins with ≥ 3 
SILAC ratio counts in all three N replicates (average of 17 SILAC counts per protein), a
similar distribution profile for the SILAC ratio Sn for nuclear proteins indicated that lower
abundance proteins and/or variation between replicates had a little effect on the observed
distribution (Table 3-3, bottom).
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For 1181 cytoplasm proteins with ≥ 5 SILAC ratio counts across the three replicates 
(average of 24 SILAC counts per protein), the most of proteins (83.7%) showed less than 2-
fold increase/decrease in abundance whereas 116 (9.8%) and 81 proteins (6.8%) reveal a
greater than 2-fold increase and decrease in nuclear abundance, respectively. Interestingly,
for the cytoplasm, similarly to the nuclear compartment, an equivalent number of proteins as
well as the ratios between the decreasing/increasing proteins in abundance were still
observed in spite of a lower limit set to ≥ 3 SILAC ratio counts.  
138
3.2.1.2 Changes of proteome after exposure to 4-OHT
In response to 4-OHT treatment, we obtained two significant datasets referred to as extended
(overall response) (270-TAM) and the core (specific response) (97-TAM) (see material and
method), when applicable, throughout the result and discussion sections. As it is not
uncommon to find a uniformed data scale and/or distributions among these two proteomics
datasets, these two datasets were obtained from the same quantitative study (Supplementary
tables 7 and 8).
Thus, we used the larger list (270-TAM) to increase the power of statistical inference when
uploading to iPathwayGuide software to predict the functional proteomics changes. Thus, a
total of 94 (31 up and 63 down), 87 (29 up and 58 down), 139 (51 up and 88 down) proteins
were selected as DE from C, N, and T samples (Figure 3-16A and C), respectively, and used
in the subsequent analysis to tell the biological theme(s) for these proteins. The general
response data set (270-TAM) contains proteins that are DE, and lacking more than one
peptide and/or more than 2 SILAC counts for identification and quantification, respectively.
Our assumption in this project is that to predict the response it is not enough to relay on the
change of expression, alone. Therefore, the reliable response data set obtained in this project
contains a list of proteins that are: (i) reliably identified (> 1 peptide count), (ii) quantified
(3 SILAC counts), and have a distribution of significance in the three sample types. Based
on these criteria, the reliable list (97-TAM) was selected from the large list (270-TAM). Of
the general response data set (270-TAM) proteins selected from the correlation data set
(CNT) according to the above mentioned criteria, a set of 97 proteins are showing the most
significant changes (Figure 3-16B). The distribution scores of significance over the CNT are
summarized in Table 3-4. In this data set, 51 proteins were selected as DE out of a total of 97
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proteins with measured expression in the cytoplasmic fraction (C), 51 proteins out of 97 in
the nuclear fraction (N), and 29 proteins out of 97 in the total lysate (T).
More than 50% of the proteins show significant changes in local abundance and/or
redistribution of their subcellular location (C and N) and only 19 proteins (19% of the entire
97-significant set) show substantial changes in the total lysate (T) (Table 3-4).
Table 3-4: The significance B scores distribution of 97-TAM proteins over the three
sample types.
Cytoplasm
(Union)
Nuclear
(Union)
Total
(Union)
Number of
proteins
Significance B score distribution
+ (6); - (18) 24
+ (10); - (15) 25
+ (6); - (13) 19
+ (5); - (14) + (5); - (14) 19
+ (1); - (4) + (1); - (4) + (1); - (4) 5
+ (1); - (1) + (1); - (1) 2
+ (4); - (4) + (3); - (5) 8
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Figure 3-16: Distribution of the significant proteins over the three sample types in 270-
and 97-TAM datasets.
Venn diagrams representing the distributions and the intersections over the three sample types
for the sets of (A) 270 and (B) 97 significantly changed proteins, unique and/or shared in the
CNT set. (C) Volcano plot: all 270 are DE proteins and represented in terms of their measured
expression change (horizontal) and the significance of their change (vertical). The significance
is represented in terms of the negative log of the p-value (i.e., larger number means more
significant). The dotted lines represent the threshold used to select the DE genes: ±1 for
expression change and 0.05 for significance.
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3.2.1.3 Meta-analysis of the functional pathways
In the union of three individual mass spectrometry runs (replicates) of each sample type,
there were 1704, 1487, and 2858 proteins with measured expression out of the total
identified proteins in the C, N, and T sample types, respectively. These protein list were
mapped to the approved gene symbols and reloaded into iPathway Guid software to compute
the impact pathway analysis using two types of probability (p-value) :(i) pOVR for the DE
proteins in a given pathway and (ii) the perturbation/accumulation p-value (pACC) that
computes the perturbation of the given pathway considering not only the enrichment analysis
of the DE proteins, but their topological information including direction and type of signals,
position, and role in the pathway (more details see materials and methods).
In summary, 94, 78, 1nd 139 proteins (270-TAM) were selected as DE proteins (<0.05 and
±1 log2 FC) out total with measured expression in the C, N, and T sample types,
respectively.
In these three sample types (CNT), there were 19 (C), 43 (N), and 28 (T) pathways found to
be significantly impacted (Supplementary Table 7). The p-value was corrected for multiple
comparison (meta analysis) using FDR (<0.05) for the number of significantly impacted
pathways in each sample type (Figure 3-17). The top ranked pathways, in each sample type,
were selected after eliminating false positives (5% FDR) (Table 3-5). This analysis showed
that protein changes in abundance with 4-OHT across multiple conditions were involved in
pathways related to metabolism, signal transduction, growth and proliferation, and
development (see Supplementary Table 9).
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Figure 3-17: Meta analysis Venn diagrams of pathways that are in common or unique
across low confidence data set, before and after p-value correction.
TAM-270 data set were filtered as to include the pathways found to be significantly
impacted based on corrected p-value (FDR).
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In the total lysate experiment (T), five top ranked pathways were identifed as signifcantly
impacted and indicate that the significantly changed proteins constitute overrepresntation of
metabolic pathways and oxidative phosophorylation (p = 9.1 e-05), and fructose and mannose
metabolism (p = 0.005). The protein alterations in the top two pathways were affecting the
oxidative phosphorylation. Proteins that were upregulated/downregulated were belonging to
the total lysate fraction (T) (Figure 3-18), wherase seven proteins, ALDOA (C), IDH1 (C),
LDHA (Sn), MTCO2 (C,N), TKT (N,T), EBP (C), NANS (C,T), all of which were
upregulated in the C and/or N fractions with or without change in total aboundance, and
seven were downregulated CKMT2 (C), NDUFV3 (N), OAT (N), P4HA1 (C), TST (C,N),
NNT (N), and PGLS (C), which were down-regulated in the subcellular fractions (Sn and/or
Sc) without change in the total aboundance.
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Table 3-5: Top KEGG pathways significantly impacted in the three sample types CNT
(TAM-270 data set) and their associated corrected (FDR) p-values.
Cytoplasmic Fraction
Pathway name Pathway Id p-value p-value (FDR)
Hypertrophic cardiomyopathy (HCM) * 5410 7.67E-05 0.008
Dilated cardiomyopathy 5414 3.16E-04 0.016
Cardiac muscle contraction * 4260 0.001 0.036
Calcium signalling pathway 4020 0.001 0.036
Adrenergic signalling in cardiomyocytes 4261 0.003 0.052
Nuclear Fraction
Pathway name Pathway Id p-value p-value (FDR)
Circadian entrainment 4713 6.20E-05 0.007
Dilated cardiomyopathy 5414 5.59E-04 0.016
Adrenergic signalling in cardiomyocytes 4261 0.001 0.018
Hypertrophic cardiomyopathy (HCM) * 5410 0.002 0.02
Pathways in cancer 5200 0.004 0.039
Total Lysate Fraction
Pathway name Pathway Id p-value p-value (FDR)
Metabolic pathways * 1100 9.48E-07 9.13E-05
Oxidative phosphorylation * 190 2.50E-06 9.13E-05
Non-alcoholic fatty liver disease (NAFLD) 4932 6.60E-06 1.78E-04
ECM-receptor interaction 4512 6.37E-05 0.001
Fructose and mannose metabolism * 51 3.55E-04 0.005
*the p-value corresponding to the pathway was computed using only over-representation analysis.
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Based on the statistical selection criteria (significance B <0.05), GSS (glutathione synthetase
) was quantified in both C, T samples with significant upregulation in the T sample (St=
5.244 and p= 0.002), only. Hence, this protein was not quantified in the nuclear fraction; it
was filtered out of the stringent list (97-TAM) showing the distribution of significance in the
three sample types based on the selection criteria described in the material and method
section.
GSS has a protective role in the cells, among other functions, that is to prevent the oxidative
damage by oxidative stress. Notably, the proteins significantly down regulated were related
to the oxidative phosphorylation pathway. Moreover, MTCO2 was shown significant
increase in the C and N sample and NDUFV3 in N without change in the total abundance
associated with either of the two proteins (Figure 3-18A).
The subcellular proteomics (C and N) results shows that the proteins that are related to
regulation of the actin cytoskeleton, focal adhesion, adherens junctions were correlated with
the overrepresentation of two pathways, in common (Figure 3-17), hypertrophic
cardiomyopathy (HCM) -and dilated cardiomyopathy (Table 3-5). Most of the proteins that
were affecting these pathways (ATP2A2, DES, DMD, ITGA3, MYBPC3, MYH6, MYL2,
MYL3, TNNC1, and GNAS) were downregulated in the subcellular data sets (C and N); the
exception was DMD that was decreased in all sample types (CNT) in both pathway and
GNAS that was increased in the N sample and affecting the dilated cardiomyopathy (Figure
3-18B).
Furthermore, circadian entailment was significantly impacted (overrepresentation verses
total perturbation) in N sample (P = 0.007) suggesting that altered proteins involved in this
pathway (CALML3, GNAI2, GNAQ, GNAS, GNB1, GNB2, and CALML5) have a role in
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the cell cycle and signal transduction; the distribution of significance of these proteins in the
three sample types is shown in Figure 3-18C.
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Figure 3-18: Identification of deregulated pathways.
Distribution of up- and down-regulation of total proteins (blue bar), nuclear proteins (green
bar) and cytoplasmic proteins (red bar) in Metabolic pathway (A) and in Hypertrophic
dilated cardiomyopathy (B) and circadian entailment (C). Note: The arrow indicates the
extra protein present only in dilated cardiomyopathy.
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A number of proteins show a possible correlation between the cross talk between pathways
and the distribution of proteins in the three sample types enriched in our method.
The data shows that there would be a possible cross talk between pathways that related to the
spatial distribution of DE proteins rather than overlapping between them. From the analytical
results, it was found that the Pathway in cancer (p = 0.039) was significantly impacted in N
sample with six Guanine nucleotide-binding proteins (G proteins) and ITGA3, all of which
were upregulated in N fraction except ITGA3 was down regulated and GNA13 was
significantly upregulated in C and N samples (Figure 3-19). Furthermore, four DE proteins
that were identified in the T sample were downregulating ECM-receptor interaction pathway
(p = 0.001). The total perturbation (overrepresentation verses total accumulation) was
depicted by iPathway software showing down-regulation of integrin alpha 1/beta 1, however,
ITGA3 was significantly decreased in the N, but not T or C samples (Figure 6). The
crosstalk analysis of signal transduction pathways in breast cancer has identified number of
DE genes were overlapped between ECM and Pathways in cancer pathways (Sun et al.,
2015).
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Figure 3-19: Enrichment of Pathways in cancer pathway (KEGG: 05200).
The pathway diagram is overlayed with the computed total perturbation of each gene. The
total perturbation accounts both for the gene's measured fold change and for the accumulated
perturbation propagated from any upstream genes which is referred to as total accumulation.
The legend highlights the different gradients from the highest negative perturbation (dark
blue) and, to the highest positive perturbation (dark red). (A) Gene perturbation bar plot: All
the genes in Pathways in cancer pathway are ranked based on their absolute perturbation in
the N sample. For each gene we represent the signed perturbation with negative values in
blue and positive values in red. (B) Distribution of up- and down-regulation of total proteins
(blue bar), nuclear proteins (green bar) and cytoplasmic proteins (red bar) in Pathways in
cancer pathway.
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Figure 3-20: Enrichment of ECM-receptor interaction pathway (KEGG:
04512).
The pathway diagram is overlayed with the computed total perturbation of each gene. The
total perturbation accounts both for the gene's measured fold change and for the
accumulated perturbation propagated from any upstream genes which is referred to as
total accumulation. The legend highlights the different gradients from the highest negative
perturbation (dark blue) and to the highest positive perturbation (dark red). (A) Gene
perturbation bar plot: All the genes in ECM-receptor interaction pathway are ranked based
on their absolute perturbation in the T sample. For each gene we represent the signed
perturbation with negative values in blue and positive values in red. (B) Distribution of
up- and down-regulation of total proteins (blue bar), nuclear proteins (green bar) and
cytoplasmic proteins (red bar) in ECM-receptor interaction pathway.
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3.2.1.4 GO enrichment analysis
We used the approval gene symbols to upload the proteomics data; therefore, to refer to
protein belonging to specific gene, we used the gene expression term in this section, instead
of protein expression. In the classical approach of GO annotation, all GO terms considered to
be independent; i.e., considering the hierarchical structure of GO terms, the list of genes
annotated to a specific term are also annotated to all ancestors in the hierarchy of that term.
To overcome this problem, iPathway Guide software uses Elim method that iteratively
removes the genes mapped to significant GO terms from more general (higher level) GO
terms (Alexa et al., 2006). Figure 3-21A and B show the number of GO terms was reduced
in all three samples after imposing Elim correction method compared to the number before
correction, thus unnecessary redundancy was removed.
Biological process (BP) annotation of genes by subcellular fractionation (C and N) revealed
significant enrichment for a interaction process of myosin located on a thick filament with
actin, signal transduction, growth and development, and apoptotic process. Whereas, among
the top ranked five BP/MF enriched with the DE genes were related to cellular respiratory
system, metabolism, protein synthesis, in the total lysate sample (T), the number of
overlapped, top ranked, BP/MF were detected among all fractions that are related to the
distribution of significance of the identified DE genes (Figure 3-21A and B). Of these is
RAGE receptor binding (4DE/6ALL), (3DE/4ALL), and (4DE/6ALL) in C, N, and T,
respectively; three out of four proteins involved in MF were down regulated in all down
regulated in all sample types (S100A7, S100A8, and S100A9), whereas S100A13 was
upregulated in T sample, only. However, Toll-like receptor 4 binding function was enriched
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in the C, T, N (2DE/2ALL), where two proteins were significantly reduced in all sample
types (S100A8 and S100A9). The distribution of significance in the proteins that are
involved cell growth, apoptotic process, platelet activation, cellular respiration biological
processes (BP) in the three sample types are shown in Figure 3-22.
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Figure 3-21: Metanalysis venn diagrams of GO terms that are in common or unique
across low confidence data set, before and after p-value correction.
TAM-270 data set were filtered as to include the biological process (A) and molecular
function (B) GO found to be significantly enriched based on corrected p-value (Elim
pruning).
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Figure 3-22: Gene ontology enrichment.
All the DE genes that are annotated to (A) cell growth (GO-0016049), (B) apoptotic process
(GO-0006915), (C) respiratory electron transport (GO-0022904), and (D) platelet activation
(GO 0030168). The distribution of significance in the three sample types is shown as total
proteins (blue bar), nuclear proteins (green bar) and cytoplasmic proteins (red bar).
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Table 3-6: Top GOBP and MF significantly enriched in the three sample types CNT
(TAM-270 data set) and their associated corrected (FDR) p-values (Elim method).
GO:BP # genes(DE/ALL)
p-
value GO:BP
# genes
(DE/ALL) p-value GO:BP
# genes
(DE/ALL)
p-
value
Cytoplasmic Fraction (C) Nuclear Fraction (N) Total Lysate (C)
muscle filament
sliding 8 / 13
4.20E-
08
muscle
filament
sliding
8 / 15 3.20E-07
mitochondrial
electron transport,
NADH to
ubiquinone
9 / 34 8.70E-05
signal
transduction 38 / 462 0.004
sarcomere
organization 4 / 9 0.00093
protein
heterotrimerization 3 / 4
3.80E-
04
cell growth 8 / 40 0.007
adenylate
cyclase-
activating G-
protein
coupled
receptor
signalling
pathway
4 / 5 0.003
respiratory
electron transport
chain
16 / 75 0.002
epidermis
development 9 / 26 0.028
platelet
activation 9 / 40 0.003 gluconeogenesis 5 / 28 0.008
apoptotic
process 21 / 242 0.044
energy
reserve
metabolic
process
5 / 20 0.004
extracellular
matrix
disassembly
4 / 19 0.01
GO:MF # genes(DE/ALL)
p-
value GO:MF
# genes
(DE/ALL) p-value GO:MF
# genes
(DE/ALL)
p-
value
calcium ion
binding 16 / 69
2.80E-
07
G-protein
beta/gamma-
subunit
complex
binding
4 / 6 1.30E-04
RAGE receptor
binding 4 / 6
5.30E-
05
structural
constituent of
muscle
4 / 10 0.001 calcium ionbinding 10 / 54 0.00059
cytochrome-c
oxidase activity 5 / 11
6.00E-
05
RAGE receptor
binding 3 / 6 0.003
RAGE
receptor
binding
3 / 4 0.00067
structural
constituent of
ribosome
13 / 117 0.002
neutral amino
acid
transmembrane
transporter
activity
2 / 2 0.003
signal
transducer
activity
8 / 42 0.002 Toll-like receptor 4binding 2 / 2 0.002
Toll-like
receptor 4
binding
2 / 2 0.003
Toll-like
receptor 4
binding
2 / 2 0.003
fructose 1,6-
bisphosphate 1-
phosphatase
activity
2 / 2 0.002
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3.2.1.5 Changes in subcellular compartments abundance and the impact on the
functional pathways
For the 97 set of proteins (reliable data set), we carried out an additional pathway analysis,
using a public data base (InnateDB) that incorporated Reactome, and we conducted pathway
analysis to envisage the possible role/impact of the distribution of proteins on the systematic
biological perturbations (Supplementary Table 12). The top pathways of upregulated
proteins for the three sample types (CNT) are shown in (Table 3-7) and the highest ranked
down regulated pathways are shown in (Table 3-8) with the deregulated proteins enriched in
each pathway. Pathways that are related to signal transductions, growth, and development
are regulated (up/down) mostly due to changes in the subcellular compartmental proteins (C
and N) rather than total changes. The total response (T) as revealed from the top ranked
pathways reflects changes in the metabolic processes associated with appreciable change that
we observed in the subcellular compartments. In the most of metabolic pathways, total
proteins were strongly downregulated, e.g. in TCA cycle and respiratory electron transport,
and upregulated for others, e.g. metabolism of carbohydrates.
Among the top ranked downregulated pathways, different distribution in the downregulation
of 12 pathways was observed for the cytoplasm (50%), nucleus (less than 10%) and total
lysate (more than 40%) (Table 3-8).
The most of proteins associated to metabolic pathways (Table 3-5) were similarly identified
by Reactome pathway analysis, which confirmed their subcellular distribution in the detected
compartment, e.g. ALDOA (Sc), MTCO2 (Sc, Sn), OAT (Sn), LDHA (Sn), COX 5A
(St), ATP5L (St), NDUFA4 (St), NDUFB6 (St). The same similarity was observed for
other proteins, e.g. GNAS (Sn), GNB1 (Sn), MYL3 (Sc, Sn), ITG3 (Sn), as some of
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these proteins representing a cross talk scenario as depicted from pathway analysis using
iPathwayGuid software.
Within the reliable data set (97-TAM) set, interestingly some proteins (20%) were shared
between nucleus and cytoplasm (Table 3-4) sowing no changes in the total abundances.
Among these proteins, 14 proteins were downregulated and 5 were upregulated for
cytoplasm and nucleus compartments (Table 3-4). The distribution calculations (Sn/Sc) and
the GOCC (cellular components), of the 19 set of proteins are shows in Table 3-9. This set of
proteins showed strong changes in nuclear and cytoplasmic abundance without showing any
significant change of total abundance.
Quantitative data show that, after the Tamoxifen stimulation, a marked decrease of
compartmental abundance were recorded for CASP14 with a more than 4-fold decrease in
the nuclear compartments (Sn -2.488107, p-value 0.000767178) and a more than 2-fold
decrease in the cytoplasmic one (Sc -1.787169, p-value 0.008297533). In absence of changes
in total abundance, CASP14 was significantly redistributed in cytoplasm (N → C). 
Otherwise, for MTCO2 protein, a greater 4-fold increase of nuclear abundance (Sn 2.873302,
p-value 0.0051) at the expense of cytoplasmic one (Sc 1.819, p-value 0.0036) pointed out an
opposite redistribution C → N. These relevant proteins, CASP14 and MT-CO2, were also 
chosen for MS validation by confocal microscopic analysis (Figure 3-11Figure 3-12).
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Table 3-7: Top ranking overrepresented upregulated reactome pathway (TAM-97)
(Innate DB).
Condition Pathway Name Pathway
uploaded
gene count
Pathway up-
regulated
genes count
Pathway up-
regulated p-
value
Genes (Symbol|Subcellular
distribution of significance)
UP:Down:No change
Sn Hemostasis 10 6 0.00184052
ALDOA|Sc:Sn:St; ATP2A2|Sc:Sn:St;
GNA13|Sc:Sn:St; GNAS|Sc:Sn:St;
GNB1|Sc:Sn:St; GNB2|Sc:Sn:St;
HBB|Sc:Sn:St; ITGA3|Sc:Sn:St;
SLC3A2|Sc:Sn:St; STX4|Sc:Sn:St;
St Disease 11 5 0.003473005
ALDOA|Sc:Sn:St; CYB5R3|Sc:Sn:St;
GNB1|Sc:Sn:St; PGAM1|Sc:Sn:St;
PSMA6|Sc:Sn:St; PSMB6|Sc:Sn:St;
PSMC6|Sc:Sn:St; RPLP1|Sc:Sn:St;
SLC25A4|Sc:Sn:St; TKT|Sc:Sn:St;
TPI1|Sc:Sn:St;
Sn GPCR downstreamsignaling 5 4 0.00347368
ANXA1|Sc:Sn:St; GNA13|Sc:Sn:St;
GNAS|Sc:Sn:St; GNB1|Sc:Sn:St;
GNB2|Sc:Sn:St;
Sn Integration ofenergy metabolism 5 4 0.00347368
GNAS|Sc:Sn:St; GNB1|Sc:Sn:St;
GNB2|Sc:Sn:St; SLC25A4|Sc:Sn:St;
TKT|Sc:Sn:St;
Sn
Platelet activation,
signaling and
aggregation
5 4 0.00347368
ALDOA|Sc:Sn:St; GNA13|Sc:Sn:St;
GNB1|Sc:Sn:St; GNB2|Sc:Sn:St;
STX4|Sc:Sn:St;
St Metabolism ofcarbohydrates 4 3 0.005725846
ALDOA|Sc:Sn:St; PGAM1|Sc:Sn:St;
TKT|Sc:Sn:St; TPI1|Sc:Sn:St;
St Metabolism 26 7 0.010673624
ALDOA|Sc:Sn:St; ATP5L|Sc:Sn:St;
CA2|Sc:Sn:St; COX5A|Sc:Sn:St;
COX5B|Sc:Sn:St; CYB5R3|Sc:Sn:St;
FAM36A|Sc:Sn:St; GNAS|Sc:Sn:St;
GNB1|Sc:Sn:St; GNB2|Sc:Sn:St;
HBA2|Sc:Sn:St; HBB|Sc:Sn:St;
LDHA|Sc:Sn:St; MT-CO2|Sc:Sn:St;
NDUFA4|Sc:Sn:St;
NDUFB6|Sc:Sn:St; OAT|Sc:Sn:St;
PGAM1|Sc:Sn:St; PSMA6|Sc:Sn:St;
PSMB6|Sc:Sn:St; PSMC6|Sc:Sn:St;
SLC25A4|Sc:Sn:St; TKT|Sc:Sn:St;
TPI1|Sc:Sn:St; TST|Sc:Sn:St;
TXNRD1|Sc:Sn:St;
St Cell Cycle, Mitotic 5 3 0.013346428
PSMA6|Sc:Sn:St; PSMB6|Sc:Sn:St;
PSMC6|Sc:Sn:St; SET|Sc:Sn:St;
YWHAE|Sc:Sn:St;
Sn Aquaporin-mediated transport 4 3 0.018559377
GNAS|Sc:Sn:St; GNB1|Sc:Sn:St;
GNB2|Sc:Sn:St; RAB11A|Sc:Sn:St;
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Table 3-8: Top ranking overrepresented downregulated reactome pathway (TAM-97)
(Innate DB)
Condition Pathway Name
Pathway
uploaded
gene count
Pathway
down-
regulated
genes count
Pathway
down-
regulated p-
value
Genes (Symbol|Subcellular
distribution of significance)
UP:Down:No change
St Respiratory electrontransport 7 6 4.54E-05
ATP5L|Sc:Sn:St; COX5A|Sc:Sn:St;
COX5B|Sc:Sn:St;
FAM36A|Sc:Sn:St;
MT-CO2|Sc:Sn:St;
NDUFA4|Sc:Sn:St;
NDUFB6|Sc:Sn:St
St
The citric acid (TCA)
cycle and respiratory
electron transport
8 6 1.67E-04
ATP5L|Sc:Sn:St;
COX5A|Sc:Sn:St;
COX5B|Sc:Sn:St;
FAM36A|Sc:Sn:St;
LDHA|Sc:Sn:St; MT-
CO2|Sc:Sn:St; NDUFA4|Sc:Sn:St;
NDUFB6|Sc:Sn:St
Sn Striated MuscleContraction 4 4 0.013796563
DES|Sc:Sn:St; MYBPC3|Sc:Sn:St;
MYH6|Sc:Sn:St; MYL3|Sc:Sn:St
St Orphan transporters 4 3 0.014456399
COX5A|Sc:Sn:St;
COX5B|Sc:Sn:St;
FAM36A|Sc:Sn:St;
MT-CO2|Sc:Sn:St
St
SRP-dependent
cotranslational protein
targeting to membrane
2 2 0.027329193 RPLP1|Sc:Sn:St; SSR4|Sc:Sn:St
St Translation 2 2 0.027329193 RPLP1|Sc:Sn:St; SSR4|Sc:Sn:St
Sc Striated MuscleContraction
4 3 0.034965836 DES|Sc:Sn:St; MYBPC3|Sc:Sn:St;
MYH6|Sc:Sn:St; MYL3|Sc:Sn:St
Sc Apoptotic cleavage ofcell adhesion proteins
2 2 0.049689441 DSG1|Sc:Sn:St; DSP|Sc:Sn:St
Sc Apoptotic cleavage ofcellular proteins 2 2 0.049689441 DSG1|Sc:Sn:St; DSP|Sc:Sn:St
Sc Apoptotic executionphase 2 2 0.049689441 DSG1|Sc:Sn:St; DSP|Sc:Sn:St
Sc
Binding and Uptake of
Ligands by Scavenger
Receptors
2 2 0.049689441 DSG1|Sc:Sn:St; DSP|Sc:Sn:St
Sc Scavenging of hemefrom plasma 2 2 0.049689441 DSG1|Sc:Sn:St; DSP|Sc:Sn:St
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Table 3-9: List of 19 proteins showing significant changes in compartmentalized
abundance (Sc, Sn), in the absence of significant changes in total fraction.
Gene
symbol GO-Cellular component
Sc
Union
Sn
Union log(Sn/Sc) Distribution
SLC3A2 Nucleus, cytoplasm, plasma membrane,
membrane, extracellular vesicular exosome
1.396 2.637 1.241 C→N 
MT-
CO2*
Mitochondrion, mitochondrial inner membrane,
membrane, extracellular vesicular exosome
1.819 2.873 1.054 C→N 
MYL3 Cytosol -1.976 -2.952 -0.977 N→C 
SLC25A4 Nucleus, mitochondrionmitochondrial inner and plasma membrane -3.033 -2.169 0.864 C→N 
MYH6 Nucleus, cytoplasm, cytosol -3.649 -3.297 0.352 C→N 
DSP
Nucleus, mitochondrion, cytoskeleton intermediate
filament plasma membrane, cell-cell junction
extracellular vesicular exosome
-2.494 -2.575 -0.081 N→C 
DES Cytoplasm, cytosol, cytoskeleton -1.803 -3.688 -1.885 N→C 
CASP14* Nucleus, cytoplasm,
extracellular vesicular exosome
-1.787 -2.488 -0.701 N→C 
HBB Extracellular region, cytosol,
extracellular vesicular exosome
-2.522 -2.812 -0.291 N→C 
HBA2 Extracellular region, cytosol,
extracellular vesicular exosome
-2.824 -4.035 -1.211 N→C 
DCD extracellular region,
extracellular vesicular exosome
-3.879 -4.513 -0.634 N→C 
DSG1 Cytosol, plasma membrane, membrane,
cell-cell junction, extracellular vesicular exosome
-2.571 -2.212 0.359 C→N 
DSC1 Plasma membrane, membrane,
gap junction, extracellular vesicular exosome
-2.594 -2.606 -0.012 N→C 
GNA13 Nucleus, plasma membrane, membrane
extracellular vesicular exosome
1.221 3.130 1.909 C→N 
TST
Extracellular space, mitochondrion, mitochondrial
inner membrane, mitochondrial matrix, extracellular
vesicular exosome
-2.131 -1.456 0.675 C→N 
FUBP1 Nucleus -1.798 -2.080 -0.282 N→C 
LYAR Nucleus, nucleolus 7.707 7.096 -0.611 N→C 
CALML5 extracellular vesicular exosome -2.752 -2.972 -0.220 N→C 
MTCH2
Nucleus, mitochondrion, mitochondrial inner
membrane, membrane, extracellular vesicular
exosome
1.489 2.220 0.730 C→N 
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Chapter 4 Discussion
4.1 Part-I: Spatial dynamics in response to oestrogen-stimulated breast cancer
cell line (MCF-7)
Overall, the present results indicate that substantial changes in protein abundance in the
nuclear/cytoplasmic compartments are observed for about ten times more proteins than those
that show large changes in total cellular abundance. To put it plainly, the prevailing outcome
of the exposure of MCF-7 cells to E2 shows broad relocation of the labelled subcellular
proteins as opposed to alterations in their aggregate abundance. To address this, the
following discussion covers three parts corresponding to the three main themes of this work:
(1) Assess the suitability and robustness of subcellular spatial razor for examination of this
predominant cell response and compare the changes on three consecutive fractions (CNT);
(2) To address the relationship between protein subcellular localizations and the
reconciliation of cell utilitarian networks, particularly in association with the nuclear
hormone receptors; (3) conceivable ramifications related to cancer.
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4.1.1 Cellular function and the properties of the spatial razor
The present results show a strong preponderance in the number of proteins with appreciable
N → C redistribution following exposure of MCF7 cells to estradiol. It is important to
emphasize that this does not imply that the total mass of nuclear proteins is dramatically
decreased, and in fact, the present results could still be consistent with an increase in the total
mass of nuclear proteins. This is on the grounds that the discrete proteins possess altogether
dissimilar cellular abundances and altogether diverse basal skewing between cytoplasm and
nucleus. Subjectively, four noteworthy classes of proteins can be recognized in the present
results (Figure 3-7). (a) Proteins show observable changes in the total abundance without
changes in the subcellular compartmentalization, suggesting minor functional role for these
proteins in the cellular response. (b) Proteins for which their reduced levels of expression
were predominantly observed in the nucleus, for the majority of this subset there were
limited changes in the cytoplasmic fraction (Figure 3-7), i.e. little extents of cytoplasmic
proteins located at the nucleus are deported after E2 stimulation. (c) Proteins that are
characterized, in this study, with the major increase in the abundance limited to the
cytoplasm were associated with minor changes in the nuclear abundance, indicating that
nuclear proteins are expelled to the cytoplasm (Figure 3-7). (d) Proteins that exhibit
generous changes in abundance in both compartments, just a minority of which (10 of 77,
Figure 3-7A) show >2-fold changes in both compartments.
We propose (see below) that proteins in classes (b) and (c) represent messengers that
transmit information about cellular state between the nucleus and other subcellular locations,
and note that although they involve smaller proportions of proteins, their influence on
cellular function can be important due to strong nonlinearities in cellular function.
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The last category of proteins in class (d) involves set of proteins that may have importance to
check and balance the overall functions states; this property is not necessarily limited to E2
stimulation and may have relevance to the numerous incitements (see below). A noteworthy
observation is that spatial razor model has helped the detection of the proteins in classes (b)
– (d); these limits of changes are basically imperceptible in estimations of total abundance by
proteomics or transcriptomics methods. Furthermore, the preservation of mass test in the
spatial razor model gives an exceptionally solid filter to distinguish and recognize the
reliable changes in abundance at various subcellular locations, regardless of the fact that
minor extents of the total protein abundances are included.
The frame work presented in this study aims to improve and validate proteomics extraction
protocols, however, there will be a room for continues improvements in terms of
experimental design, subcellular fractions, complete protein extraction, and sample
preparation.
In general, the present results and various other late results on the static and dynamic
subcellular spatial dissemination of proteins (see below) propose that dynamic spatial
proteins relocation is an essential phenomenon that enables the cells to react in response to
either internal or external stimuli, and that it ought to be considered in frameworks
investigating the system biology.
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4.1.2 Protein subcellular distribution and integration of function
There is increasing evidence that substantial proportions of cellular proteins have multiple
subcellular locations and may have different functional roles in different locations. This is
implicit in available database information where, for example, 36% of human proteins with
current GO CC annotation show multiple locations at the level {nucleus, cytoplasm, plasma
membrane, and extracellular region}. There are multitudinous researches demonstrating that
particular alteration in protein locations is associated with alteration in functional capacities
of that protein in response to cellular environment. For instance, many of the proteins
required in the glycolysis/gluconeogenesis enzymatic course are known to have distinctive
functions in the nucleus (Qattan et al., 2012), incorporating into processes associated with
hypoxia, cellular proliferation, and cancer (Luo and Semenza, 2011, Vander Heiden et al.,
2010). Furthermore, large scale systematic dynamic changes of the subcellular proteins
associated with cell response/capacity is being tracked and recorded. For instance, more than
200 yeast proteins required in an extensive variety of cellular functions display subcellular
spatial translocation in response to hypoxia (Henke et al., 2011). The researchers also
demonstrated that an assortment of proteins represent changes in the nucleus/cytoplasm
dispersion are observed when human fibroblasts (IMR90 cells) are exposed to the cell cycle
arrest at the original enactment checkpoint (Mulvey et al., 2013) or to oxidative stress
(Baqader et al., 2014). In short, dynamic changes in the subcellular distribution of numerous
proteins in response to cellular environment are an increasingly well established
phenomenon. It is noteworthy that in these previous studies 2–5% of monitored proteins
were found to show appreciable spatial redistribution in response to various stimulations.
The roughly 20% of proteins for which such redistribution was detected in the present
experiments is so far a striking outlier, which may reflect that MCF7 cells are cancer cells.
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There is a clear need for many more global studies of dynamic protein distribution for a
variety of cell types and functional contexts.
In current research, the principle question for the more than 230 proteins of sorts (b) and (c)
that we recognized (Figure 3-7A) is: do the extents of these proteins in the "wrong" location
in respect to their characterized predominant location/functions have a significance alteration
to the functional role of the redistributed proteins? This can at last just be answered by
further examinations focused on these proteins; yet we note that the idea of moonlighting
proteins (Jeffery, 2009) has been has been extensively studied for more than ten years. One
of the proteins that has been clearly distinguished as moonlighting protein that have
distinctive function at different locations is GADPH. Some of these functions are (a)
controlling cell cycle and transcriptional activity (He et al., 2012, Zheng et al., 2003), (b)
forming a complex with a hypoxia inducible Siah, an E3-ubiquitin-ligase, causing the
translocation of this complex to the nucleus and consequent enhancement of the cellular
apoptosis/dysfunction (Hara and Snyder, 2006, Tristan et al., 2011), and (c) interaction with
apurinic/apyrimidinic endonuclease (APE1), leading to the DNA repair functions and to a
role in maintaining the integrity of the genome (Azam et al., 2008). Many authors have
provided the scientific evidences for multifunctional roles of GAPDH in different subcellular
locations (Sirover, 2012, Tristan et al., 2011). Other recently elucidated examples of crucial
moonlighting proteins are the glycolytic enzymes PKM2 and PFKFB3. Nuclear PKM2 is
crucial to the response to hypoxia through participation in transcription complexes with
HIFα, (Luo and Semenza, 2011), regulates β-catenin (Yang et al., 2011), and as a a 
coactivator for Oct4 transcriptional complexes (Lee et al., 2008), may likewise have other
nuclear functions. Additionally, nuclear PFKFB3 seems to be essential for cyclin-dependent
kinase (CDK) regulated cell cycle and proliferation (Yalcin et al., 2009) and in adjusting
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glutamine/glycolysis use over the cell cycle, incorporating into growth of cancer cells
(Colombo et al., 2011).
Such moonligting activities are not often feasiable from the presenetly defined protein
topology networks, most of those proteins have been distinguished, individually, as case by
case. The subcellular spatial razor approach would help to reveal much information and
provides a platform for systematic discovery of such proteins. In the present work, an
analysis of subcellular proteomics results reveals that many more proteins might be
candidates for being moonlighting class in the nucleus that are crucial to specific cellular
functions. For example, upon exposure to E2, NQO1 displayed ~ 4-fold reduction in the
nucleus and relocalization to the cytoplasmic participation in regulation of the ornithine
decarboxylase complex (ODC) and hence participation in polyamine metabolism (Asher et
al., 2005). In addition, the influence of ODC on ERα expression (Zhu et al., 2012), suggests 
potentialy moonlighting roles for this protein.There is some evidence consistent with
nuclear "moonlighting" roles for NQO1; it is localized primarily in the cytoplasm, but it has
been observed associated with mitotic spindles in the nuclei of a variety of human cells
where it has been suggested to possibly play roles in protection against electrophic quinones,
aid in the generation of oxidized pyridine nucleotides or shield selected proteins from
proteasomal degradation (Siegel et al., 2012). There are many examples of “moonlighting
candidates” obtained in the current study such as PARK7 and the 5 enzymes of glycolysis
that redistribute to the cytoplasm following estradiol exposure. Furthermore, there were
further 60 proteins in the 134-set that Reactome did not place in known functional networks
and which might represent “moonlighting” activities.
The present data also suggest that there may be protein complexes and individual proteins
that are involved in more general balancing of cellular function. The demonstration that
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numerous proteasomal proteins redistribute in response to estradiol and the participation of
these proteins in numerous critical functions in both the cytoplasm and nucleus (Table 3-2)
suggests that redistribution of proteasomal subunits may represent general mechanisms for
balancing different cellular functions at different subcellular locations. Proteasomal
degradation of ERα is important to response to estradiol and it may be that the complexity of 
this (Alarid, 2006, Le Romancer et al., 2011, Nonclercq et al., 2007) reflects subcellular
mobility of proteasome components in addition to many other influences. The redistribution
of the CCT protein-folding complex between the nucleus/cytoplasm (Table 3-2) may be
another such example. Nuclear import and/or activity of some proteins, including nuclear
hormone receptors (Echeverria and Picard, 2010, Renoir, 2012), involves chaperone-assisted
processes and nucleo-cytoplasmic redistribution of the CCT complex is also observed in the
response of primary human fibroblasts to oxidative stress. We also observed redistribution
between the nucleus/cytoplasm of numerous chaperones (HSP90B1, HSPA9, HSPB1,
HSP90AA1, HSP90AB1, HSPA6, HSPA8, Supplementary Table 2) and HSP90 chaperones
are known to play key roles in nucleo-cytoplasmic trafficking of nuclear hormone receptors
(Echeverria and Picard, 2010, Renoir, 2012). A similar balancing role may be played by
some highly abundant proteins such as the human transcriptional positive coactivator PC4
(mammalian orthologue of yeast SUB1), which has established roles in multiple cellular
functions involving stabilization of DNA−protein interactions, chromatin organization, 
transcriptional activation and repression, DNA elongation, reinitiation and DNA replication
and repair (Conesa and Acker, 2010, Das et al., 2006, Malik et al., 1998). This was one of
the few proteins to show C  N redistribution (without change in total abundance), a
phenomenon that we have previously also observed in the response of primary human
fibroblasts to cell cycle arrest at the origin activation checkpoint (Mulvey et al., 2013).
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Although not usually discussed as “moonlighters”, nuclear hormone receptors are inveterate
subcellular travellers that have a plethora of nuclear, cytoplasmic, plasma membrane and
mitochondrial activities associated with their mobility. ERs regulate the expression of
numerous nuclear genes (Frasor et al., 2003, Marino et al., 2006). ERs have plasma
membrane interactions that involve numerous kinase-dependent signalling pathways
(Heldring et al., 2007, Le Romancer et al., 2011, Madak-Erdogan et al., 2008, Renoir, 2012),
and there is increasing evidence that these signalling pathways are critical for acquired
resistance to therapeutic compounds (Iorns et al., 2008, Yeh et al., 2013). Cooperative
organization of nuclear and mitochondrial ERs and their coactivators may have crucial
influences on regulation of the mitochondrial respiratory chain (Chen et al., 2009). Many of
these activities seem to be directly associated with subcellular mobility of ER and other
proteins. For example, efflux of ERα from the nucleus is associated with repression of cell 
cycle progression and S-phase proliferation in MCF-7 cells (Castoria et al., 2009, Lombardi
et al., 2008).
We note that in general nuclear hormone receptors (NHRs) show many of the characteristics
that would be expected for proteins with important roles in “polling”, integrating and
balancing functions occurring at different subcellular locations. They appear to shuttle
between different locations and may have many different localization determinants, e.g.
different nuclear import/export sequences and pathways (Echeverria and Picard, 2010,
Mavinakere et al., 2012) including ERα (Renoir, 2012). They are often subject to a large 
variety of post-translational modifications.
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In the case of ERα these include phosphorylation, acetylation, ubiquitination, sumoylation, 
methylation, and palmitoylation in at least 22 sites (Le Romancer et al., 2011). Many of
these sites are subject to alternative types of modifications and/or modification by alternative
kinases in the case of phosphorylation (Le Romancer et al., 2011). It is possible that such
post-translational modifications relay information about functional state between different
functions/subcellular locations either directly by “carrier” NHRs or indirectly via the
subcellular localization of the proteins executing the modifications. The lifetime of NHRs
may also be consistent with continuous “polling” of functional state, e.g. in the absence of
oestrogen ERα is very stable, with a half-life of up to 5 days (Nirmala and Thampan, 1995). 
This drops to 3-5 hours in the presence of estradiol and the receptors are targeted for
degradation through a transcription-coupled pathway requiring new protein synthesis
(Alarid, 2006, Alarid et al., 1999, Nirmala and Thampan, 1995). In the nucleus NHRs are
mobile and characterized by transient interactions with numerous chromatin response
elements (Elbi et al., 2004, McNally et al., 2000, Reid et al., 2003). For ERα many of the 
early response chromatin binding sites are only transiently occupied and may be abortive or
result in repression (Stossi et al., 2009), which may reflect the presence of appropriate co-
factors in the nucleus.  Furthermore, in the nucleus ERα and ERβ have been shown to 
interact with 498 other proteins, only 70 of which are common to both (Nassa et al., 2011).
Of these proteins, 357 were detected in the present experiments: with a minimum of 5
SILAC ratio counts 58 proteins show >2-fold decrease in nuclear abundance and a further 76
show appreciable nucleo-cytoplasmic redistribution (|log2(Sn/Sc)| > 1). The present results
then suggest that the outcome of the “polling” by ERs is likely to be dependent on the
nuclear/cytoplasm distribution of numerous other proteins as a function of cellular state. It
seems likely that other NHRs fulfill similar “polling” roles, which may include cross-talk
between different NHRs (Bolt et al., 2013).
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Attempts have been made to use protein-protein interaction (PPI) networks to analyse
cellular response to various nuclear hormone receptors. Almost 20% of the proteins involved
were connected to chaperone/nuclear import machinery and many have multiple subcellular
locations (Echeverria and Picard, 2010), which emphasizes further the importance of
dynamic subcellular distribution of proteins. The authors concluded that whole cell analyses
only allowed limited inferences and that new high-throughput methodologies that monitor
different subcellular locations are needed (Echeverria and Picard, 2010). The proteomics
subcellular spatial razor is able to provide the kind of information required.
4.1.3 Possible relationships to breast cancer
Hormone receptor positive breast cancers (luminal subtypes) are the most commonly
diagnosed subtypes of breast cancer. The luminal subtypes showed high expression of many
proteins that may complex with the receptor pathways and may provide a platform for early
detection and differentiation between malignant and benign form of breast cancer (Lam et
al., 2014). ERs are groups of proteins of closely related variants (superfamily) integrated in
multiple networks with multiple organelles at multiple subcellular locations (Kampa et al.,
2013). Interestingly, dynamic shuttling of nuclear ERs between the nucleus and cytoplasm
via nuclear import/export can be modulated by agonists/antagonists actions (Kocanova et al.,
2010). Accordingly, wide range of observations related to E2 extranuclear ER actions have
been reported. Of these, triggering kinases at membrane level (cAMP, cGMP, protein
kinases, lipid kinases, and Src kinases with EGFR) and activation of downstream signalling
cascades that lead to transcriptional activation (Kim and Bender, 2009).
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The present results indicate that in MCF-7 cells estradiol causes much more substantial
changes in subcellular protein distribution than have previously been appreciated. Indeed,
the dominant response to estradiol appears to be changes in compartmentalized protein
abundances rather than in total protein abundance, including numerous proteins that are
present in both the nucleus and mitochondria (Qattan et al., 2012). This pattern is consistent
with other recent proteomics studies (Baqader et al., 2014, Mulvey et al., 2013, Pinto et al.,
2015, Pinto et al., 2016). For 76 proteins involved in central metabolic roles in MCF-7 cells,
time-dependent monitoring of total abundance by proteomics single reaction product
methods indicated that none had 2-fold changes in total abundance over the first 24 hours of
exposure to estradiol (Drabovich et al., 2012). Similarly, study of a tamoxifen resistant
MCF-7-derivative cell line also showed only a few proteins with >2-fold changes in total
abundance compared to the parent MCF-7 cells (Zhu et al., 2012). Finally, although many
proteins showed small changes, only moderate differences in total protein abundance
between nontumorigenic MCF10A, MCF-7 and highly invasive MDA-MB-231cells were
found (Bateman et al., 2010, Pavlou et al., 2013). Recent work has shown that miRNAs may
also play a role in regulation of protein expression and in the initiation and progression of
breast cancer (Klinge, 2012), but at the level of mRNA, study of the miR-191/425 cluster
also found very few proteins with 2-fold changes in total abundance (Di Leva et al., 2013).
Taken together with the present results, this suggests that the modified metabolic properties
of cancerous MCF-7 cells may be mainly based on perturbed spatial distribution of proteins
and opens the possibility that transformation and tumorigenicity may also be strongly
influenced by perturbed spatial distribution of proteins. Refocusing on the dominant
mechanism of cellular response to estradiol may have strong implications for development of
therapeutic compounds.
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Much recent work on the role of oestrogen in breast cancer has focussed on the relative
importance of ER-dependent activities versus direct genotoxic effects of oestrogen
metabolites, with both seemingly relevant (Yue et al., 2013). Chromatin organization is
highly linked to cellular state and to subcellular distribution of proteins and recent work has
shown strong epigenetic changes in the chromatin landscape related to oestrogen response
and resistance to endocrine therapy (Magnani et al., 2013). In short, both of the presently
most discussed mechanisms for involvement of oestrogen in breast cancer could be
influenced by major perturbations in subcellular protein spatial organization. Whether highly
perturbed spatial distributions are a by-product or represent a facilitator for
transformation/tumorigenicity remains to be investigated. An intriguing observation is that
cells may be transformed by perturbations in nucleo-cytoplasmic shuttling of nuclear
hormone receptors and other proteins (Bonamy and Allison, 2006, Bonamy et al., 2005,
Mavinakere et al., 2012).
The proteins involved in the metabolic pathways have been found to be relatively changed
after 24 h exposure of MCF-7 to various conditions mimicking the biological perturbations,
E2 exposure and hypoxia (Drabovich et al., 2012), these results are consistent with the
current findings. Furthermore, novel localizations of both ERα and β within the 
mitochondria of MCF-7 were significantly increased after E2 treatment and the possible
explanation was related to ER-mediated genomic transcription of mitochondria (Chen et al.,
2004). Perinuclear location, dynamic structure, and ability to produce the reactive oxygen
species (ROS) are all unique observations related to the possible role of mitochondria in
growth signalling in response to the external biological perturbations (Felty and Roy, 2005).
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4.2 Part-II: Spatial dynamics in response to tamoxifen-stimulated breast cancer
cell line (MCF-7)
The response of MCF-7 cells to the tamoxifen treatment shows significant changes in
subcellular abundance rather than in their total abundance. In the following part, we discuss
three main topics: 1) extensive redistribution of the subcellular abundance as a consequence
of 4OHT; 2) the relevance of moonlighting proteins in this proteomics study; and 3) the most
relevant pathways associated to agonistic and antagonistic response of Tamoxifen in MCF-7.
4.2.1 Redistribution of subcellular proteins and moonlighting proteins
From the large MaxQuant dataset, we selected an overall response list of proteins (270-
TAM) and a more reliable response (97-TAM) for which more significant changes actually
occurred in response to treatment (see Material and Method Section). Within the 97 proteins,
it was possible to observe three major grouping of proteins that differently responded to 4-
OHT: a) Proteins with exclusive changes in total abundance without redistribution in the
nucleus/cytoplasm. They represent 20% and give a low contribution to the cellular response;
b) Proteins with abundance changes only in one of two compartments (nucleus or
cytoplasm); c) Proteins with significant abundance changes in both compartments
(nucleus/cytoplasm) with any change in total abundance (20%). Whether the (a) group is
equally important for the large scale studies, we are more interested in (b) and (c) groups,
representing the majority (70%) of proteins responsive to 4-OHT. Based on the latest
studies, the extensive spatio-temporal redistribution of subcellular proteins is an evidence of
cellular response to various stimuli (Jung et al., 2013). Extensive changes by quantitative
proteomics were also observed for hundreds of proteins, significantly changing in abundance
(Zhou et al., 2012) as well as in the phosphorylation level (Oyama et al., 2011), that
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adaptively response to the long term treatment of the MCF-7 cell line. In this study, the
massive changes of subcellular proteins have allowed to figure out numerous pathways
involved in 4-OHT response of MCF-7, some of which explain the agonistic role of drug
while others point to the antagonistic role. This dual behaviour observed by us demonstrates
that in a complex system like cell the “real” response to 4-OHT follows more complicated
ways than those imagined and those recorded with monitoring single proteins. Thus, the
study of pathways or metabolic processes of the most significantly changed proteins by
quantitative proteomics is undisputedly of relevant importance in revealing molecular basis
of any disease.
4.2.2 Multiple locations of subcellular proteins and moonlighting proteins
The cellular compartmentalization, the highly specialization of organelle functions and
particularly the changes in subcellular localization of each protein seem to support the
existence of an evolutionary retargeting (Gabaldón and Pittis, 2015). As already mentioned,
large scale studies are revealing that organellar proteomes not only differ from cell type but
also dynamically change as a result of a massive trafficking of subcellular proteins in
response to perturbations (Radulovic et al., 2016). The targeting of the same protein to
multiple locations is the evidence of a strong and intertwined communication between
organelles within which different targeting signals can be differently activated. The cross-
communication ensuring a checked cellular response to external environment determines
protein dynamic fluxes versus specific locations for spatial partitioning of major cellular
functions.
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In the dynamic studies, the isolation of “permanent resident” proteins by highly purified
subcellular organelles, that should be more representative possible of the fractionated
compartment, has been surpassed by the existence of numerous “moonlighting” proteins that
escape to crystallized concept of one protein → one compartment → one function. Actually, 
the finding of hundreds of moonlighting proteins brings forth the importance of cellular
function at the proteome level and the need to deal with them by subcellular proteomics
rather than by genomic/transcriptomic approaches. A recent mass spectrometry review has
pointed out the limitations of fractionation process based on the assumption that each
organelle cannot be completely separated from the rest of cell (Pinto et al., 2016). The
isolation of mitochondria or other organelle can cause the loss of membrane proteins
stripped by fractionation. Even the nucleus, rather than as a shiny ball, it is depicted as
highly complex “reticulum” (Malhas et al., 2011) containing large numbers of previously
unsuspected proteins associated with the nuclear envelope (Talamas and Capelson, 2015). In
the present study, within the (b) group, some proteins (25%) have shown only changes in
cytoplasm abundance without any significant change in total or nuclear abundance as a
response of 4-OHT stimulation. Within this group, ALDOA, an interesting protein well-
known for its glycolytic role, has revealed to perform numerous moonlighting activities in
both cytoplasm and nuclear compartments (Lincet and Icard, 2015), besides being involved
in tumorigenesis (Chang et al., 2015, Du et al., 2014). The main functions, absolved in
cytoplasm and nucleus, have been summarized in Figure 4-1.
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Figure 4-1: Schematic representation of non-glycolytic functions of aldolase
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The upregulation of ALDOA, as found in our study, has been demonstrated to promote
epithelial-mesenchymal transition (EMT) and cell migration by inducing an expression
decrease of epithelial markers, E-cadherin and β-catenin, with a concomitant increase of 
Fibronectin and Vimentin, both events favouring tumorigenicity (Du et al., 2014). The
ALDOA phosphorylation of by Akt or Erk 2 kinases triggers the nuclear translocation of
aldolase enzyme, which contributes to regulate the transcription of some genes of cell cycle
progression, to protect DNA in response to the damage and to stabilise some transcripts
particularly with AT-rich DNA sequences (Lincet and Icard, 2015). Other non-glycolytic
functions for ALDOA are related to cell mobility, signal transduction, vesicle trafficking,
etc., as listed in Figure 4-1.
Distinct from the known mitochondrial role in energy generating process, some proteins of
oxidative phosphorylation, like MT-CO2, shown to bind directly to cytochrome c, have been
demonstrated to regulate apoptosis (Acehan et al., 2002, Kulms and Schwarz, 2002). A small
fraction of cytochrome c, more weakly attached to inner membrane of mitochondria, is
presumably more available for compartmental shuttling within cell. Its redistribution from
mitochondria to cytosol occurs in response to pro-apoptotic stimuli activating, through the
interaction with Apaf-1, caspase cascade events that lead to apoptosis (Acehan et al., 2002,
Kulms and Schwarz, 2002). Then, a cytochorme accumulation in nucleus compartment
triggers massive translocation of acetylated histone H2A from nucleus to cytoplasm with
irreversible consequence on chromatin condensation (Nur-E-Kamal et al., 2004).
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The cytoplasm cytochrome can further block calcium-dependent inhibition of IP3 receptor
on the endoplasmic reticulum (ER) and increase the calcium release from ER that in turn
activates cytochrome c release (Boehning et al., 2003). In addition, the depletion or altered
expression of some of OXPHOS proteins (MT-CO2, COX I, III) has been also implicated
in tumorigenic transformation (Abril et al., 2008, Chatterjee et al., 2011).
Another moonlighter, downregulated in our cytoplasm and nucleus fractions, is CRYAB, a
potential biomarker of several tumours included in triple-negative breast cancer (TNBC)
(Malin et al., 2014, Tsang et al., 2012). Whether CRYAB has been found as a major
structural protein in ocular lens for transparency maintenance, in non-lenticular tissues, it
functions as cytoprotective molecular chaperone capable to prevent non-specific protein
interactions under particular cellular stress. It specifically binds and corrects intracellular
misfolded/unfolded proteins such as vascular endothelial growth factor (VEGF), promoting
angiogenesis in metastatic event (Chen et al., 2014, Ruan et al., 2011). An anti-apoptotic
function has been attributed to this protein by inhibiting the autoproteolytic cleavage of
caspase3 (Kamradt et al., 2001, Kamradt et al., 2002), or by directly interacting with the pro-
apoptotic Bax and Bcl-xs (Mao et al., 2004), in response to diverse stimuli. Moreover, in
response to heat-stress, CRYAB translocated from cytoplasm to nucleus and complexed to
F-actin for regulating cytoskeletal stability and dynamics (Singh et al., 2007) but also it
shuttles to mitochondria where inhibits cytochrome c release into cytosol during MI by
binding to VDAC1 channel under cellular stress (Chis et al., 2012).
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Some discrepancies between the GO annotation and the present subcellular locations
confirm further the underestimation of subcellular annotations related to the GO CC
database. The high dispersion of proteins over multiple locations as recently reported in large
scale proteomics papers (Qattan et al. 2010, 2012 and Pinto 2014) suggests that the real
spatial distribution of cellular functions is much more complicated than that annotated in
current GO CC. In the present study, for more than 60% of proteins (all 97 dataset), there is
at least one location omitted in GO annotation. While for some proteins the additional
subcellular location found is not well documented, for others it is. For example, the finding
of LDHA in nuclear fraction is in agreement with hypothesis that some cytoplasmic
metabolic enzymes translocate into nucleus for moonlighting transcription functions under
stress condition. LDHA would seem to translocate to nucleus for taking part to OCA-S
transcriptional coactivator complex and regulate indirectly the S phase-specific H2B
transcription (Zheng et al., 2003) but also directly functioning as metabolic/redox sensors
(He et al., 2013). The nuclear upregulation of LDHA has been attributed to the
transcriptional and translational regulation by HIF-1α in cancer cells (Koukourakis et al., 
2005, Miao et al., 2013, Semenza, 2013). Further example is the translocation of ALDOA to
nucleus in response to stimulus (Figure 4-1).
Within the (c) group, an additional nuclear location has been found also for MT-CO2, DES,
HBB, DCD, mainly GO annotated in cytoplasm and/or in extracellular region (Table 3-9).
For other proteins annotated with a single location, e.g. MYL3 (Cytosol), FUBP1 (Nucleus),
LYAR (Nucleus) CALML5 (extracellular vesicular exosome), a subcellular redistribution
between nucleus and cytoplasm have been found following the 4-OHTam treatment (Table
3-9).
180
For example, LYAR, a zinc finger protein, more frequently found in the nucleolus for
promoting cell growth by preventing nucleolin self-cleavage (Wang et al., 2012), has been
also associated to cytoplasmic ribosomes in human cancer cells (Yonezawa et al., 2014).
From the cytoplasmic compartment, LYAR protein dissociates from the cytoplasmic 60S
ribosomial subunit for shuttling rapidly to the nucleolus for absolving nuclear functions. The
abnormal expression of these ribosome-interacting proteins has been associated to the
deregulation in growth and viability of malignant neoplasms (Stumpf and Ruggero, 2011).
Studies entirely referred to GO-database suffer from the limitation that less functions and
locations than those actually explorable are considered, leaving just a small space to the
investigation of the changes induced from cellular response to stimuli. In this contest, the
finding of new locations for subcellular proteins should be a lighthouse for further studies.
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4.3.3 Possible implication in cancer and/or cancer resistance
Tamoxifen and its active metabolite, 4-OHT, are known as selective ER modulators (SERM)
that are not pure ER antagonist (anti- oestrogenic) in all tissues; rather 4-OHT has been
observed as ER antagonist in the treatment of breast cancer (Osborne 1998, Riggs and
Hartmann 2003). The efficacy of this treatment was limited by the development of resistance
in nearly 30 % of ER-positive breast cancers whom they were responding to the initial
tamoxifen (SERM) treatment that interrupted the breast tumour growth for a while (Jiang et
al., 2013). Commencing the growth of breast cancer tumours, despite the presence of 4-OHT
and ER expression (Lewis and Jordan, 2005), linked the resistance to the modulation of
response due to the agonistic (oestrogenic) activity of tamoxifen (Dorssers et al., 2001).
However, about tamoxifen resistance, there are several mechanisms suggested to attribute to
the acquired resistance and they have been reviewed in details (Chang, 2012, Dixon, 2014).
In the wild type MCF-7 used in this study, there were agonist–antagonist properties
representing the inducible changes following 4-OHT treatment. An appreciable number of
proteins showing up- or down-regulation is involved in regulation of many cellular
mechanisms that are involved in metabolic, reduction/oxidation cycling process, signal
transduction, cell cycle, cross-talk between signalling pathways, maintenance of
cytoskeleton, adhesion, progression, and apoptosis processes. In the following discussion,
we address some of the proteome changes that contribute to the modulation of
carcinogenesis regarding loss or gain of functions with emphasis on those mediating cancer
development as an agonistic activity of 4-OHT. However, in the beginning, this discussion
might shed some light on some of the results that are supporting the antagonistic activity
(tumour suppression), to flavour the complexity which is an innate characteristic of cancer.
For example, 4-OHT demonstrated an antagonistic effect and was able significantly to
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reduce the expression of OAT (Sn), Ornithine aminotransferase (OAT) (Figure 3-18A). In
addition to its known key role in mitochondrial arginine synthesis, a novel role for OAT was
revealed as to participate in control of the mitosis of cells (Wang et al., 1995). It has been
reported that, instead of tubulin, OAT is the cellular target for AB-5, an alkaloid drug that
block cancer cell division through binding to OAT (Wang et al., 2007). Androgens can
modulate OAT expression, and therefore, modulate the severity of cancer (Jariwala et al.,
2007). In U87MG-AAV-decorin cells that show slower cell proliferation, OAT was
observed significantly reduced in response to decorin (Ma et al., 2014). Results from the
current study demonstrate that there is a significant reduction of OAT and localization to the
nuclear fraction, suggesting that the compartmental distribution of OAT is important as
much as the level of expression for the mitotic role. Furthermore, 4-OHT could have
paradoxical actions inside the cells that need further investigation.
It has been known for many decades that normal and cancer cells are different in many
aspects including metabolism. It is observed that nearly all cancers express aerobic
glycolysis, suggesting that cancer may be primarily a metabolic disease. Many metabolic
alterations are associated with the increased biomass of cancer cells to replace the normal
energetic source of mitochondrial oxidative phosphorylation with aerobic glycolysis,
glutaminolysis or fatty acid synthesis that are abnormally increased to meet cell proliferation
(Munoz-Pinedo et al., 2012, Vander Heiden, 2013, Warburg et al., 1927). These observations
have been reported independently from mitochondrial malfunctioning in many tumours
(Vander Heiden et al., 2009, Ward and Thompson, 2012).
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Although the exact biochemical and/or molecular mechanism behind the “Warburg effect”
or aerobic glycolysis in the presence of oxygen is not completely elucidated due to
complexity (Woo et al., 2015), lactate fermentation in the cytosol is widely accepted as an
alternative source for ATP production in cancer cells and replacing the oxidative
phosphorylation of pyruvate in mitochondria as in normal cells (Christofk et al., 2008, Kim
and Dang, 2006). Moreover, an increased rate of lactate production has been associated with
the aggressiveness of cancer, which is the more metastatic and drug-resistant cancers, the
higher lactic acid level is produced (Lu et al., 2002, Semenza, 2009).
The findings of the present study indicate that appreciable number of proteins are
major regulatory proteins in the metabolic pathways. Proteins involved in glycolysis are
upregulated while those involved in citric acid cycle and oxidative phosphorylation are
aberrantly downregulated as these proteins were overrepresented in pathways analysis (Table
3-5Table 3-7, andTable 3-8 and Figure 3-18A). Some proteins were showing substantial
variations in the subcellular locations (C and N) with or without modifications in the total
abundance (Figure 3-18A) including MTCO2 (Sc, Sn), LDHA (Sn), TKT (Sc, St),
IDH1 (Sc), and ALDOA (Sc). There is exponential growth of papers that point a link
between alteration in glucose metabolism and the acquired resistance to chemotherapeutic
drugs such as doxorubicin, cytosine arabinoside, taxol, cisplatin, and vincristine (Clarke et
al., 2009, Lu et al., 2008, Lyon et al., 1988, Pelicano et al., 2006, Woo et al., 2015, Xu et al.,
2005). Furthermore, as mentioned in the previous section, many of these proteins may have
moonlighting functions that are distinctive from their metabolic roles, for example ALDOA
found to have different roles, apart from its glycolytic activity, such as signal transductions
(Ishida et al., 2005, Orosz et al., 1988), vesicle trafficking and transport of materials from
site to site (Lundmark and Carlsson, 2004), and increased rate of cell motility (Jewett and
Sibley, 2003). Therefore, its non-catalytic role in cancer transformation has been
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investigated using RNAi in Ras-transformed NIH-3T3 cells; the authors observed
consequences of ALDOA knockdown in cell proliferation rather than glycolytic flux/ATP
level; the cell proliferation was restored by expression of exogenous ALDOA (Lew and
Tolan, 2012).
However, the number of studies that have demonstrated a link between abnormal glycolytic
metabolism and the development of tamoxifen resistance is still minimal in comparison with
other drugs that are used in cancer treatment (Woo et al., 2015).
The rationale behind identifying the metabolic alterations that promote carcinogenesis and/or
resistance to the treatment is to understand and validate the cellular pathways interaction and
contribution to malignancy. Although the mechanisms of either developing or resisting
treatment in relations to the altered metabolic pathway remains to be elucidated, there is a
plethora of evidence, provided by many studies, supporting the link between oncoproteins
and glycolysis (Ganapathy-Kanniappan and Geschwind, 2013) and glutaminolysis
(DeBerardinis and Cheng, 2010), to regulate the cellular metabolism and provide the energy
and new cellular components to the highly demanding proliferative cancer cells.
Furthermore, glycolysis has been attributed to the treatment resistance in cervical cancer
cells through two isoforms, pyruvate dehydrogenase kinases (PDK) (PDK1 and PDK3) (Lu
et al., 2008), and accumulation of lactate in colon cancer cells (Fanciulli et al., 2000).
However, inhibition of PDK has induced apoptosis and inhibited the cell growth, in many
types of cancer, by restoration of glucose oxidation and oxidative phosphorylation (Bonnet
et al., 2007).
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Glycolytic intermediates are essential fuels to the pentose phosphate pathway (PPP), in
animals, to maintain the production of NADPH reducing power and 5-carbon sugar (ribose-
5-phosphate) that are required for lipid and nucleic acid synthesis (Horecker, 2002).
Also, NADPH serves as an electron donor that maintain the cellular level of the reduced
form of a tripeptide antioxidant glutathione (GSH); chemotherapy resistance in cancer has
been linked to the cellular level of GSH and related enzymes that are contributing to the cell
survival through the activated antioxidant dynamic cascade (Backos et al., 2012, Estrela et
al., 2006). Isocitrate dehydrogenase 1 (NADP+, soluble) (IDH1) is the cytoplasmic enzyme
that serves a significant role in cytoplasmic NADPH production and found to be upregulated
in the cytoplasmic fraction in our study. IDH1 has been reported as one of five critical
components of GSH pathway and contributed to the development of chemoresistance in
breast cancer (Wang et al., 2015). From general response proteomics data obtained in this
study (TAM-270), no conflict was observed with the published studies where glutathione
synthetase (GSS) was highly expressed (St = 5.244) in the total lysate (Supplementary Table
7).
The expression of glycolytic intermediate, transketolase (TKT1) a key enzyme in PPP, has
been found of particular importance in sustaining the cancer cells viable while inhibition of
TKT has reduced the growth, glucose consumption, and lactate production in HCT116 colon
carcinoma cells, moreover, the stress-induced apoptosis was commenced in the TKT1
knocked down cells (Xu et al., 2009). The catalytic activity of TKT was upregulated (Sc,
St) in response to 4-OHT.
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Several mechanisms have been suggested to explain the utilization of cancer cells to aerobic
glycolysis for ATP generation. In general, alterations in proteins that are essential to
glycolysis or truncating TCA cycle by the mitochondria, are the two most important themes
that can accumulate lactate and enhance the use of lactate fermentation as an alternative
source of energy.
Several glycolytic enzymes like glucose transporters (GLUTs), hexokinase, pyruvate kinase,
lactate dehydrogenase A (LDHA) and monocarboxylate transporter (MCT) are oncogenes
and hypoxia-inducible factor (HIF) induced expressional, promoting glycolytic flux in
cancer cells. On the other side, citric acid cycle is truncated due to frequent mutations in
mitochondrial DNA (mtDNA), dysfunctional tumour suppressor genes, and the most
important one is the reduced level of respiratory substrates (Ju et al., 2014, Levine and
Puzio-Kuter, 2010, Simon, 2006, Zhang et al., 2015). In consistency with these findings, for
central metabolic pathways, glycolysis and TCA, the induced level expression of glycolytic
enzymes lactate dehydrogenase A (LDHA) and isocitrate dehydrogenase 1 (IDH1) as high
SILAC ratios were determined in nuclear and cytoplasmic fractions, respectively. Table 3-8
shows that both respiratory electron transport and TCA were the top ranked down-regulated
pathways. Moreover, identification of nuclear DE LDHA in the proteomics analysis
generated from this work is consist out with nuclear localization/synthesis of LDHA that
was shown in the rat’s liver and the in the nucleus of several cell lines (Cattaneo et al., 1985,
Kuehl, 1967).
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Furthermore, we observed that 4-OHT may exert agonistic activity via enhancing the
protective mechanism of cancer cells. The treatment of wild type MCF-7 with 4-OHT has
induced the change in a total abundance (St) with no subcellular distribution of a key protein
involved in oxidative stress control, thioredoxin reductase 1 (TXNRD1). Increased
expression of TXRND1 is associated with some essential functions that are contributing to
the hallmarks of cancers, including enhanced proliferation and avoiding apoptosis, and self-
sustaining of blood supplies (angiogenesis).
For these key hallmarks, TXRND1 is essentially activated to maintain the cellular redox
homeostasis, turn on the DNA synthesis via activating ribonucleotide reductase, deactivating
ASK1 (apoptosis signal-regulating kinase 1) and activating HIF-1 and VEGF (Cadenas et al.,
2010, Nishiyama et al., 1999). In contrast, thioredoxin-interacting protein (TXNIP) is an
apoptosis-inducing protein that is known to bind the reduced TXRND1. Using MCF-7 cells,
the influence of oncogenic ERBB2 on the level of expression of these proteins was
investigated, it was demonstrated as an immediate increase of TXNRD1 and decrease in
TXNIP (Cadenas et al., 2010).
It has been reported that oestrogens through sequential events taken place in nuclear,
mitochondria, and plasma membrane, play a fundamental role in regulating the
mitochondrial biogenesis (Klinge, 2008). Ivanova et al. (2013) have found that both active
metabolites of oestrogen and tamoxifen, E2 and 4-OHT, cause efficient transcription
initiation of nuclear-encoded nuclear respiratory factor 1 (NRF-1) by binding, respectively,
to the classical ERs, ERα and ERβ in MCF-7 cells. Subsequently, NRF acts as a 
transcriptional activator that upregulates the transcription of nuclear-encoded mitochondrial
genes, and nuclear-encoded components of OXPHOS, e.g., cytochrome c family of proteins
(Cyclooxygenases) (Fong et al., 2007, Fong et al., 2010).
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Recently, MT-CO2 was remarkably increased (>20 fold), in hTERT-GFP(+) MCF-7 Cells;
this result reveals a reflection to be a powerful mechanism behind mitochondrial biogenesis
(Lamb et al., 2015). Interestingly, in this project, the significant data sets have shown
increased expression of MTCO2 in the subcellular compartments, (Sc, Sn), only.
Adenylate cyclase-activating G-protein coupled receptor signalling pathway and G-protein
beta/gamma-subunit complex binding are among the top ranked GO terms that were
enriched in the nuclear fraction for biological processes and molecular functions,
respectively (Table 3-6), furthermore, applying the restrictive measures of identification and
SILAC on the significance data set (97-TAM) has introduced no difference in the
enrichment analysis (Table 3-7). Figure 3-19, shows that Guanine nucleotide-binding protein
subunits GNAI2 (Gα), GNAQ (Gqα), GNAS (Gs-α), GNB1(Gβ1), and GNA13 (Gα) were 
overrepresented in Pathways of cancer pathway, moreover, in the nuclear fraction the
Circadian entrainment pathway was a top ranked pathway as it was enriched with the
upregulation of these proteins (Figure 3-18C and Table 3-5). These findings imply the
importance of the heterotrimeric G-proteins in transducing the non-genomic and genomic
(transcriptional) signalling in response to the clinical relevant dose (I µM) 4-OHT (Castoria
et al., 2009). Although the active tamoxifen metabolite, 4-OHT, is known as a selective
modulator for ER (SERM), 4-OHT, in breast cancer cells, acts as agonist on a member of the
7-transmembrane G protein-coupled receptor (GPCR) family that is now recognized as a
novel ER and also known as G-protein coupled receptor 30 (GPR30) (Fitts et al., 2011), and
G protein-coupled receptor 30/G protein-coupled oestrogen receptor-1(GPR30/GPER-1)
(Prossnitz et al., 2008, Wei et al., 2012).
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G-protein coupled receptors (GPCRs) are cell surface receptors; they have wide spectrum of
functions in the context of physiological and pathophysiological processes. From tumour
formation to the spread of cancer cells, ligand-dependent GPCRs, e.g. SDF-1, thrombin,
LPA, S1P, and endothelin, found to have pivotal roles in many forms of tumours including
prostate and breast cancer (Lappano and Maggiolini, 2012). The downstream signalling
cascades are transduced through G-Alpha12 (GNA12) and G-Alpha13 (GNA13) subunits
constituting the subfamily of heterotrimeric G-Proteins.
Indeed, invasion and metastasis have been attributed to GNA proteins in many cancer types
(Kelly et al., 2007, Malchinkhuu et al., 2008). Some finding reported in (Rasheed et al.,
2015) suggested that GNA13 is highly upregulated in the aggressive form of breast cancer
cells, moreover, restoration of GNA13 activity has been shown to enhance the progression
and invasion characteristics of prostate cancer cells (Rasheed et al., 2013).
Our findings reported here that under 4-OHT stimulation GNA13 was highly expressed in
the nuclear fraction with an appreciable change in the cytoplasmic sample while GNA12 and
GNAQ were upregulated exclusively to the nuclear fraction (Figure 5B). In addition to the
localization of 7TMR to the plasma membrane, subcellular localization of GPR30 was
reported to localize as bound to endoplasmic reticulum (Revankar et al., 2005), with possible
localization in Golgi (Sakamoto et al., 2007). Furthermore, shuttling of GRP30 nucleus and
cytoplasm was suggested (Wang et al., 2008).
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The ligand binding to the most described ERs (termed ERα and ERβ) initiates a sequence of 
events that result in genomic (transcriptional) and non-genomic signalling processes; GPR30
has been found to be expressed in 50% of cancer patients and could induce the non-genomic
mediated tumour progression through mitogen-activated protein kinase (MAPK) even when
ERs are absent or blocked (Prossnitz and Maggiolini, 2009, Wang et al., 2010). The time
frame for these two responses is not the same, the genomic response is slower than non-
genomic and lasts hours to days while the later lasts seconds to minutes. The rapid (non-
genomic) oestrogen response transfers the signals/information to the subsequent effectors in
the cascade that include second messengers (Ca2+, cAMP, and NO), and kinase activation
(e.g. PI 3-kinase, Akt, and MAPK) (Prossnitz et al., 2008). The discoveries of these two
receptors has complicated the interpretation of their actions and functions; their localizations
in the cytosol and/or nucleus justifying the slow response, genomic actions (transcriptional),
on the other hand, the non- genomic actions (rapid) that involve pathways and signalling
transactions was linked to the existence of membrane-associated ERs that are structurally
distinguished from the classical ERs (Govind and Thampan, 2003, Mizukami, 2010). A
number of studies have demonstrated that tamoxifen and its metabolites have a profound
effect on breast cancer proliferation through GPR30 implying the role of upregulation of this
protein in the acquired resistance to targeted tamoxifen treatment in breast cancer patients
(Ariazi et al., 2010, Pandey et al., 2009, Vivacqua et al., 2009). Furthermore, one of the
suggested mechanism that induce the tamoxifen resistance is to activate the epidermal
growth factor receptor (EGFR). An expression of GPR30 in 50% of ER + breast cancer 
patients (Wang et al., 2010), which happen together with the overexpression of EGFR and
acquired resistance, suggests that Gβγ subunit protein of GPR30 induces the GPR30/EGFR 
signalling cascade (Mo et al., 2013).
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The downstream ligand-activated GPR30 signalling involves activation of SRC-like tyrosine
kinase and metalloproteinases leading to activate the HB-EFG (heparan-bound) which, in
turn, activates the EGFR signalling pathway. Subsequently, the cells are commencing
growth in response to the phosphorylated Erk1/2 (Filardo et al., 2000, Mo et al., 2013).
Non-genomic actions of oestrogen occurr rapidly and are accompanied with
intercompartmental ions flux and flux of other molecules across the plasma membrane
(extracellular to intracellular), (Saint-Criq et al., 2012). Several proteins were related to
solute transporters were DE (Supplement tables 5&6 ) in response to 4-OHT, of these are
SLC1A5, SLC25A24, SLC25A4, SLC3A2, and SLC7A5. Alanine, serine, cysteine-
preferring transporter 2 (ASCT2; SLC1A5) and SLC3A2 were upregulated in the (Sc) and
(Sc,Sn), respectively. They play a role in mediating the amino acids transport particularly
glutamine (Kanai and Hediger, 2004, Kekuda et al., 1996).
Glutamate pool is critical for normal and abnormal cells; the demand is exponentially
increased in the cancer cells from transformation through proliferation and metastasis stages,
to compensate the needs for detoxification and metabolism that is needed for high rate
proliferated cancer cells (DeBerardinis et al., 2007). Furthermore, mTORC1 is the master
regulator signalling for growth and protein biosynthesis (Duran et al., 2012, Wullschleger et
al., 2006). It also needs a level of glutamic acid to be maintained to sustain its functions
(DeBerardinis et al., 2007). Some studies have found a link between oncogenes and
glutamate metabolism by linking the deregulation of c-Myc gene to the upregulation of
glutamate metabolism (Dang et al., 2006, Little et al., 1983). SLC1A5 was found to be a
direct target for c-MYC gene, supporting the increase in the glutamic influx (Dang, 2010).
Another study was shown that autophagy was induced in relation to the inhibition of
glutamine-dependent activation of mTORC1, that was shown to be initiated via inhibition of
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SLC7A5/SLC3A2 (Esslinger et al., 2005). Combining the in vitro and in vivo approaches of
gene expressions, (van Geldermalsen et al., 2015) have investigated the role of SLC1A5
(ASCT2) in breast cancer triple negative cell lines (TN) and patients. They have shown in
the cell line that targeted knockdown of ASCT2, alone, was enough to inhibit rapidly in vitro
growth and reduce the xenografted cells, suggesting the dynamic regulation of ASCT2 by
MYC- and ATF4-driven transcriptional in triple negative breast cancer cells. Furthermore,
mRNA measurement was highly expressed in both cell line (TN) and patient samples.
Our study identified several proteins involved in cell growth and apoptotic process. A
general response set enrichment analysis (270-TAM) reveals that of the 40 proteins involved
in the cellular growth function, 27.5% representing 11 proteins were significantly changed in
the three sample types (CNT), and the major changes were associated with the subcellular
compartments and involved eight proteins.
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For number of DE proteins involved in the apoptotic process, out of 32 proteins (Table 3-6),
there were 24 proteins DE in the subcellular compartments (75%), two proteins were DE in
all three sample types (S100A8 and A100A9), the rest were changed in the total abundances
only (Figure 3-22A and B). Some of these proteins are known to promote tumorigenesis and
progression but their changes in response to tamoxifen treatment were favouring a selective
action rather than pure agonist or antagonist mode of action, furthermore, roles of some of
these proteins in relation to tamoxifen resistance is yet to be revealed. For example,
YWHAE (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein,
epsilon) is one of seven isoforms constituting 14-3-3 protein family (β, γ, ε, ζ, η, σ, and τ) 
that are expressed in all eukaryotic cells (Aitken, 2006) and via interacting with phospho-
serine or phospho-threonine motifs, they are involved in wide ranges of cellular functions,
including those related to metabolic, survival, and signal transduction, and transcriptional
activities. In relation to tumorigenesis, they found to play both roles as tumour suppressor
(14-3-3σ, SFN) and oncogene that contributes to the malignancy transformation (14-3-3ζ, 
YWHAZ) (Hermeking, 2003, Morrison, 2009). We found that 14-3-3ζ (YWHAE) 
expression was up-regulated in the cytoplasmic fraction (Sc) with no significant changes in
Sn or St. Various forms of cancers, including breast cancer, have shown increased level of
expression of YWHAE implying its role in inhibiting the cell detachment-induced apoptosis
(Anoikis) via activation of TGF-β/Smads (Transforming growth factor-β) leading to 
anchorage-independent growth in anoikic cells and promoting the metastasis of the tumour
cells (Li et al., 2008, Lu et al., 2009, Neal et al., 2009). Moreover, the nucleo-cytoplasmic
distribution of 14-3-3 proteins is of a profound importance to control the cell cycle and
prevent apoptosis, Brunet et al. (2002) have shown that the majority of these proteins, upon
ligand activation, are relocalized to the cytoplasm and home to the nucleus in the absence of
ligand binding.
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Anchorage-independent manifestation, in the present work, was observed as the decreased
expression of proteins that are components of tight junctions that stabilize the tissue/cell seal
such as DSP, DES, DSG1, and DSC1 (Al-Jassar et al., 2013, Waschke, 2008), in the
subcellular compartments (Sc, Sn). In the absence of changes in total abundance, the
distribution calculations (Sn/Sc) show that these proteins are redistributed in the cytoplasm
(N → C) or vice versa (Table 3-9). Therefore, tamoxifen seems to exert its “antagonistic” 
effects releasing anchorage-independent cells that appear to undergo “agonistic” effects
enhancing their proliferation individually (anoikis cells) via upregulated YWHAE and
downstream effectors; however, this needs further investigations. Interestingly, the cross-talk
between pathways as depicted in Figure 3-19 demonstrates the overlap between ECM-
receptor pathway and Pathways in cancer pathway (focal adhesion). This was observed as an
impact of protein distribution to the subcellular compartment rather than overlapping
between the DE genes/proteins. Recently, Sun et al. (2015), using the Rank Product method
to identify DE genes in five sets of breast cancer gene expression data, have identified the
lists of overlapping proteins and constructed crosstalk analysis of pathways. They concluded
that the greatest degree overlapping was observed between ECM and focal adhesion
pathway, furthermore, Pathways in cancer was the main pathway in breast cancer showing
the crosstalk between different pathways. We found that proteins enriched ECM (CLO1A2,
COL6A2, COL1A1, and COL6A3) (Figure 3-20A), were significantly reduced in the total
lysate fraction while two more components related to this pathway were observed as
significantly decreased in the nuclear sub-compartment (COL6A1 and ITGA3) as shown
(Figure 3-20B).
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Cross-talk between pathways is a phenomenon that has been addressed as suggestive
mechanisms of tamoxifen related resistance in breast cancer (Dixon, 2014), moreover, a
group of researchers has determined the changes in metabolic pathways and ceoss-talk
phenomenon were observed in 17β-Estradiol treated breast cancer cells at 3 timepoints (12h, 
24h, and 34h), the most remarkable finding of this study was that the changes were
fundamentally related to Pathways in cancer, Focal adhesion, and Chemokine signalling
pathways (Huan et al., 2014).
In the current project, 4-OHT induced significant changes in expression of the SET nuclear
oncogene; the upregulated SET protein was relocalized to the cytoplasm. This protein,
among other, has been found to have overexpression in MCF-7 resistant form to paclitaxel
increasing multidrug resistance (MDR) (Chen et al., 2014a), and has been previously shown
to relocalize from nucleus to cytoplasm following inhibition of DNA replication origin
activation checkpoint kinase in CDC7-depleted fibroblasts (Mulvey et al., 2013).
Additionally, exposure to genetic insults has caused the nucleocytoplasmic distribution of
SET protein in neurons (Qu et al., 2007). In cancer cells, proliferation induction can be
achieved via inhibition of the tumour suppressor genes, SET known as a potent inhibitor of
the tumour suppressor proteins phosphatase 2A (PP2A) and Nm23-H1 (Fan et al., 2003).
Truncating the antagonistic effects of PP2A on AKT and ERK phosphorylation was
suggested as a role that SET may play to enhance the resistance to chemotherapy
(Christensen et al., 2011).
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The multifunctional ANXA1 is well known protein that contributes to variety of functions
within the cells that determine differential, proliferative, or apoptotic fates of the cells (Lim
and Pervaiz, 2007, Mussunoor and Murray, 2008). Moreover, the spatiotemporal distribution
of annexins grounds for their regulation to the signal transductions (Monastyrskaya et al.,
2009). It has been indicated that subcellular localization of ANXA1 is an essential detriment
for the role that this protein may play in all stages of cancer development. In contrast to the
normal epithelial cells where ANXA1 was mainly localized in the cytoplasm, the
transitional cells carcinomas (TCC) was shown that ANXA1 was redistributed primarily to
the nucleus, suggesting a role in mediating the transition and differentiation of cancer cells
(Cui et al., 2007). Furthermore, ANXA1 expression found to be context dependent and
differs from cancer type to another implying its role in cancer progression as a tumour
suppressor and/or promoter (Guo et al., 2013). In a study carried out on the poor response of
breast cancer patients to neoadjuvant chemotherapy, ANXA1 was downregulated and was
associated with poor pathological response (Chuthapisith et al., 2009). However, the
mechanism is not completely elucidated.
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Chapter 5 Conclusions
The high degree of spatial/functional inhomogeneity of cells and the need for efficient
subcellular communication means that the study of dynamic spatial distribution of
subcellular proteins is of fundamental importance for the improvement of the understanding
of cellular processes underlying human disease. Indeed, this remarkable phenomenon occurs
in any kind of cell: roughly half of all subcellular proteins are known to translocate into
another compartments to reach their functional location (Chacinska et al., 2009), while most
of the ~1,000 different ‘resident’ proteins contained in mitochondria are imported from the
cytosol to exert their functional role (Schmidt et al., 2010). Moreover, numerous mis-
localised proteins have been associated with human diseases as diverse as Alzheimer’s or
various types of cancer and aberrant localisation of proteins has been shown to contribute to
the pathogenesis of many human diseases (Hung and Link, 2011).
It is becoming more apparent that relying on global genomics information is a valuable asset
to formulate a hypothesis, identify recognisable tissue signatures, and seek correlations to
medical conditions, but the functional states of cells are beyond the scope of genomics alone.
The more focussed approach of proteomics is complementary to genomics and can define
the functional products (proteins) of the deregulated genes in space and time, which
increases our understanding of the underlying biological processes (Lam et al., 2014, Scott
and Pawson, 2009).
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Recent advances in the characterisation of the subcellular location of proteins now indicate
that dynamic trafficking of multitudinous proteins over many subcellular locations is a
central mechanism in cellular function. There is now an urgent need for global
characterisation of the dynamic subcellular partitioning of proteins for many cell types and
functional contexts.
The main conclusions of this work are now summarised as follows:
1. Numerous existing evidence suggests that the subcellular location of proteins is
being as much important as the change in total protein abundance in cellular
response to environmental cues, cell cycle stages, hormonal stimulation, oxidative
stress, among others.
2. Healthy and diseased states can be further characterised and distinguished by
developing appropriate model systems allowing us to follow the dispersion of
functional systems over multiple subcellular locations and include the dynamic
redistribution of proteins. This would need more integration of the large scale
technologies including genomics, transcriptomics, metabolomics and proteomics.
3. This concept of cellular functions that are revealed via the subcellular spatial razor
method, may contribute to an advance in effective medical diagnostics and safe
therapeutics.
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4. In adopting practical and suitable biological modelling systems, the dynamicity of
highly complex systems such as cells can be systematically investigated at different
scales.
5. The goals of studying largescale changes in protein abundances and modifications of
changes in subcellular compartments have become feasible, owing to the maturity of
MS-based proteomics into state of art technologies.
6. There is also a need for improved databases that explicitly tie together
function/location as pair relationships for individual proteins; at present, databases
such as GO obscure crucial information by neglecting this.
7. Discrete functional roles, and dual or multiple roles of proteins that are disseminated
to multiple subcellular locations are thought to play a role in modulating cellular
response to stimulation, treatment or insults. Therefore, ‘moonlighting’ phenomena
are more visible at proteome level, than through genome or transcriptome
approaches.
8. Proteins are the terminal players involved in highly complex processes that are
connected via multiple networks linking hierarchical anatomical system entities and
formulating the function or dysfunction of an organism. Thus, the subcellular spatial
distribution of proteins is dynamic; a change in cellular state is a central mechanism
of cellular functions.
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9. Change in subcellular localisation and abundance in response to biological
perturbations was the dominant response of MCF-7 cells exposed to oestrogen and
antioestrogen (tamoxifen). The nuclear-cytoplasmic trafficking of proteins is a major
response to hormonal stimulation, rather than changes in total abundances.
10. Distribution of sub-proteome changes in subsystems of MCF-7 cancer cells appear
to be essential for tumour survival and/or resistance to treatment that to adapt
metabolism, oxidative phosphorylation, signalling transduction, cell adhesion, cross
talk between pathways, cell growth, cell cycle and non-apoptotic proteins that are
spatially distributed to enhance the progression of cancer cells.
11. Tamoxifen resistance is correlated to numerous mechanisms that are involved in
changes in order and magnitude of a large number of proteins, elucidating
complexity and heterogeneity of cancer cells. Most of the subcellular changes
associated with tamoxifen stimulation in this project were of upregulation of
proteins known to enhance tumour proliferation rather than suppression, therefore,
an agonist or partial agonistic effects of the drug could be predicted in light of the
subcellular localisation of proteins and/or moonlighting roles of
localised/redistributed proteins.
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Chapter 6 Future directions
Elucidating the exact mechanisms underlying the proliferative actions of hormonal exposure,
particularly E2, and overcoming the failure of the endocrine-targeted therapy (ETT) to
prevent the relapse of the disease in (HR+ve) positive breast cancers, will remain extremely
challenging. However, the new high performance technologies are helping to gain better
insight using modelling systems without jeopardising the dynamics of the integral cellular
parts.
In this project, the spatial distribution of proteins between subcellular compartments and
their possible functions involved in cancer formation and progression following biological
perturbations, mainly E2 and 4-OHT, was investigated. The conclusions were reached using
stimulated MCF-7 and were consistent to those previously reported in this laboratory
(Baqader et al., 2014, Mulvey et al., 2013, Pinto et al., 2016, Qattan et al., 2012, Radulovic
et al., 2016), and using different stimuli and/or cell lines demonstrates that the spatial-
temporal dynamics of the subcellular proteomes appears to be an essential cellular control of
major cell processes such as metabolism, oxidative phosphorylation, signalling transduction,
cell cycle and cell growth, to name a few.
Carcinogenesis is a multistep process and involves many biological alterations that are
accumulated over time due to specific and nonspecific causes and effects. The complexity of
neoplasm prompted the need to develop methods for subcellular proteomic analysis to obtain
an in-depth understanding of the molecular basis of cancer.
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In breast cancer, cell growth can be mediated by genomic and non-genomic pathways,
therefore, in the rapid (non-genomic) response numerous cross talked pathways, different
forms of receptors, and activated protein kinases are involved and eventually lead to
enhanced transcriptional activities and tumour survival and progression. For example, in
response to tamoxifen treatment we have shown that the upregulated G proteins (GNA12,
13, GNAS) are significantly redistributed in the subcellular compartments. Moreover, they
are significantly impacted in suggested cancer pathways. They are constituting subunits of
GPCR, particularly GRP30, which is a new form of ERs that can modulate non-oestrogenic
pathways by attenuating a cyclic adenosine pathway (cAMP), activating ERK1 and ERK2,
and PIP3/AKT pathways (see discussion). Additionally, SET oncoprotein was upregulated in
nuclear compartment, indicating that multiple cellular inhibition, such as protein phosphatase
2A (PP2A), and activation, such as AKT signalling, are likely to take place as a consequence
to the potent actions of SET.
Future studies will need to gain more understanding of cellular signalling networks. Thus, an
extension of the current subcellular fractionation model, designing a suitable experiment to
involve other selective oestrogenic down regulators (SERDs) and a pure ER antagonist ICI
182,780 for quantitative phosphoproteomic analysis and a spatial razor model for
interpretation would help to highlight many aspects related to signalling in cancer cells and
interaction with ER receptors that are far from elucidation.
Recently the effort was made to address the total changes of phosphorylation in a
phosphoproteome study of tamoxifen stimulated wild type MCF-7 and tamoxifen resistant
MCF-7 cell lines. Although this is a valuable approach, no attempt was made to study the
dynamics of sub cellular distribution (Wu et all, 2015).
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Comparing phosphoproteomics dynamics in response to SERM (Tamoxifen), SERD
(Fulvestrant), oestrogen, and pure antagonist ICI 182,780 would generate a massive number
of phosphoproteins that change in abundance, or in subcellular localisation that needs to be
integrated with publicly available data on breast cancer and ETT clinical trials. Therefore,
using an advanced knowledge management software package would offer a graphical,
interactive and dynamic map of breast cancer and ETTacquired chemoresistance based on
connecting the obtained research data with patient clinical information. BioXM™
Knowledge Management Environment (Blake et al., 2011, Cano et al., 2014, Losko et al.,
2006, Suh et al., 2013) can be used to create an interactive, semantically integrated map of
breast cancer and targeted therapy resistance in which pre-existing knowledge on protein-
protein interactions, subcellular localisation, gene expression, pathway activation, protein
modification, drugs and drug treatments and clinical data and trials will be integrated with
experimental data obtained in phosphoproteomics.
Cell line models are not ideal biological representatives in all forms of resistance, as seen in
clinical patients. For example, aromatase inhibitors target the peripheral tissues and inhibit
the oestrogen production via enzymatic conversion of androgens by aromatase (Dixon, 2014,
Miller and O'Neill, 1987). It would be interesting to feed the xenograft with diets of heavy
amino acids instead of the light (SILAC in vivo) which would give rise, after one generation,
to a spike-in standard model organism that can be used for further analysis of tissues or body
fluids (Krüger et al., 2008, Sury et al., 2010). This would allow the investigation of the
peripheral conversion of progestogens into active metabolites (E2) by aromatase, and
therefore, ER-induced cellular proliferation, aromatase inhibition and suppression of ER, and
ultimately, the acquired resistance to tamoxifen. Furthermore, this method may also be used
as a long term future approach and may also be extended to involve other forms of ETT.
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In terms of mass spectrometry-driven proteomics, the future direction is pointing towards the
development of DIA (data independent acquisition) (Bruderer et al., 2015) in mass
spectrometric experiments, thus increasing the number of observed proteins. However this
approach needs to be balanced against an increase in false positive results. Bioinformatic
analyses are expected to evolve in ‘Big Data’ systemic analyses, which in turn can
revolutionise cellular biology.
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